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Esta memoria de Tesis Doctoral consta de una parte que incluye una introducción 
general de los temas principales, un apartado de resultados y una parte experimental. 
 
El trabajo es fruto de una colaboración con PharmaMar y está encaminado a la 
síntesis convergente del producto natural myriaporone 4, así como a la síntesis de 
nuevos derivados bioactivos. 
 
Para hacer que las comparaciones entre las estructuras de myriaporone 4 y de tedanolide 
sean más claras, los números de los átomos de carbono de myriaporone 4 y sus análogos 
se han asignado como los del tedanolide. 
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En el transcurso de los últimos veinte años el mar se ha convertido en la 
principal fuente natural de moléculas bioactivas. Esto no es sorprendente si se tiene en 
cuenta que representa el 70 % de la superficie terrestre y su biodiversidad, el 90 % de la 
biosfera. Además, estadísticamente, los compuestos de origen marino son más activos 
que los de origen terrestre ya que el 1.8 % de los productos activos aislados son marinos 
frente al 0.4 % que representan los de origen terrestre.1 
 
En las últimas tres décadas se han registrado cerca de 300 patentes de productos 
naturales bioactivos de origen marino. El número de productos aislados de varios 
organismos marinos sobrepasan los 10000, y cada año se descubren cientos de 
productos nuevos. 
 
Myriapora Truncata es un briozoo aislado en el Mar Mediterráneo. En 1995, 
Reinehart, aisló cuatro compuestos activos a los que denominó miriaporona, entre los 
cuales se encontraba la miriaporona 4 (1) (Figura 1)2. La configuración fue determinada 
por síntesis total casi simultánemante por PharmaMar3 y Taylor.4 Esta molécula de tan 
sólo trece carbonos está muy funcionarizada. En su estructura cabe destacar un anillo de 
oxirano, una olefina de configuración Z, cuatro grupos hidroxilo y siete estereocentros. 
Esta molécula presenta una interesante actividad anticancerígena. 
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Figura 1 
 
                                                 
1  (a) Blunt, J. W.; Copp. B. R.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. Nat. Prod. Rep. 
2004, 21, 1-49. (b) Faulkner, D. J. Nat. Prod. Rep. 2002, 19, 1-48. (c) Jiménez, J. C.; Marfil, M.; 
Francesch, A.; Cuevas, C.; Álvarez, M.; Albericio, F. Investigación y Ciencia 2007, 365-374. 
2  (a) Rinehart, K. L.; Cheng, J.-F.; Lee, J.-S. US patent 5,514,708, 1996. (b) Rinehart, K. L.; 
Tachibana, K. J. Nat. Prod. 1995, 58, 344-358. 
3  Pérez, M.; del Pozo, C.; Reyes, F.; Rodríguez, A.; Francesch, A.; Echavarren, A. M.; Cuevas, C. 
Angew. Chem. Int. Ed. 2004, 43, 1724-1727. 
4  (a) Fleming, K. N.; Taylor, R. E. Angew. Chem. Int. Ed. 2004, 43, 1728-1730. (b) Taylor, R. E.; 
Hearn, B. R.; Ciavarri, J. P. Org. Lett. 2002, 4, 2953-2955. (c) Taylor, R. E.; Ciavarri, J. P.; 
Hearn, B. R. Tetrahedron Lett. 1998, 39, 9361-9364. 
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 La estructura de la miriaporona 4 (1) es equivalente al fragmento C10-
C23 del macrólido tedanólido (2), un potente anticancerígeno aislado previamente de la 
esponja Tedania Ignis (Figura 2).5 La miriaporona 4 (1) es un poco menos activa que el 
tedanólido 2, pero el pequeño tamaño de esta molécula y la poca cantidad de que se 
dispone en la naturaleza, la hacen interesante desde el punto de vista sintético. 
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Figura 2 
 
Recientemente Taylor ha publicado un estudio comparativo de la actividad entre 
la miriaporona 4 (1) y el tedanólido 2 así como la relación estructura-actividad de cada 
uno de ellos. Llegando a la conclusión, en el caso de 1 de que el anillo de oxirano y los 
grupos hidroxilo confieren la actividad a la molécula.6 
 
 Hasta la fecha se han descrito dos síntesis de miriaporona 4 (1), la 
primera fue descrita por PharmaMar3 y la segunda por Taylor4. Ambas están inspiradas 
en las diferentes síntesis descritas para el fragmento C10-C23 del tedanólido (2).7 
                                                 
5  (a) Schmitz, F. J.; Gunasekera, S. P.; Yalamanchili, G.; Hossain, M. B.; Van der Helm, D. J. Am. 
Chem. Soc. 1984, 106, 7251-7252. (b) O’Hagan, D. Nat. Pod. Reports 1993, 593-625. 
6  Hines, J.; Roy, M.; Cheng, H.; Agapakis, C. M.; Taylor, R.; Crews, C. M. Mol. Biosyst. 2006, 2, 
371-379. 
7  (a) Matsushima, T.; Horita, K.; Nakajima, N.; Yonemitsu, O. Tetrahedron Lett. 1996, 37, 385. 
(b) Matsushima, T.; Mori, M.; Nakajima, N.; Maeda, H.; Uenishi, J.; Yonemitsu, O. Chem. 
Pharm. Bull. 1998, 46, 1335. (c) Liu, J.-F.; Abiko, A.; Pei, Z.; Buske, D. C.; Masamune, S. 
Tetrahedron Lett. 1998, 39, 1873. (d) Taylor, R. E.; Ciavarri, J. P.; Hearn, B. R. Tetrahedron 
Lett. 1998, 39, 9361. (e) Roush, W. R.; Lane, G. C. Org. Lett. 1999, 1, 95. (f) Matsushima, T.; 
Mori, M.; Zheng, B.-Z.; Maeda, H.; Nakajima, N.; Uenishi, J.; Yonemitsu, O. Chem. Pharm. 
Bull. 1999, 47, 308. (g) Jung, M. E.; Karama, U.; Marquez, R. J. Org. Chem. 1999, 64, 663. (h) 
Matsushima, T.; Zheng, B.-Z.; Maeda, H.; Nakajima, N.; Uenishi, J.; Yonemitsu, O. Synlett 
1999, 780. (i) Smith, A. B., III; Lodise, S. A. Org. Lett. 1999, 1, 1249. (j) Zheng, B.-Z.; Maeda, 
H.; Mori, M.; Kusaka, S.-i.; Yonemitsu, O.; Matsushima, T.; Nakajima, N.; Uenishi, J. Chem. 
Pharm. Bull. 1999, 47, 1288. (k) Jung, M. E.; Marquez, R. Tetrahedron Lett. 1999, 40, 3129. (l) 
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 La síntesis de PharmaMar se resume en el siguiente esquema 
retrosintético (Esquema 1). El resto etilo y el alqueno de configuración Z se introducen 
empleando la amida de Weinreb 3, la cual se obtiene por reacción aldólica entre el 
compuesto 4 y la acetamida 5. Para controlar la estereoselectividad en la formación del 
enlace C6-C7 entre 5 y 7, emplean la oxazolidinona de Evans 6 en la reacción aldólica 
con el aldehído7. Para evitar la epimerización y reacciones no deseadas como 
retroaldólicas o de elminación, la oxidación a cetona del C7 la posponen a los últimos 
pasos de la síntesis. 
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Esquema 1 
 
                                                                                                                                               
Matsushima, T.; Nakajima, N.; Zheng, B.-Z.; Yonemitsu, O. Chem. Pharm. Bull. 2000, 48, 855. 
(m) Zheng, B.-Z.; Yamauchi, M.; Dei, H.; Kusaka, S.-i.; Matsui, K.; Yonemitsu, O. Tetrahedron 
Lett. 2000, 41, 6441. (n) Zheng, B.-Z.; Yamauchi, H.; Dei, H.; Yonemitsu, O. Chem. Pharm. 
Bull. 2000, 48, 1761. (o) Jung, M. E.; Marquez, R. Org. Lett. 2000, 2, 1669. (p) Jung, M. E.; 
Lee, C. P. Org. Lett. 2001, 3, 333. (q) Loh, T.-P.; Feng, L.-C.; Tetrahedron Lett. 2001, 42, 6001. 
(r) Loh, T.-P.; Feng, L.-C. Tetrahedron Lett. 2001, 42, 3223. (s) Matsui, K.; Zheng, B.-Z.; 
Kusaka, S.-i.; Kuroda, M.; Yoshimoto, K.; Yamada, H.; Yonemitsu, O. Eur. J. Org. Chem. 2001, 
3615. (t) Hearn, B. R.; Ciavarri, J. P.; Taylor, R. E. Org. Lett. 2002, 4, 2953. (u) Wong, C.-M.; 
Loh, T.-P. Tetrahedron Lett. 2006, 47, 4485  
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En la síntesis de Taylor, a diferencia de en la de PharmaMar, el anillo de oxirano 
se introduce en las etapas finales. La ruta que siguen para la síntesis de 1 está resumida 
en la retrosíntesis del Esquema 2. Como producto de partida utilizan el intermedio 10 
que habían descrito previamente para la síntesis total de otra de las miriaporonas 
naturales, la miriaporona 1.4b,c 10 se transforma en 9 mediante una cicloadición 
regioselectiva de óxido de nitrilo. Posteriormente se obtiene 8 mediante la oxidación a 
cetona la posición C7, la reducción de la isoxazolina con Mo(CO)6 y la epoxidación del 
doble enlace. Finalmente, tras una olefinación para introducir el alqueno de 
configuración Z y la desprotección global se obtiene 1. 
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Esquema 2 
 
Ambas síntesis responden a un esquema lineal de síntesis, así pues uno de los 
objetivos que nos planteamos en este trabajo de investigación es la aproximación 
convergente a la síntesis total de la miriaporona 4 (1). El esquema retrosintético que nos 
planteamos se recoge en el Esquema 3. La retrosintesis se basa en la desconexión de la 
molécula 1 en dos aldehídos (11-13 y 16) y una cetona (14-15) que se unen mediante 
dos reacciones aldólicas estereoselectivas.8, una para la formación del enlace C8-C9 con 
                                                 
8  (a) Reiser, O.; Mengel, A. Chem. Rev. 1999, 99, 1191.(b) Masamune, S.; Choy, W.; Petersen, J. 
S.; Sita, L. R. Angew. Chem. Int. Ed. Engl. 1985, 24, 1-76 
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una configuración relativa anti9 y la otra para formar el enlace C5-C6 con configuración 
relativa syn.10 
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Esquema 3 
 
Para la síntesis del aldehído 11 nos basamos en la síntesis del tedanólido 2 
publicada por Kalesse.11 A partir del hidroxiester comercial (−)-17 se obtiene el alcohol 
α,β-insaturado 18 el cual, mediante una epoxidación de Sharpless y posterior oxidación 
del grupo hidroxilo de 19 nos permite acceder al aldehído 11 (Esquema 4). 
 
                                                 
9 a)Walker, M. A.; Heathcock, C. H. J. Org. Chem. 1991, 56, 5747-5750. b) Raimundo, B. C.; 
Heathcock, C. H. Synlett 1995, 1213-1214. c) Wang, Y.-C.; Hung, A.-W.; Chang, C.-S.; Yan, 
T.-H. J. Org. Chem.1996, 61, 2038-2043. 
10 Abiko, A.; Liu, J.-F.; Masamune, S. J. Am. Chem. Soc. 1997, 119, 2586-2587. 
11  Hassfeld, J.; Kalesse, M. Synlett 2002, 2007-2010. 
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Esquema 4 
 
De manera análoga se sintetizaron los aldehídos 12 y 13 con buen rendimiento 
(Esquema 5). 
 
7 etapas
CO2Me
HO
(-)-17
RO
CO2Et
12: R = PMB (21%)
13: R = TBDPS (18%)  
Esquema 5 
 
Para la síntesis de las cetonas 14-15 obtuvimos un intermedio común, el diol 22 
que obtuvimos a partir del cetodiester comercial 20 (Esquema 6). 
 
MeO2C CO2Me
O
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MeO2C CO2Me
O O
LiAlH4
THF
40 ºC
4 h, 96%
O O
HO OH
20 21 22  
 
Esquema 6 
 
Posteriormente, para la síntesis de 14 seguimos el procedimiento detallado en el 
Esquema 7. Protegiendo el diol 22 en forma de p-metoxibencilo se obtiene 23 que tras 
hidrólisis del acetal da la cetona 14 deseada. 
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Esquema 7 
 
Para la síntesis de 15 no pudimos seguir la misma ruta que la de la obtención de 
14, puesto que en el paso de hidrólisis del acetal los grupos t-butildimetilsilanos 
también se hidrolizaban. Por lo tanto la estrategia que seguimos consistía en la hidrólisis 
del acetal del compuesto 22 para obtener la dihidroxicetona 24 que por su tamaño y 
polaridad no se aislaba por lo que directamente la tratábamos con TBSCl para obtener la 
cetona 15 Esquema 8). 
 
14
TBSO OTBS
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TBSCl
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CH3CN
r.t., 16 h
15
(58% 2 steps)
O O
HO OH
22
HO OH
Amberlyst-15
CH2Cl2-MeOH
rt, 16 h O
24
 
 
Esquema 8 
 
El tercer fragmento de la molécula 1, el aldehído 16 se sintetizó a partir del 
cetoester 25 cuya cetona se protegió en forma de acetal (26), el cual mediante una 
secuencia de reducción-oxidación se transformó en el aldehído 16 (Esquema 9). 
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Esquema 9 
 
La reacción aldólica entre el aldehído 12 y la cetona 15 dio lugar a un producto 
inesperado, el pirano 27. Durante la reacción el epóxido se rompía dando como único 
producto de la reacción el ciclo (Esquema 10). 
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Esquema 10 
 
Después de este resultado decidimos posponer la introducción del oxirano a los 
pasos finales de la síntesis de 1 por lo que sintetizamos los análogos 28-30. Para la 
síntesis de estos productos seguimos un procedimiento análogo al de la obtención de 11-
13, las etapas seguidas se resumen en el siguiente (Esquema 11). 
 
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h
(+)-17 RO OH RO CHO
29: R = PMB (75%)
30: R = TBDPS (68%)
5 steps
CHO
MnO2, THF
rt, 1 h
89% 28
8 steps
18%
OHCO2Me
HO
(+)-17 18
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Esquema 11 
 
La reacción aldólica entre la cetona 15 y los aldehídos 28-30 se realizó 
utilizando las condiciones descritas por Paterson12 para la obtención de aldoles de 
configuración relativa anti. Se realizaron diversas reacciones aldólicas modelo para 
poner a punto las condiciones de reacción empleando diversos aldehídos comerciales de 
estructura similar a la del fragmento real de la miriaporona 4 (1). Finalmente obtuvimos 
los aldoles 31-33 (Esquema 12). 
 
CHOR1
Cy2BCl, Et3N
Et2O−78 ºC→ −20 ºC
16 h
(7:3 anti/sin)
R1
O
TBSO OTBS
OH
15 28-30 31-33
O
TBSO OTBS
 
Entrada Aldehído R1 Aldol 
Rdto. 
(%) 
dr (anti:sin) 
1 28 (Z) -CH=CHMe 31 72 7:3 
2 29 -CH2OPMB 32 81 7:3 
3 30 -CH2TBDPS 33 89 7:3 
 
Esquema 12 
 
Posteriormente se intentó la reacción aldólica con configuración relativa sin 
entre 31-33 y el aldehído 16 sin éxito. Por lo que decidimos cambiar la estrategia de 
síntesis uniendo los tres fragmentos en que habíamos dividido la molécula en otro 
orden, es decir, uniendo primero la cetona 15 con el aldehído 16 y por último 
introduciendo el fragmento 31-33. La reacción aldólica entre 15 y 16 se hizo empleando 
Bu2BOTf y DIPEA con el fin de obtener la relación sin en los centros generados en la 
reacción, pero sólo se recuperaron los productos de partida. Probamos la enolización de 
15 con Ti (IV). En estas condiciones se obtuvo el aldol 34 cuyo OH se protegió como 
TBS obteniendo el producto 35(Esquema 13). 
                                                 
12  Paterson, I.; Gibson, K. R.; Oballa, R. M. Tetrahedron Lett. 1996, 37, 8585-8588. 
Resumen 
 22
 
15 16
O
OTBSTBSO
CHO
OO
TiCl4, DIPEA
CH2Cl2−78 ºC,1.5 h
68%
(>95:5 sin/ant i)
O
TBSO OTBS
O OHO
34
TBSOTf,
2,6-lutidine
CH2Cl2
rt, 16 h
97%
O
TBSO OTBS
O OO
TBS
35  
 
Esquema 13 
 
Al hacer reaccionar 35 con cualquiera de los aldehídos 28-30 sólo se obtuvieron 
los productos de partida. Con objeto de evitar el posible impedimento estérico que 
ejercen los grupos TBS de la cetona 15 se planteó la síntesis del derivado 36, el cual es 
la versión desoxidada de 1. Para la síntesis de 36 se planteó una retrosíntesis análoga a 
la de 1 empleando 3-pentanona (37) en lugar de la cetona 15 y los aldehídos 29-30 
(Esquema 14). 
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OH O OH O
RO
CHO
O
29: R= PMB
30: R= TBDPS
37
36
CHO
OO
16
 
 
Esquema 14 
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Los aldoles 38/38’-39/39’ se obtuvieron como mezcla inseparable de 
diasterómeros 1:1 anti/sin con buen rendimiento mediante reacción aldólica entre 37 y 
29-30 (Esquema 15). Posteriormente se probó la reacción entre 38-39 y el aldehído 16 
sin éxito. 
 
CHO
R
O
R
OOH
29: R = PMBO
30: R = TBDPS
38: R = PMBO
39: R = TBDPS
37 R
OOH
38': R = PMBO
39': R = TBDPS
Cy2BCl, Et3N
CH2Cl2−78 ºC→ −20 ºC
 
Aldehyde Products Yield (%) 
29 38/38’ 91 
30 39/39’ 98 
 
Esquema 15 
 
A la vista de estos resultados se volvió a intentar la estrategia de unir los 
fragmentos en diferente orden. El aldol 40 se obtuvo mediante la reacción entre la 
cetona 37 y el aldehído 16, en el medio de reacción el acetal se hidroliza por lo que la 
síntesis no se podía seguir por este camino. Se probaron otras condiciones para obtener 
el aldol de configuración relativa sin pero sin éxito por lo que finalmente se decidió 
continuar la síntesis con el aldol de configuración relativa anti (41) obtenido haciendo 
uso de Cy2BCl y Et3N (Esquema 16). Pero una vez más todos los intentos para unir el 
aldol 41 con el fragmento 29-30 fracasaron y sólo se recuperaron los productos de 
partida. 
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1637
TiCl4, DIPEA
CH2Cl2−78 ºC,1.5 h
77%
O HO O
40
O
CHO
OO
1637
O HO O O
Cy2BCl, Et3N
Et2O−78 ºC, −20 ºC
18 h, 71% 41  
 
Esquema 16 
 
Otro objetivo de esta tesis es la síntesis de derivados de 1 para medir su 
actividad antitumoral. Así pues se sintetizaron los derivados ciclopropanados 42-43 
(Esquema 17). Para la etapa de ciclopropanación se emplearon las metodologías 
decritas por Simmons y Smith13 y también la de Charette14 obteniendo resultados 
similares en ambos casos. 42-43 se obtienen a partir del hidroxiester comercial (+)-17 
en 7 etapas con un rendimiento del 22% y del 18% respectivamente. 
 
RO
CHO
42: R = PMB (22%)
43: R = TBDPS (18%)
(+)-17
CO2Me
HO
7 etapas
 
 
Esquema 17 
 
De esta manera se obtuvo el aldol 44 resultante de la reacción entre 15 y 42 
(Esquema 18). La reacción entre 44 y el aldehído 16 para unir los tres fragmentos nos 
condujo una vez más a recuperar los productos de partida inalterados. 
 
                                                 
13  (a) Simmons, H. E.; Smith, R. D. J. Am. Chem. Soc. 1959, 81, 4256-4264. (b) Simmons, H. E.; 
Smith, R. D. J. Am. Chem. Soc., 1958, 80, 5323-5324. 
14  Lebel, H.; Marcoux, J.-F.; Molinaro, C.; Charette, A. B. Chem. Rev. 2003, 103, 977-1050. 
Resumen 
 25
PMBO
CHO
42
O
OTBSTBSO
Cy2BCl, Et3N
CH2Cl2−78 ºC, −20 ºC
16 h, 61%
15
PMBO
O
TBSO OTBS
OH
44
 
 
Esquema 18 
 
Finalmente se probó la actividad biológica de los nuevos intermedios 
sintetizados en este trabajo (11, 40-41, 45-49) (Figura 3), para ello se eliminaron todos 
los grupos protectores. Ningún intermedio resultó activo frente a las dianas probadas. 
 
O
HO OH
OH
HO
O
HO OH
OH
HO
O
HO OH
OH
CHO
O
11
45 46 47
48
O
HO
HO
OH
HO
OH
HO
OOH
O HO O OO HO O
49
40 41
 
 
Figura 3 
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In this document the abbreviations and acronyms most commonly used in organic 
chemistry have been used, according to the recommendations of “Guidelines for 
authors” J. Org. Chem. 2007, 72, 23A-24A. 
Additionally, the following abbreviations and acronyms have been used: 
 
Cy cyclohexyl 
TBAF tetrabutylamonium fluoride 
IBX o-iodoxybenzoic acid 
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1. The sea as a source of medicinal natural products 
 
Our planet offers a wide diversity of life, with an extraordinary number of animal 
and vegetal species that have evolved to adapt to their different ecosystems. As a 
consequence of this adaptation a huge variety of chemical structures are produced by 
these numerous species. In no other place the biological spectrum is as extensive as in 
the sea, which covers 70% of the earth surface. The immense majority of the animal 
families, or phyla, are related to the sea: 33 of the 34 animal phyla are of marine origin. 
During the past 30 years a very large number of novel marine natural products with 
useful and sometimes extraordinary pharmacological properties have been reported.1 
 
In order to evaluate the biomedical potential of any organism, both the chemical 
ecology of the organism and its evolutionary history must be considered. It is probable 
that chemical defense mechanisms evolved with the most primitive microorganisms but 
have been replaced in many more advanced organisms by physical defenses and/or the 
ability to run or swim away and hide. The specific evolutionary pressures that led to 
chemically rich organisms need not be defined but with a longer period of evolution, 
                                                 
1  (a) Blunt, J. W.; Copp. B. R.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. Nat. Prod. Rep. 
2004, 21, 1-49. (b) Faulkner, D. J. Nat. Prod. Rep. 2002, 19, 1-48. (c) Jiménez, J. C.; Marfil, M.; 
Francesch, A.; Cuevas, C.; Álvarez, M.; Albericio, F. Investigación y Ciencia 2007, 365-374. 
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the surviving organism has had more time to perfect its chemical arsenal. Sessile, soft-
bodied marine invertebrates, without physical defenses, have had ample opportunity to 
improve their chemical defenses during millions of years and are therefore prime 
candidates to posses bioactive metabolites. 
 
Among the many phyla found in the oceans, the best sources of 
pharmacologically active compounds are bacteria, fungi, certain groups of algae, 
sponges, soft corals, nudibranchs, bryozoans, and tunicates. Some marine organisms 
such as dinoflagellates, echinoderms and some fish are known for their ability to 
produce potent toxins, but these are usually too toxic for medicinal use. 
 
Chemical defense mechanisms cannot be directly related with potential 
biomedical activity, but it is remarkable how well the two correlate in reality.1b Nature 
has continuously provided a broad and structurally diverse arsenal of 
pharmacologically active compounds that are still used as highly effective drugs to 
combat a multitude of deadly diseases or as lead structures for the development of 
novel synthetic derivatives. Traditionally, higher plants and, since the discovery of the 
penicillins, terrestrial microorganisms had proven to be the richest sources of natural 
drugs that are indispensable especially for the treatment of diseases such as cancer. 
Well known examples of plant-derived anti-cancer drugs include paclitaxel (taxol), 
from Taxus brevifolia,2 etoposide (vepesid), derived by partial synthesis from the 
lignan podophyllotoxin isolated from Podophyllum peltatum,3 and irinotecan 
(campthosar), which was obtained by optimizing the structure of the alkaloid 
camptothecin from Camptotheca acuminata.4 Examples from bacterial sources include 
doxorubicin (adriamycin) and bleomycin from various Streptomyces strains.5 
 
                                                 
2  Huang, C. H. O.; Kingston, D. G. I.; Magri, N. F.; Samaranayake, G.; Boettner, F. E. J. Nat. 
Prod. 1986, 49, 665-669. 
3  Kutney, J. P.; Chen, Y. P.; Gao, S.; Hewitt, G. M.; Kuri-Brena, F.; Milanova, R. K.; Stoynov, N. 
M. Heterocycles 1993, 36, 13-20. 
4  (a) Curran, D. P.; Ko, S.-B.; Josien, H. Angew. Chem. Int. Ed. Engl. 1996, 34, 2683-2684. (b) 
Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. J. Am. Chem. 
Soc. 1966, 88, 3888-3890. 
5  Rishel, M. J.; Hecht, S. M. Org. Lett. 2001, 3, 2867-2869. 
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Serious attempts to explore the potential of marine organisms as sources of 
bioactive metabolites started in the late 1960s. The discovery of sizeable quantities of 
prostaglandins in the gorgonian Plexaura homomalla6 in 1969 is considered as the 
“take-off point” of the drug search from the sea. 
 
In the last three decades, approximately 300 patents on bioactive marine natural 
products were issued. Since the beginnings, the number of compounds isolated from 
various marine organisms exceeds 10000, with hundreds of new compounds still being 
discovered every year.1 Through the combined efforts of marine natural product 
chemists and pharmacologists, a number of promising compounds that have been 
identified are at advanced stages of clinical trials or have been selected as promising 
candidates for extended preclinical evaluation. The majority of marine natural products 
currently in clinical trials or under pre-clinical evaluation are produced by invertebrates 
such as sponges, tunicates, mollusks or bryozoans but not by algae. This is in sharp 
contrast to the terrestrial environment where plants by far exceed animals with regard 
to the production of bioactive natural products (also called secondary metabolites). The 
wealth of bioactive metabolites isolated from sessile or slowmoving marine 
invertebrates that usually lack morphological defense structures such as spines or a 
protective shell is no coincidence and reflects the ecological importance of these 
constituents for the respective invertebrates. It has been repeatedly shown that chemical 
defense through accumulation of toxic or distasteful natural products is an effective 
strategy to fight off potential predators (e.g. fishes) or to force back neighbors 
competing for space. The majority of drug candidates from the sea have so far been 
isolated from invertebrates that thrive in tropical or subtropical seas where the grazing 
pressure by predators such as fishes is higher than in any other ecosystem of the world.7 
Under these severe selective pressures only those organisms that can rely on effective 
means of chemical defense will survive. Thus, organisms that thrive in spite of 
pronounced biotic pressures can be expected to contain metabolites that are of interest 
for drug prospectors searching the oceans. 
                                                 
6  Light, R. J.; Samuelsson, B. Eur. J. Biochem. 1972, 28, 232-240. 
7  On tropical coral reefs fish have been estimated to bite the bottom in excess of 150,000 times per 
m2 and day. Proksch, P.; Edrada, R. A.; Ebel, R. Appl. Microbiol. Biotechnol. 2002, 59, 125–
134. 
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Marine natural products such as the ion channel-blockers tetrodotoxin and 
saxitoxin and the phosphatase inhibitor okadaic acid have long been used extensively 
as research tools. More recent research into marine sources has led to the discovery of 
novel anticancer drug candidates, such as eteinascidin-743 (a transcription inhibitor 
from Ecteinascidia turbinate),8 didemnin B (a protein translation inhibitor from 
Trididemnum solidum),9 discodermolide (a microtubule stabilizer/senescence 
accelerator from Discodermia sp.),10 tedanolide (a cytotoxic agent from tedania 
ignis),11 13-deoxytedanolide (agonist of SAPK/JNK and p38 MAP kinases from 
Mycale adhaerens),12 and myriaporone 3 and 4 (cytotoxic agent from Myriapora 
truncata).18  
 
The next Table 1 shows the status of some of the most outstanding marine-
derived natural products in clinical trials against several cancer types.13 
 
Name Source Phase 
Didemnin B Trididemnum solidum II 
Dolastatin 10 Dolabella auricularia I/II 
Girolline Pseudaxinyssa cantharella I 
Bengamide derivative Jaspis sp. I 
Cryptophycins Nostoc sp. & Dysidea 
arenaria 
I 
                                                 
8  (a) Friedman, D.; Hu, Z.; Kolb, E. A;. Gorfajn, B.; Scotto, K. W. Cancer Res., 2002, 62, 3377–
3381. (b) Cuevas, C.; Pérez, M.; Martín, M. J.; Chicharro, J. L.; Fernández-Rivas, C.; Flores, M.; 
Francesch, A.; Gallego, P.; Zarzuelo, M.; de la Calle, F.; García, J.; Polanco, C.; Rodríguez, I.; 
Manzanares, I. Org. Lett. 2000, 2, 2545-2548. 
9  Crews, C. M.; Collins, J. L.; Lane, W. S.; Snapper M. L.; Schreiber, S. L. J. Biol. Chem., 1994, 
269, 15411–15414. 
10  (a) Hung, D. T.; Chen, J.; Schreiber, S. L. Chem. Biol., 1996, 3, 287–293. (b) Klein, L. E.; 
Freeze, B. S.; Smith, A. B., III; Horwitz, S. B. Cell Cycle, 2005, 4, 501–507. 
11  Schmitz, F.J.; Gunasekera, S.P.; Yalamanchili, G.; Hossain, M. B.; van der Helm, D. J. Am. 
Chem. Soc. 1984, 106, 7251-7252. 
12  Fusetani, N.; Sugawara, T.; Matsunaga, S.; Hirota, H. J. Org. Chem. 1991, 56, 4971-4974. 
13  Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2004, 67, 1216-1238. 
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Bryostatin Bugula neritina II 
TZT-1027 Synthetic dolastatin II 
Cematodin Derivative of dolastatin 15 I/II 
ILX 651 Derivative of dolastatin 15 I/II 
Ecteinascidin 743 Ecteinascidia turbinata II/III 
Aplidine Aplidium albicans II 
E7389 Lissodendoryx sp. I 
Discodermolide Discodermia dissolute I 
Discodermolide Discodermia dissolute I 
Kahalalide F Eylsia rufescens/Bryopsis sp. II 
ES-285 (spisulosine) Spisula polynyma I 
HTI-286 Cymbastella sp. II 
KRN-7000 Agelas mauritianus I 
Squalamine Squalus acanthias II 
Tedanolide Tedania Ignis I 
Myriaporone 4 Myriapora truncata I 
13-Deoxitedanolide Mycale adhaerens I 
Neovastat Shark cartilage II/III 
Table 1 
 
2. Myriaporone in Nature. Isolation and characterization 
 
There are four naturally occuring myriaporones 1-4 (Figure 1). 
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Figure 1 
 
These compounds were isolated by Rinehart in 199514 from the bryozoan 
Myriapora Truncata, which means “false coral” because of its appearance (Figure 2). 
 
                                                 
14  (a) Rinehart, K. L.; Cheng, J.-F.; Lee, J.-S. US patent 5,514,708, 1996. (b) Rinehart, K. L.; 
Tachibana, K. J. Nat. Prod. 1995, 58, 344-358. 
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Figure 2 
 
The bryozoans are a group of primitive colonial animals widely distributed 
throughout the world’s marine and fresh-water enviroments.15 Myriapora truncata is 
collected in the Western Mediterranean. 
 
The characterization of myriaporone 4 (4) was firstly described by Reinehart14, 
and the absolute configuration determined by PharmaMar16 and Taylor17 by total 
synthesis. This molecule of only thirteen carbons is very densely funcionalized. The 
main structural features of myriaporone 4 (4) are an oxirane ring, a Z-olefin, four 
hydroxyl groups and seven stereocenters (Figure 3). 
 
                                                 
15  (a) Christophersen, C. Acta Chem. Scand Ser.B, 1985, 39, 517-529; (b) Faulkner, D. J. Nat. 
Prod. Rep. 1993, 10, 497-539. 
16  Pérez, M.; del Pozo, C.; Reyes, F.; Rodríguez, A.; Francesch, A.; Echavarren, A. M.; Cuevas, C. 
Angew. Chem. Int. Ed. 2004, 43, 1724-1727. 
17  (a) Fleming, K. N.; Taylor, R. E. Angew. Chem. Int. Ed. 2004, 43, 1728-1730. (b) Taylor, R. E.; 
Hearn, B. R.; Ciavarri, J. P. Org. Lett. 2002, 4, 2953-2955. (c) Taylor, R. E.; Ciavarri, J. P.; 
Hearn, B. R. Tetrahedron Lett. 1998, 39, 9361-9364. 
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Figure 3 
 
3. Structural relations between myriaporone 4 and 
tedanolide 
 
Myriaporone 4 (4) is structurally related to the C10-C23 region of the macrolides 
tedanolide 5 and deoxytedanolide 6 (Figure 4). The structure of myriaporone 4 (4) is 
shown in blue in Figure 4 overlapped to the structure of 5 and 6. 
 
O
23
O
OH
O
O
OMe O
OH
10
OR
OH
5 R =OH
6 R = H  
Figure 4 
 
Tedanolide (5) is a potent cytotoxic macrolide isolated from the Caribbean 
sponge Tedania ignis.18 The in vitro biological data of tedanolide is remarkable, with 
ED50= 0.25 ng/mL in KB cells and 1.6 pg/mL in PS cells, and causes accumulation of 
cells at the S face in the cell cycle at concentrations as low as 0.01 µg/Kg. In vivo, 
                                                 
18  (a) Schmitz, F. J.; Gunasekera, S. P.; Yalamanchili, G.; Hossain, M. B.; Van der Helm, D. J. Am. 
Chem. Soc. 1984, 106, 7251-7252. (b) O’Hagan, D. Nat. Pod. Reports 1993, 593-625. 
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tedanolide has been shown to increase the lifespan of mice implanted with lymphocytic 
leukemia by 23% at 1.5 µg/Kg body weight. 
 
Fusetani and co-workers reported the isolation of 13-deoxytedanolide (6) from 
the marine sponge Mycale adhaerens.19 This related molecule also showed 
extraordinary biological activity, exhibiting an IC50 of 94 pg/mL against P388 murine 
leukemia cell lines, with a T/C value of 189% at a dose of 0.125 mg/Kg. 
 
More recently, Ireland et al. reported the isolation of tedanolide C (7) (Figure 5) 
from the marine sponge Ircina sp,20 which exhibits less biological activity than the 
other two tedanolides (5 and 6). In this case the C13-C23 region is not too similar to 
myriaporone 4 (4) . 
 
O
O
OH
HO
O
O
OH O
OHOH
7  
Figure 5 
As natural analogues of tedanolide, must be mentioned the candidaspongiolides 
8a and 8b (Figure 6) described recently by McKee et al21. Which are acyl esters 
isolated from sponges of the genus Candidaspongia and present antitumor activity. 
                                                 
19  Fusetani, N.; Sugawasara, T.; Matsunaga S. J. J. Org. Chem. 1991, 56, 4971-4973. 
20  Chevallier, C.; Bugni, T. S.; Feng, X.; Haper, M. K.; Orendt, A. M.; Ireland, C. M. J. Org. 
Chem. 2006, 71, 2510-2513. 
21  Meragelman, T. L.; Willis, R. H.; Woldemichael, G. M.; Heaton, A.; Murphy, P. T.; Snader, K. 
M.; Newman, D. J.; van Soest, R.; Boyd, M. R.; Cardellina II, J. H.; McKee, T. C. J. Nat. Pod. 
2007, 70, 1133-1138. 
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Figure 6 
As a result of the limited availability of both myriaporones (1-4) and tedanolides 
(5-7), their biology remains unknown. 
 
4. Myriaporone 4 activity and structure-activity 
relationship 
 
Recently, Taylor and Crews reported a structure-activity relationship of 
myriaporone to define a pharmacophore eukaryotic protein synthesis.22 
 
The biological activity of myriaporone 4 (4) was examined against two different 
mammalian cells: P388 mouse leukemia cells and bovine aortic endothelial cells. The 
former is a transformed cell line which grows in suspension and the latter are adherent, 
primary cells. Despite significant differences in the growth patterns of these cells, 
myriaporone 4 (4) effectively inhibited the proliferation of both with IC50 values in the 
low nanomolar range (IC50 = 15.9 ± 1.0 nM for endothelial cells; IC50 = 15.4 ± 1.7 nM 
for P388 cells), which is approximately 18-fold more potent than was reported in the 
initial discovery of myriaporone.14  
                                                 
22  Hines, J.; Roy, M.; Cheng, H.; Agapakis, C. M.; Taylor, R.; Crews, C. M. Mol. Biosyst. 2006, 2, 
371-379. 
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Compared in terms of potency to the known members of the tedanolide family, 
myriaporone 4 (4) falls in the middle of them: it is more potent than the recently 
discovered tedanolide C (7), but less potent than 13-deoxytedanolide (6)19 or tedanolide 
(5) itself.18 Further, the biological activity of myriaporone 4 (4) was not restricted to 
mammalian cells in assays performed on Saccharomyces cerevisiae and 
Schizosaccharomyces pombe. Myriaporone 4 (4) inhibited the growth of both with S. 
pombe showing slightly greater sensitivity. Sensitivity of yeast to this inhibitor is not as 
pronounced as in mammalian cells: use of dot titration assay to determine a well-
defined concentration of myriaporone 4 (4) that would inhibit S. cerevisiae 
proliferation showed that concentration up to and including 2 µM failed to have any 
effect. Moreover, deletion of the pleiotropic drug resistance membrane transport 
protein ( pdr5) in S. cerevisiae failed to alter the sensitivity of S. cerevisiae to 4, 
although the mutation did have a general growth-retarding effect. This indicates that 
the yeast is decreased sensitivity to myriaporone 4 (4) relative to that of mammalian 
cells is not due to more effective drug efflux. The antiproliferative activity appears to 
be restricted to eukaryotic organisms, in that simultaneous halo assay performed on E. 
coli did not produce any 4 growth inhibition zones (although E. coli was sensitive to 
the prokaryotic ribosome inhibitor, erythromycin). 
 
In order to identify those functional groups of myriaporone 4 (4) which might be 
most responsible for its potent biological activity, analogues 9a-b were synthesized by 
Taylor and co-workers (Figure 7). 
 
OH O
OHHO
OOH OH O
HO
OOH
O
9a 9b  
Figure 7 
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Given the evidence indicating a reversible interaction with its target, removal of 
the C8–C9 epoxide (9a) surprisingly had a profound effect on the activity of 
myriaporone 4, resulting in a 500- to 1000-fold decrease in activity. This unexpectedly 
showed that the epoxide is indeed important for activity. Replacement of the C4 
hydroxymethyl group with a methyl group (9b) had a similar effect on the activity. 
 
5. Synthetic approaches to the myriaporone 
 
There are many approximations to the synthesis of tedanolide-type macrolides in 
the literature that makes the synthesis of myriaporones easier. In this section and in 
following are summarized the different scientific groups efforts to construct the 
skeleton of both classes of marine natural products. Only the group of PharmaMar16 
and Taylor17 have completed the total synthesis of myriaporone 4 (4). 
 
The first synthetic approach was published by Taylor in 1998.23 In this work, 
Taylor described the synthesis of a common intermediate 11a to myriaporones (1 and 
4) and tedanolides (7 and 8) exploiting a zirconium allylation to generate the C16, C17 
anti stereochemical relationship from aldehyde 10 (Scheme 1). However, with this 
reaction it was impossible to find the conditions to provide both high aldehyde facial 
stereoselectivity and the desired anti relative stereochemistry, and mixtures of 11a  and 
11b were obtained. 
 
                                                 
23  Taylor, R. E.; Ciavarri, J. P.; Hearn, B. R. Tetrahedron Lett. 1998, 39, 9361-9364. 
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Scheme 1 
 
In a later work based on the sythesis of myriaporone 1 (1) , Taylor24 solved this 
problem using an Evans oxazolidinone 12 as external chiral auxiliary, which provided 
the desired aldol adduct 15 (Scheme 2). 
PMBO
CHO
10
O
PMBO 17
13
O
16
OH
Xc
N
O
O O
Et3N, Bu2BOTf
CH2Cl2, −78 ºC
78%
1. TBSOTf; 85%
2. LiBH4
3. Ac2O
> 59% 2 steps
12
PMBO
14
O
OTBS
OAc
OsO4, NaIO4
91%
PMBO
15
O
O
OTBS
OAc
 
Scheme 2 
                                                 
24  Taylor, R. E.; Hearn, B. R.; Ciavarri, J. P. Org. Lett. 2002, 4, 2953-2955.  
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In this same work, Taylor and co-workers24 completed the skeleton of 
myriaporone 1 (1) by a stereoselective homoallenylboration25 and a regio- and 
chemoselective nitrile oxide cycloaddition26 (Scheme 3). 
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17
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O
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O N
 
Scheme 3 
Exposure of isoxazoline 17 to a Raney Ni hydrogenation in the presence of boric 
acid provided hydroxyketone 18 (Scheme 4). The TMS ether was selectively removed 
by treatment with TBAF at low temperature followed by selective protection of C13 
hydroxyl and Dess-Martin oxidation27 to give 19 Attempted deprotection of the silyl 
ethers of advanced intermediate 19 led to decompotition, therefore, myriaporone 1 (1) 
could not be achieved by this route. 
                                                 
25  Soundararajan, R.; LI, G.; Brown, H. C. J. Org. Chem. 1996, 61, 100-104. 
26  For recent work exploiting nitrile oxide cycloadditions as an alternative to aldol chemistry see: 
(a) Bode, J. W.; Carreira, E. M. J. Org. Chem. 2001, 66, 6410-6424. (b) McGarvey, G. J.; 
Mathys, J. A.; Wilson, K. J. Tetrahedron Lett. 2000, 41, 4151-4155. 
27  Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155-4156. 
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5.1. The total synthesis of myriaporone by PharmaMar 
 
The retrosynthetic approach followed by PharmaMar is outlined in Scheme 5.28 
 
                                                 
28  Pérez, M.; del Pozo, C.; Reyes, F.; Rodríguez, A.; Francesch, A.; Echavarren, A. M.; Cuevas, C. 
Angew. Chem. Int. Ed. 2004, 43, 1724-1727. 
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Scheme 5 
 
The introduccion of the ethyl side chain and the Z alkene from Weinreb amide 
20, itself available by aldol reaction between 21 and 22 was planned. For the key of 
stereoselective C-C bond formation, this group relied on an Evans aldol reaction29 
between chiral oxazolidinone 23 and aldehyde 24.30 To avoid epimerization and retro-
aldolization, oxidation of the keto group at C7 was postponed until the final steps of the 
synthesis. 
 
Aldehyde 24 was prepared from 25 (Scheme 6), readily available in nine steps 
from methyl (S)-(+)-3-hydroxy-2-methylpropionate by the procedure described by 
Roush and Lane.31 Protection of the primary alcohol of 25 as a TBS ether and oxidative 
cleavage of the olefin furnished aldehyde 26. Reaction of the boron enolate of chiral 
crotonate imide 23 with 26 furnished aldol 27 with excellent diastereoselectivity 
                                                 
29  Evans, D. A.; Sjogren, E. B.; Bartroli, J.; Dow, R. L. Tetrahedron Lett. 1986, 27, 4957-4960. 
30  Evans, D. A.; Chapman, K. T.; Bisaha, J. J. Am. Chem. Soc. 1984, 106, 4261-4263. 
31  Roush, W. R.; Lane, G. C. Org. Lett. 1999, 1, 95-98. 
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(>99:1). Reduction of the acyl oxazolidinone and oxidative protection as TBS ether. 
Cleavage of the terminal double bond provided 21 with a 41% overall yield from 25. 
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90%
2. O3, Ph3P; 70%
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N
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Bu2BOTf, Et3N
CH2Cl2−78 ºC→ −30 ºC
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PMBO
O
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O
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OH
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O
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O
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PMBO
O
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O
28
OH
TBS
OH
1. TBSCl, imidazol;
92%
2. O3, Ph3P; 82%
PMBO
O
TBSO
O
OH
TBS
OTBS
O
21  
Scheme 6 
 
Aldol reaction between aldehyde 21 and Weinreb acetamide 22 proceeded readily 
in the presence of LDA to give 29a y 29b in good yield but with low stereoselectivity 
(1:2.5) (Scheme 7). The use of sodium or potassium enolates of 22 furnished almost 
exclusively anti 29b. 
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Selective protection of the less hindered secondary alcohol of 29a as TBS ether, 
followed by oxidation of C7 hydroxyl group and oxidative removal of the PMB group 
with DDQ, gave 30. The Z olefin was then constructed by a Wittig reaction giving 31. 
Ethyl ketone 32 was then obtained by addition of ethylmagnesium bromide to the 
Weinreb amide 31 (Scheme 8). 
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Scheme 8 
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Global deprotection of the silyl ethers with TBAF/HOAc in DMF gave 
myriaporone 3 (3) and myriaporone 4 (4). The myriaporones 3-4 undergo partial 
dehydration on silica gel. Accordingly, acetylation of the crude dehydration products 
obtained after column chromatography of 3-4 gave myriaporone 1 (1) in a 35% yield 
over two steps (Scheme 9). 
 
O
TBSO
O
O
TBS
OTBS
O O
TBS
32
TBAF,
HOAc
DMF;
35%
4
OH O
OHHO
OOH
O
OH O
OHO
OH
O
OH
Et
3  
Scheme 9 
 
5.2. The total synthesis of myriaporone by Taylor 
 
Following the same strategy for the completion of myriaporone 1 previously 
reported by the group of Taylor23,24(see Schemes 1-4 of this section) Scheme 2. 
Construction of myriaporone 4 (4) began with known alcohol 33 (Scheme 10).17 
Oxidation with IBX followed by an Evans aldol reaction gave 35. 
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Scheme 10 
 Aldol 35 was converted into bis-TBSether 36 by protection, reductive cleavage 
of the chiral auxiliary, and a second protection step. Oxidative cleavage of the terminal 
olefin was followed by a second Evans aldol reaction with oxazolidinone 37 reaction to 
provide 38 in excellent yield. The chiral auxiliary was removed reductively and the 
primary alcohol was protected with TBSCl to provided 38 (Scheme 11). 
 
1. TBSOTf; 85%
2. LiBH4
3. TBSCl
> 8% 2 steps
PMBO
36
OTBS
OTBS
35
N
O
O O
37
1. OsO4, NMO, 95%
2. NaIO4, 84%
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CH2Cl2, -78 ºC
99%
PMBO
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TBSO XcO
OH
1. LiBH4
2. TBSCl
92% 2 steps
PMBO
39
TBSO
TBSO OTBS
OH
38  
Scheme 11 
Regioselective nitrile oxide cycloadition led to the formation of isoxazoline 40 as 
an inseparable mixture of diastereomers. Removal of the PMB protecting group was 
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followed by oxidation to the aldehyde and olefination to give 41a and 41b (Scheme 
12). 
39
PrNO2
PhNCO
64%
PMBO
40 1:1 mixture of
diastereomers
TBSO
TBSO OTBS
OH O N
1. DDQ, 88%
2. IBX
3. Ph3PCHCH3
63% 2 steps
PMBO
TBSO
TBSO OTBS
OH O N
PMBO
TBSO
TBSO OTBS
OH O N
41a 41b  
Scheme 12 
The less polar diastereomer, 41a, was converted into myriaporones 3 and 4 (3-4) 
by the sequence outlined in Scheme 13. DMP was used to oxidize the secondary 
hydroxy group to the corresponding ketone. Subsequent global silyl deprotection and 
reprotection provided 42a. Reduction of the isoxazoline group with Mo(CO)6 and 
epoxidation gave 43a. Finally, deprotection of the primary alcohols with 
tris(dimethylamino)sulfur (trimethylsilyl)difluoride (TAS-F) resulted in the formation 
of myriaporone 4 (4) as an equilibrium mixture with myriaporone 3 (3) (Scheme 13). 
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Scheme 13 
 
The use of acetate protecting groups instead of TBS ethers led to an unexpected 
reaction (Scheme 14). An attempted mild deprotection of 43a induced selective 
elimination to form myriaporone 1. 
43a
KCN, 66%
PMBO
HO
AcO
O OOH
1  
Scheme 14 
 
6. Synthesis of C10-C23 region of tedanolide 
 
In this section we summarize the synthesis of tedanolide (5) with a focuse on the 
C10-C23 region, which is similar to the myriaporone 4 (4) (Figure 8) 
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The synthesis reported by Taylor23,24 explained in the previous section (see 
Schemes 1-2) is one of the more interesting approaches for C10-C23 tedanolide 
fragment. The commomn intermediate 11a for the synthesis of tedanolides (5-7) and 
myriaporones (1 and 4) is shown in Figure 9. 
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Loh et al.32 proposed a synthesis of this fragment using a boron-mediated aldol 
reaction as the key step to control the configuration of the new stereocenters. The 
retrosynthetic plan for this approach is shown in Scheme 15. 
 
                                                 
32  Loh, T.-P.; Feng, L.-H. Tetrahedron Lett. 2001, 42, 3223-3226. 
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Scheme 15 
 
Aldehyde 45 was synthesized from commercially available methyl (S)-3-
hydroxy-2-methylpropionate.33 With the two fragments, 45 and 46, a boron-mediated 
aldol reaction using Paterson’s conditions33 proceeded smoothly to give as a 9:1 
mixture of separable diastereomers, 47a (major) and 47b (minor) in 95% yield 
(Scheme 16). 
O
TBDPSO
OH
OTBS
OPMB
O
OTBS
OPMB
TBDPSO
CHO
45
46
O
TBDPSO
OH
OTBS
OPMB
47a
47b
Cy2BCl, Et3N
CH2Cl2
-78 ºC, 0 ºC
95%
 
                                                 
33  Paterson, I.; Tillyer, R. D. J. Org. Chem. 1993, 58, 4182-4184. 
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Scheme 16 
 
In the approach reported by Miyashita34 a higher diastereoselective synthesis of 
subunit C13-C23 (48) of tedanolide is described. The procedure involved two 
stereoselective epoxidations of regioisomeric trisubstituted double bonds and a 
stereospecific SN2’ methylation reaction of a trans-γ,δ-epoxy-cis-α,β-unsaturated ester 
as the key steps. The starting material of the synthesis is the ester 49 shown in Scheme 
17. 
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48 49  
Scheme 17 
 
The synthesis of fragment 50 by Yonemitsu et al.35 with the 3,4-dimethoxybenzyl 
protecting group (DMPM) results from the coupling of fragments C13-C17 (51) and 
C18-C21 (52) (Scheme 18). 
 
                                                 
34  Iwata, Y.; Tanino, K.; Miyashita, M. Org. Lett. 2005, 7, 2341-2344. 
35  (a) Matsushima, T.; Horita, K.; Nakajima, N.; Yonemitsu, O. Tetrahedron Lett. 1996, 37, 385-
388. (b) Matsushima, T.; Mori, M.; Nakajima, N.; Maeda, H.; Uenishi, J.; Yonemitsu, O. Chem. 
Pharm. Bull. 1998, 46, 1335-1336. 
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The key step for the synthesis tedanolide 5 carried out by Roush36 is a 
stereoselective methyl ketone aldol reaction of aldehyde 53 and ketone 54 (Scheme 
19). They chose to protect the C16 hydroxymethyl group of 53 as an allyl carbonate 
(Alloc) and the C1 acid of 54 as an allyl ester, to deprotect them simultaneously prior 
to macrolactonization. 
                                                 
36  (a) Roush, W. R.; Lane, G. C. Og. Lett. 1999, 1, 95-98. (b) Roush, W. R.; Palkowitz, A. D.; 
Ando, K. J. J. Am. Chem. Soc. 1991, 113, 1047-1049. 
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Scheme 19 
 
A recent synthesis of the C13-C23 segment of tedanolide was described by 
Kalesse37 making use of orthogonal protecting groups in the construction of the carbon 
skeleton of 55 (Scheme 20), allowing a selective deprotection of hydroxyl groups at the 
end. Kalesse decided to perform the epoxidation as one of the latest steps in the 
synthesis. Additionally, he protected the hydroxyl groups at C17 as a TBS ether and at 
C15 as a PMB ether, respectively. In order to find the optimal protecting group for the 
primary alcohol he established a route that could be used for introducing the MOM, 
MEM or SEM protecting groups. The correct choice of this protecting group is key for 
the success of the synthesis. 
 
                                                 
37  (a) Erlich, G.; Hassfeld, J.; Eggert, U. M Kalesse, M. J. Am. Chem. Soc. 2006, 128, 14038-
14039. (b) Kalesse, M.; Ehrlich, G. Synlett 2005, 4, 655-657. 
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7. Synthesis of the C10-C23 region of 1,3-deoxytedanolide 
 
There are also some works based on the synthesis of 1,3-deoxytedanolide 8. As in 
the previous section we comment briefly the synthesis of the C10-C23 region of this 
molecule (Figure 10). 
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Figure 10 
The synthetic plan for the synthesis of the (+)-13-deoxytedanolide (8) reported 
by Smith38 is outlined in Scheme 21. The group recently reported a convergent total 
synthesis of tedanolide 7, based in the same retrosynthetic plan.39 Which comprise a 
dithiane union followed by an Evans-Tischemko reaction. The oxirane ring was 
introduced at the end of the synthesis. 
 
                                                 
38  (a) Smith, A. B., III; Adams, C. M.; Lodise Barbosa, S. A.; Degnan, A. P. J. Am. Chem. Soc. 
2003, 125, 350-351. (b) Smith, A. B., III; Adams, C. M.; Lodise Barbosa, S. A.; Degnan, A. P. 
Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12042-12047. 
39  Smith, A. B., III; Lee, D. J. Am. Chem. Soc. 2007, 129, 10957-10962. 
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8. Aldol reactions with boron enolates. 
 
Aldol reaction is one of the best general methods for the stereocontrolled 
construction of C-C bonds.40 Therefore, the reaction has been studied in great detail. 
Among the many enolate types investigated, boron enolates have proved to be 
particulary interesting because their good reactivity and excellent stereoselectivity.41 
 
                                                 
40  (a) Evans, D. A.; Nelson, J. V.; Taber, T. R. Top. Stereochem. 1982, 13, 1-115. (b) Mukaiyama, 
T. Org. React. 1982, 28, 203-331. (c) Evans, D. A. Asymmetric Synthesis; Morrison, J. D., Ed.; 
Academic: New York, 1984; Vol. 3, pp. 1-110. (d) Heathcock, C. H. Asymmetric Synthesis; 
Morrison, J. D., Ed.; Academic: New York, 1984; Vol. 3, pp. 111-212. (e) Heathcock, C. H. 
Aldrichim. Acta 1990, 23, 99-111. (f) Comprehensive Organic Synthesis; Trost, B. M., Fleming, 
I., Winterfeldt, E., Eds.; Pergamon: Oxford, 1993; Vol. 2. (g) Franklin, A. S.; Paterson, I. 
Contemp. Org. Synth. 1994, 1, 317-338. (h) Braun, M. HoubenWeyl's Methods of Organic 
Chemistry, Stereoselective Synthesis; Helmchen, G., Hoffmann, R. W., Mulzer, J., Schaumann, 
E., Eds.; Georg Thieme: Stuttgart, 1996; Vol. 3, pp. 1603-1666, also pp. 1713-1735. 
41  Cowden, C. J.; Paterson, I. Org. React. 1997, 51, 1-200. 
Introduction 
 60
The stereoselectivity of the reaction has been accounted asuming that the aldol 
addition takes place through a cyclic chair-like transition state42,43 in which the boron 
atom bonded to the enolate and aldehyde oxygen atoms (Scheme 22). The 
comparatively short boron-oxygen bonds give rise to a compact arrangement which 
maximizes the stereoselectivity. In agreement with this mechanistic view, Z enol 
borinates give rise to syn aldols while E enolborinates are precursors of anti aldols. 
Therefore, controlling the E/Z configuration of the enolate good stereoselectivities are 
observed. 
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Scheme 22 
Several methodologies have been developed to achieve this stereochemical 
control. For instance, the stereoselective formation of syn aldols via Z enolates can be 
performed with boron triflate reagents L2BOTf (L = alkyl group) in the presence of a 
tertiary amine.44 
                                                 
42  Zimmerman, H. E.; Traxler, M. D. J. Am. Chem. Soc. 1957, 79, 1920-1923. 
43  For recent theoretical studies on boron aldol reactions, see: (a) Li, Y.; PaddonRow, M. N.; Houk, 
K. N. J. Org. Chem. 1990, 55, 481-493. (b) Bernardi, A.; Capelli, A. M.; Comotti, A.; Gennari, 
C.; Gardner, M.; Goodman, J. M.; Paterson, I. Tetrahedron 1991, 47, 3471-3484. (c) Vulpetti, 
A.; Bernardi, A.; Gennari, C.; Goodman, J. M.; Paterson, I. Tetrahedron 1993, 49, 685-696. 
44  Mukaiyama, T.; Inoue, T. Bull. Chem. Soc. Jpn. 1980, 53, 174-178. 
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The first studies on the effect of the substrate and the Lewis acid in the 
enolization under kinetic conditions of ethyl ketones with L2BOTf and DIPEA were 
described by Evans.45 The most important results are summarized in Scheme 23. 
 
R1
O
L2BOTf
DIPEA
-78 ºC, 0 ºC R
1
O
BL2
R1
O
BL2
 
Entry L R1 Z enolate E enolate 
1 n-Bu Et >97 <3 
2  iPr 45 55 
3  tBu 25 75 
4 c-C5H9 Et 82 18 
5  iPr 19 81 
Scheme 23 
The study showed that the steric hindrance of the L and R1 have a decisive 
importance in the selectivity of the enolization. With bulky L and R1, E enolates were 
selectively obtained (entries 3 and 5 of the table in Scheme 23). 
 
On the other hand, Brown et al. reported a study of enolizations of ethyl ketones 
with a wide range of Lewis acids of general formula L2BX46 (Scheme 24). In this 
study, Brown concluded that when X is a good leaving group, such as, -OTf, the Z 
enolate is formed, and when the leaving group is poor, such as –Cl, the E enolate is 
                                                 
45  Evans, D. A.; Vogel, E.; Nelson, J. V. J. Am. Chem. Soc, 1979, 101, 6120-6123. 
46  (a) Brown, H. C.; Dhar, R. K.; Bakshi, R. K.; Pandiajaran, P. K.; Singaram, B. J. Am. Chem. 
Soc. 1989, 111, 3441-3442. (b) Brown, H. C.; Dhar, R. K.; Ganesan, K.; Singaram B. J. Org, 
Chem. 1992, 57, 499-504. (c) Brown, H. C.; Dhar, R. K.; Ganesan, K.; Singaram B. J. Org, 
Chem. 1992, 57, 2716-2721. (d) Brown, H. C.; Dhar, R. K.; Ganesan, K.; Singaram, B. J. Org, 
Chem. 1992, 57, 3767-3772. (e) Brown, H. C.; Ganesan, K. J. Org, Chem. 1993, 58, 7162-7169. 
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favored. Whith less hindered L and bases, the preferred enolate has the E configuration. 
The E enolate is also favored in apolar solvents and at low concentration. 
 
R1
O L2BX
R23N
R1
O
BL2
L2BX
R23N
R1
O
BL2
Z- E-
Small R1
Small L
Good X
Large R2
Large R1
Large L
Poor X
Small R2  
Scheme 24 
Thus, Cy2BCl gives E enolates, whereas Bu2OTf leads to the formation of Z 
enolates (Scheme 25).47 
 
E-Z-
R1
O L2BX, R3N
R1
O
BL2
R1
O
BL2
 
Entry R1 X L R3N Z-  E- 
1 Et Cl Cy Et3N 21 79 
2 iBu Cl Cy Et3N 12 88 
3 iPr, Ph Cl Cy Et3N <3 >97 
4 Et OTf Bu DIPEA >97 <3 
5 iBu OTf Bu DIPEA >97 <3 
6 Ph OTf Bu DIPEA >99 <1 
Scheme 25 
                                                 
47  Evans, D. A.; Vogel, E.; Nelson, J. V. J. Am. Chem. Soc, 1979, 101, 6120-6123. 
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The E boron enolates react with aldehydes to give anti aldols. Thus, Evans29 
obtained E enolborinates with good diastereomeric ratios (Scheme 26). 
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Scheme 26 
Paterson48 also used the same conditions to obtain anti aldols with excellent 
diastereoselectivity with chiral ethyl ketones (Scheme 27) 
 
O
Cy2BCl
Et3N
O OH
dr = 97:3
BnO
CHO BnO
 
Scheme 27 
One of the first models to explain the stereoselectivity of the reactions with chiral 
enolborinates esters and tioesters was proposed by Corey.49 He established that tert-
buthylpropanoate enolate 60 obtained with diazaborilidine/Et3N (Scheme 28), reacts 
                                                 
48  Paterson, I.; Goodman, J. M.; Isaka, M. Tetrahedron Lett. 1989, 30, 7121-7124. 
49  Corey, E. J.; Kim, S. S. J. Am. Chem. Soc. 1990, 112, 4976-4977. 
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with aldehydes to give the corresponding anti aldols 61, which indicates that the 
reaction takes place via E enolates. Considering that these processes are not affected by 
solvent polarity, an E2 mechanism was proposed. 
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Scheme 28 
On the other hand, the enolization of S-phenylthiopropionate 62 with the same 
oxazaborolidine used before and diisopropyethylamine (DIPEA) as a base, gives syn 
aldols 65. In this case an E1-type mechanism was proposed (Scheme 29). Accordingly, 
the enolate is generated by the following steps. First, the Lewis acid-carbonyl complex 
suffers the loss of bromide promoted by sulfur atom. In a second step, deprotonation 
occurs with the bulky DIPEA. 
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Scheme 29 
These results are obtained in a polar solvent (e.g. CH2Cl2), but if the reaction is 
performed under apolar conditions (e.g. 1:2 toluene-hexane) and with less hindered 
bases (e.g. Et3N), the diastereoselectivity diminishes drastically because the polar 
intermediate is not favored. 
 
These mechanistic proposals also explain the results previously described by 
Brown for enolizations with L2BOTf, which evolves via an E1 mechanism because the 
triflate is a good leaving group, while L2BCl as Lewis acids favors an E2 mechanism. 
 
Paterson and Goodman proposed a mechanism supported by ab initio calculations 
to explain the formation of the complex between aldehydes and ketones with H2BF.50 
Accordingly to these calculation, the most stable conformation of the complex ketone-
BH2F is that in which the B-F bond eclipses the ketone C=O double bond (Figure 11). 
 
                                                 
50  Paterson, I.; Goodman, J. M. Tetrahedron Lett. 1992, 33, 7219-7222. 
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Figure 11 
 
For L2BCl it was concluded that if complex 66 (Scheme 30) is favored, the 
methyl group will be perpendicular to the carbonyl group and, with a less hindered 
amine, the abstraction of the H α to the carbonyl  will lead to the enolate with the E 
configuration. 
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Scheme 30 
For L2BOTf mediated reactions, it is the steric hindrance which determines the 
enolate geometry. Considering both possible complexes when the Lewis acid is 
coordinated to the carbonyl, the preferred enolate 68 is the one which results from the 
approach in which the base finds less steric hindrance (Scheme 31). 
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Scheme 31 
More recently other calculations on boron-mediated aldol reactions have been 
reported by the group of Marco and Carda.51 This group reported a study of 3-
pentanone enolization with triethylamine and several L2BCl Lewis acids, where L can 
be H, Me or iPr groups. They arrived to the same conclusion as Paterson and Goodman 
(Figure 12). 
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Figure 12 
This study established that for less bulky ligands (L) the Z enolates are favored 
while, for bulky ligands, E enolates are preferred. 
                                                 
51  Murga, J.; Falomir, E.; Carda, M.; Marco, J. A. Tetrahedron 2001, 57, 6239-6247. 
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Only two synthesis of 11 have been developed up to date, which proceed by a 
linear approach. Therefore, we set as a goal to accomplish a first convergent synthesis 
of 1 (figure 1). 
 
O
HO
OH O
OH
OH O
1  
Figure 1 
 
This modular approach would allow the obtention of new derivatives of 1 for their 
biological evaluation. With this purpose, and in collaboration with PharmaMar, we 
embarked in the total synthesis of 1 and derivatives. 
 
                                                 
1  (a) Hines, J.; Roy, M.; Cheng, H.; Agapakis, C. M.; Taylor, R.; Crews, C. M. Mol. Biosys. 2006, 
2, 371-379. (b) Fleming, K. N.; Taylor, R. E. Angew. Chem., Int. Ed. 2004, 43, 1728-1730. (c) 
Perez, M.; del Pozo, C.; Reyes, F.; Rodriguez, A.; Francesch, A.; Echavarren, A. M.; Cuevas, C. 
Angew. Chem., Int. Ed. 2004, 43, 1724-1727. (d) Perez, M.; del Pozo, C.; Francesch, A.; Cuevas, 
C. WO2004011458 A1. (e) Taylor, R. E.; Hearn, B. R.; Ciavarri, J. P. Org. Lett. 2002, 4, 2953-
2955. (f) Zheng, B.-Z.; Yamauchi, M.; Dei, H.; Yonemitsu, O. Chem & Pharm. Bull. 2000, 48, 
1761-1765. (g) Zheng, B.-Z.; Yamauchi, M.; Dei, H.; Kusaka, S.-I.; Matsui, K.; Yonemitsu, O. 
Tetrahedron. Lett 2000, 41, 6441-6445. (h) Taylor, R. E.; Hearn, B. R.; Ciavarri, J. P. 
Tetrahedron. Lett. 1998, 39, 9361-9364 
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1. Retrosynthetic analysis and strategies 
 
Our retrosynthetic plan designed to synthesize myriaporone 4 (1) is outlined in 
Scheme 1. 
O
HO
OH O
OH
OH O
R1 CHO
O
R2O
O
OHC
OR2
O O
2a: R1 = -CH=CHMe
2b: R1 = -CH2OPMB
2c: R1 = -CH2OTBDPS
3a: R2 = PMB
3b: R2 = TBS
4
1
 
Scheme 1 
 
The retrosynthesis hinges upon the three fold disconnection of 1 in two aldehydes 
(2a, 2b or 2c and 4) and a ketone (3a or 3b), which could be assembled using two 
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stereoselective aldol reactions,1 one with an anti2 relative stereochemistry and another 
syn.3 
 
For the construction of the left-hand aldehydes 2a-c, two different synthetic plans 
were devised (Scheme 2). On the one hand, for the synthesis of the a series, the Z-
double bond would be introduced in the early stages. On the other hand, in the b and c 
series a protected alcohol was used as an equivalent of the double bond, which would 
be built after the assembly of the fragments. We chose two different protections of the 
alcohol: the p-methoxybenzyl group (PMB) (allowing for chelation on the oxygen 
atom) and the bulkier, non-chelating tert-butyldiphenylsilyl group (TBDPS). 
 
R1 CHO
O
R1
OH
R1 CO2Et
R1 CHO R1 CO2Me CO2Me
HO
2a-c 5a-c 6a-c
7a-c 8a-c (+)-9
a: R1 = -CH=CHMe, b: R1 = -CH2OPMB and c: R1 = -CH2OTBDPS  
 
Scheme 2 
 
We focused on the allylic alcohol scaffold embedded on the structure of 2 so that 
it could be generated from 5 by an asymmetric epoxidation followed by a Swern 
oxidation4 to furnish the desired aldehyde. In turn, 5 derives from the α,β-unsaturated 
ester 6 resulting from the olefination of aldehyde 7, which could be obtained from the 
ester 8 by functional group interconversion. Esters 8b and 8c could derive from readily 
                                                 
1  (a) Reiser, O.; Mengel, A. Chem. Rev. 1999, 99, 1191.(b) Masamune, S.; Choy, W.; Petersen, J. 
S.; Sita, L. R. Angew. Chem. Int. Ed. Engl. 1985, 24, 1-76 
2 a) Walker, M. A.; Heathcock, C. H. J. Org. Chem. 1991, 56, 5747-5750. b) Raimundo, B. C.; 
Heathcock, C. H. Synlett 1995, 1213-1214. c) Wang, Y.-C.; Hung, A.-W.; Chang, C.-S.; Yan, 
T.-H. J. Org. Chem.1996, 61, 2038-2043. 
3 Abiko, A.; Liu, J.-F.; Masamune, S. J. Am. Chem. Soc. 1997, 119, 2586-2587. 
4  Mancuso, A.J.; Swern, D. Synthesis 1981, 165-185. 
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available Roche’s ester (+)-9 by simple protection with the appropriate reagents, 
whereas 8a would be achieved from this same ester by oxidation and Z-selective 
Wittig-type olefination. 
 
The carbonyl compounds 3a and 3b could be obtained from acetal 10. Acetal 10 
could be prepared from 11 by acetalization followed by reduction of the diester to the 
diol (Scheme 3). 
 
O
R2O OR2 HO OH
O O
MeO2C CO2Me
O
3a (R2= PMB)
3b (R2= TBS)
10 11
 
Scheme 3 
 
Finally, the right-hand aldehyde 4 posed less problems due to the minor level of 
complexity. We planned to prepare 4 by reduction of 12, which can be obtained from 
13 as shown in Scheme 4. 
 
O O
OHC
O O
MeO2C MeO2C
O
4 12 13  
Scheme 4 
 
The planned coupling of the fragments is outlined in Scheme 5. We decided to 
exploit the chiral information of the aldehyde 2, relying on a substrate controlled 
stereoselective aldol reaction. Then, the second aldol reaction between fragment 14 and 
aldehyde 4 would be again substrate controlled. Therefore, our synthetic plan hinged on 
the transmission of the stereochemical information of the aldehyde 2 to the 
myriaporone backbone via the coupled fragment 14. 
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2a: R1 = -CH=CHMe
2b: R1 = -CH2OPMB
2c: R1 = -CH2OTBDPS
R1
O
O O
OR2R2O
R3
1
14
R1 CHO
O
O
R2O OR2
3a (R2= PMB)
3b (R2= TBS)
O O
OHC
4
 
Scheme 5 
 
In summary, we designed our synthesis so that all the chiral information 
embedded in the myriaporone backbone emanates from the configuraton of aldehyde 2. 
Our plan, then, intended to avoid the use of other elements of chiral induction such as 
ligands or auxiliaries. 
 
2. Synthesis of central ketone 
 
2.1. Synthesis of ketone 3a 
 
We began the synthesis of ketone 3a using the methodology described by Reagan 
and Davenport.5 Dimethyl acetonedicarboxylate 11 was chosen as the starting material 
for the preparation of ketone 3a. The ethylene acetal 15 was prepared in a conventional 
manner6 ( 
Scheme 6), and the two ester groups were then reduced to primary alcohols using 
LiAlH4 to give diol 10 in good yield (85% in two steps). 
 
                                                 
5  (a) Davenport, R. J.; Regan, A. C. Tetrahedron Lett. 2000, 41, 7619-7622. (b) Yadav. J. S.; 
Bandyopadhyay, A.; Kunwar, A. C. Tetrahedron Lett. 2001, 42, 4907-4911. 
6  Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, Wiley-Interscience, 
New York, 1999, 308-322, 724-727. 
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MeO2C CO2Me
O
(CH2OH)2
p-TsOH
toluene
ref lux
16 h, 89%
MeO2C CO2Me
O O
LiAlH4
THF
40 ºC
4 h, 96%
O O
HO OH
11 15 10  
Scheme 6 
 
The next step was the protection of both hydroxyl groups of 10 as PMB ethers 
with NaH and PMBCl, to furnish compound 16 in good yield. Finally, the desired 
ketone 3a was obtained by hydrolysis of acetal 16 with aqueous HCl (Scheme 7). 
 
PMBCl, NaH
CH2Cl2
r.t.
16 h, 79%
O O
PMBO OPMB PMBO OPMB
O
HCl (5%)
THF
reflux
1 h, 96%
11
16 3a  
Scheme 7 
 
2.2. Synthesis of ketone 3b 
 
The synthesis of central ketone 3b was very similar to the p-methoxybenzyl 
protected one (3a, Scheme 6). We cleaved the acetal protecting group of 10 using 
Amberlyst-15 in MeOH-CH2Cl2 to give dihydroxyketone 17. Nevertheless, the yield 
was poor because the compound was very difficult to handle due to its water solubility. 
For that reason we decided to avoid the isolation of 17 and attempt to postpone the 
purification step until both hydroxyl groups would be protected (Scheme 8). 
 
O O
HO OH
10
HO OH
Amberlyst-15
MeOH-CH2Cl2
rt, 16 h
28 %
O
17  
Scheme 8 
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After much experimentation we found that the best procedure to obtain 17 was 
filtering the Amberlyst-15 resin off, concentrating the crude to dryness and directly 
submitting it to the protection reaction of the hydroxyl groups as TBS ethers.7 Ketone 
3b was obtained in 50% yield (2 steps) (Scheme 9). 
 
TBSO OTBS
O
TBSCl
imidazole
CH3CN
r.t., 16 h
3b
(58% 2 steps)
O O
HO OH
10
HO OH
Amberlyst-15
CH2Cl2-MeOH
rt, 16 h O
17
 
Scheme 9 
 
2.3. Alternative synthesis of ketone 3b 
 
Alternatively, while the improval of the synthesis described above was carried on, 
a new strategy was envisioned in which the key step was an ozonolysis. Thus, a Wittig 
reaction was performed between 11 and the commercially available phosphonium salt 
18 to give the alkene 19 in 72% yield (Scheme 10). 
 
MeO2C CO2Me
CO2Me
Ph3P
CO2Me
toluene
110 ºC
18 h, 72%
1918
MeO2C CO2Me
O
11  
Scheme 10 
 
The triester 19 was reduced to triol 20 using LiAlH4. Protection of the alcohols of 
20 as TBS ethers gave 21 in a 54% yield in three steps (Scheme 11). 
 
                                                 
7  Corey, E. J.; Venkateswarlu, A. J. Am. Chem. Soc. 1972, 94, 6190-6191. 
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19
LiAlH4
THF
0 ºC→ 40 ºC
4 h, 82%
20
OHHO
OH
TBSCl
imidazole
CH2Cl2
30 ºC, 91%
21
OTBSTBSO
OTBS
 
Scheme 11 
 
Finally, the ozonolysis of compound 21 was carried out at low temperature to 
afford the desired ketone 3b with 23% overall yield (Scheme 12). 
 
i. O3, CH2Cl2− 78 ºC, 10 min
ii. Me2S
30 ºC, 3 h
42%, 2 steps
O
OTBSTBSO
3b21
OTBSTBSO
OTBS
 
Scheme 12 
 
3. Synthesis of left side aldehydes 
 
3.1. Synthesis of aldehyde 2a 
 
As it has been shown in Scheme 2 of the retrosynthesis, our first effort in the 
synthesis of 2a was to introduce the Z-double bond directly after the oxidation of 
alcohol (+)-9 to aldehyde (Scheme 13). However this route failed, probably due to the 
lability of the intermediate β-aldehyde ester, so another path had to be developed. 
 
CO2Me
HO
(+)-9
CO2Me
 
Scheme 13 
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The new strategy started with the protection of the hydroxyl group of alcohol (+)-
9 as the PMB ether using the readily prepared PMB-TCA reagent.8 Subsequently, by 
reduction of the ester function in 8b with LiAlH4, alcohol 22 was obtained in 80% yield 
in two steps (Scheme 14). 
 
PMB-TCA
Et3N
CH2Cl2
rt
16 h, 98%
CO2Et
PMBO
LiAlH4
THF
reflux
1.5 h, 82%
PMBO OH(+)-9
8b 22  
Scheme 14 
 
A Swern oxidation9 of 22 and a Wittig olefination of the resulting aldehyde lead 
to the α,β-insaturated ester 6b (52% yield, 2 steps) (Scheme 15). 
 
PMBO OH
22
CHO
PMBO
Ph3P=C(CO2Et)Me
CH2Cl2
rt
16 h, 76%
PMBO
CO2Et
7b
6b
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 68%
 
Scheme 15 
 
Then, oxidative cleavage of the PMB protecting group was performed using 2,3-
dichloro-5,6-dicyano-p-benzoquinone (DDQ) in aqueous CH2Cl2 to give alcohol 23 
(Scheme 16), which was oxidized to aldehyde 24 following the Swern oxidation 
protocol (49% yield in two steps). 
 
                                                 
8  Patil, V. J. Tetrahedron Lett. 1996, 37, 1481-1484. 
9  (a) Mancuso, A. J.; Brownfain, D. S.; Swern, D. J. Org. Chem. 1979, 44, 4148-4150. (b) Omura, 
K.; Swern, D. Tetrahedron 1978, 38, 1651-1660. (c) Mancuso, A. J.; Huang, S.-L.; Swern, D. J 
Org. Chem. 1978, 43, 2480-2482. 
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DDQ
CH2Cl2:H2O
rt, 4.5 h
85%
HO
CO2Et
OHC CO2Et
6b
23
24
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 58%  
Scheme 16 
 
We planned to introduce the Z-double bond of 2a by a Wittig olefination. 
However, the reaction of 24 with the commercially available 
ethyltriphenylphosphonium bromide failed to yield the desired product (Scheme 17). 
Apparently compound 24 is as labile as the aldehyde derived from hydroxyester (+)-9 
(Scheme 13). 
 
Ph3PEtBr
BuLi
THF−78 ºC → rt
5 h
CO2Et
6a
OHC CO2Et
24
 
 
Scheme 17 
 
Alternatively we envisioned the possibility to introduce the Z-double bond in an 
earlier step. We started this new synthetic plan protecting alcohol 22 as acetate 
(Scheme 18).10 Subsequently, the PMB protecting group of 25 was cleaved using the 
oxidative procedure described in Scheme 16 furnishing 26, which was subjected to 
Wittig olefination to give 27 in 8% yield from 22 in four steps. The attempt to isolate 
the corresponding alcohol, once the acetate group of 27 was removed, failed due to its 
volatility. 
 
                                                 
10  Hoefle, G.; Steglich,W. Synthesis,1972, 619-621. 
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Ac2O, Et3N
DMAP, CH2Cl2
rt
6 h, 93%
PMBO OAc
25
PMBO OH
22
OHC
OAc
1. DDQ
CH2Cl2-H2O
rt, 56%
2. (COCl)2, Et3N
DMSO, CH2Cl2−78 ºC → rt
3 h, 72%
OAc
EtPPh3Br
BuLi, THF
21%
26 27
 
 
Scheme 18 
 
At this point of the synthesis, Kalesse reported the synthesis of the alkene 
derivative of 2a (Figure 1).11 
 
CHO 
Figure 1 
 
We followed the same strategy starting from the ester (−)-9 by protecting the 
hydroxyl function with the acid labile trityl group.12 Reduction with LiAlH4 provided 
alcohol 28 in 93% yield (Scheme 19). 
 
CO2Me
HO
1. TrCl, E3N
CH2Cl2, rt
2. LiAlH4
THF, 40 ºC
93%, 2 steps
TrO OH
(−)-9 28  
Scheme 19 
 
Subsequently a Swern oxidation was performed furnishing aldehyde 29 in 81% 
yield (Scheme 20). This step was also carried out by a Parikh-Doering oxidation,13 
                                                 
11  Hassfeld, J.; Kalesse, M. Synlett 2002, 2007-2010. 
12  (a) Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis. 2nd ed.; John Wiley 
& Sons: New York, 1999; 17–292. (b) Kocienski, P. J. Protecting Groups; Georg Thieme: New 
York, 1994; 21–117. 
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obtaining 29 in 78% yield. After an aqueous treatment, 29 was directly subjected to a 
Wittig olefination to form the desired Z-double bond. Alkene 30 was obtained as the 
major product of the reaction in 72% yield (95:5 Z/E). 
 
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 81%
OHC
OTr28
29
OTr
30
Ph3PEtBr
BuLi, THF, −78 ºC
89%
 
Scheme 20 
 
Removal of the trityl group using p-toluenesulfonic acid (p-TsOH) afford alcohol 
7a; which, by a sequence of Swern oxidation, Wittig olefination and reduction 
furnished the allylic alcohol 5a (Scheme 21). 
 
p-TsOH
MeOH, CH2Cl2
OH
7a 5a
30 OH
1. (COCl)2, Et3N
DMSO, CH2Cl2−78 ºC→ rt
3 h
2. Ph3P=C(CO2Et)Me
CH2Cl2, rt
16 h
3. DIBAL-H, THF−78 ºC
2 h
35%, 3 steps  
Scheme 21 
 
In this pathway we encountered problems handling alcohol 7a due to its volatility. 
To solve this problem we performed Swern oxidation and Wittig olefination without 
isolation aldehyde 7a. Nevertheless, we obtained sufficient amounts of 5a (35% from 
30) to proceed with the synthesis of the desired aldehyde 2a. 
 
Next we performed a Sharpless epoxidation14 of the allylic alcohol 5a to give the 
epoxyaldehyde 31 as a 10:1 mixture of diastereomers in favor of the desired one 
(Scheme 22). 
                                                                                                                                               
13  Parikh, J. P.; von Doering, W. E. J. Am. Chem. Soc. 1967, 89, 5505-5507. 
14  Katsuki, T.; Sharpless, B. J. Am. Chem. Soc. 1980, 102, 5974-5976. 
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Ti(O-iPr)4, TBHP
(−)-DET
CH2Cl2−78 ºC → rt
2.5 h, 45%
OH
O
31
CHO
O
2a
OH
5a
MnO2, THF
rt, 2 h
78%
 
Scheme 22 
 
Finally, the resulting epoxyalcohol 31 was oxidized with MnO2 to give the 
desired epoxyaldehyde 2a in an overall yield of 18% from (−)-9. It must be noted that 
for this oxidation step other procedures were successfully tested. Thus, the Swern and 
Parikh-Doering oxidations of 31 provided 2a with comparable results in all cases. 
 
3.2. Synthesis of aldehyde 2b 
 
Starting with the common intermediate 6b depicted in Scheme 2 and following a 
similar synthesis than the one proposed by Taylor15 and PharmaMar16 in their respective 
syntheses of myriaporone 4 (1), the desired aldehyde 2b was obtained. Ester 6b was 
reduced with diisobutyl aluminum hydride DIBAL-H to furnished alcohol 5b in 81% 
yield. Then, a Sharpless epoxidation over 5b led to 3217 as a 10:1 mixture of epoxides in 
72% yield. Finally, epoxyaldehyde 2b was obtained by the Swern oxidation of the 
corresponding alcohol 32 in 21% overall yield from (+)-9 (Scheme 23). 
                                                 
15  (a) Fleming, K. N.; Taylor, R. E. Angew. Chem. Int. Ed. 2004, 43, 1728-1730. (b) Taylor, R. E.; 
Hearn, B. R.; Ciavarri, J. P. Org. Lett. 2002, 4, 2953-2955. (c) Taylor, R. E.; Ciavarri, J. P.; 
Hearn, B. R. Tetrahedron Lett. 1998, 39, 9361-9364. 
16  Pérez, M.; del Pozo, C.; Reyes, F.; Rodríguez, A.; Francesch, A.; Echavarren, A. M.; Cuevas, C. 
Angew. Chem. Int. Ed. 2004, 43, 1724-1727. 
17  (a) Meyers, A. I., Hudspeth, J. P. Tetrahedron Lett. 1981, 22, 3925-3928. (b) Meyers, A. I., 
Babiak, K. A., Campbell, A. L., Comins, D. L., Fleming, M. P., Henning, R., Heuschmann, M., 
Hudspedth, J. P., Kane, J. M., Rider, P. J., Roland, D. M., Shimuzu, K., Tomioka, K., Walkup, 
R. D. J. Am. Chem. Soc. 1983, 105, 5015-5024. 
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PMBO OH
DIBAL-H
CH2Cl2
rt
3 h, 88%
5b
PMBO
CO2Et
6b
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 79%
PMBO OH
O
PMBO
CHO
O
Ti(O-iPr)4, TBHP
(−)-DET
CH2Cl2−78 ºC→ rt
2.5 h, 72% (10:1) 32
2b  
 
Scheme 23 
 
3.3. Synthesis of aldehyde 2c 
 
In order to establish the effect of the protecting group in the outcome of the aldol 
reaction, our strategy aimed for the introduction of different groups in the left side 
aldehyde. Thus, an analog of 2b in which the alcohol is protected as a tert-
butyldiphenylsilyl (TBDPS) group was prepared.  
 
The synthesis of aldehyde 2c followed a synthetic plan similar to the one devised 
for 2b. Starting with (+)-9, after protection of the alcohol as the TBDPS ether, 8c was 
obtained in quantitative yield. Reduction of the ester function of 8c to the alcohol 33 
was accomplished with DIBAL-H at 0 ºC (71%, Scheme 24). 
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CO2Et
TBDPSO
DIBAL-H
0 ºC, 71%
TBDPSO OH
8c
33
TBDPSCl
imidazole
rt, 98%CO2Me
HO
(-)-9
 
Scheme 24 
 
A Swern oxidation and a Wittig olefination were subsequently performed to give 
6c as detailed in Scheme 25. The α,β-unsaturated ester 6c was obtained in 59% yield 
from 33. 
 
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 77%
CHO
TBDPSO
Ph3P=C(CO2Et)Me
CH2Cl2
rt
16 h, 76%
TBDPSO
CO2Et
33
7c
6c  
Scheme 25 
 
Reduction of ester 6c with DIBAL-H afforded alcohol 5c which was subjected to 
Sharpless epoxidation yielding epoxyalcohol 34 as a 10:1 mixture, favoring the desired 
diastereomer. Finally, Swern oxidation of 34 furnished the desired aldehyde 2c in 28% 
yield (3 steps) (Scheme 26). 
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6c TBDPSO OH
TBDPSO OH
O
TBDPSO
CHO
O
DIBAL-H
CH2Cl2
0 ºC, 3 h
96%
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 69%
5c
34 2c
Ti(O-iPr)4, TBHP
(−)-DET
CH2Cl2−78 ºC → rt
2.5 h, 68% (10:1)
 
Scheme 26 
 
 
3.4. Synthesis of aldehyde 35  
 
We also synthesized new series of derivatives of left hand aldehydes without the 
oxirane ring. For the synthesis of these products we used the strategy reported by 
Kalesse et al.11 
 
From the intermediate 5a described above in Schemes 22 and 23, we obtained 35 
by the oxidation of the primary alcohol to the aldehyde as outlined in Scheme 27. The 
oxidation of 5a was performed using MnO2 furnishing aldehyde 35 in a 16% overall 
yield from (+)-9. 
 
CHO
MnO2, THF
rt, 1 h
89% 35
8 steps
18%
OH
5a
CO2Me
HO
(+)-9  
 
Scheme 27 
 
3.5. Synthesis of aldehyde 36 
 
The derivative of aldehyde 2b without the oxirane ring was also prepared starting 
from allylic alcohol 5b (Scheme 24), previously synthesized from (+)-9 (Schemes 14 
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and 15). Thus, the hydroxyl group of 5b was oxidized to aldehyde 36 by the Swern 
oxidation with an overall yield of 27% (six steps) (Scheme 28) 
 
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 75%
PMBO
CHO
(+)-9 5b
36
5 steps
36%
CO2Me
HO PMBO OH
 
Scheme 28 
 
3.6. Synthesis of aldehyde 37 
 
The analogue of 36 with a TBDPS protective group was also prepared. In this 
case, the previously synthesized allylic alcohol 5c (Schemes 26 and 27), was oxidized 
to give aldehyde 37 in good yield (27%, from (+)-9) (Scheme 29). 
 
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 68%
(+)-9
CO2Me
HO TBDPSO OH
5c
TBDPSO
CHO
37
5 steps
39 %
 
 
Scheme 29 
 
3.7. Synthesis of aldehyde 38 
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We also decided to prepare analogues of 1 with a cyclopropane ring instead of the 
oxirane.18 The strategy followed started with allylic alcohol 5b which was obtained 
from (+)-9 in 5 steps and with a 36% yield as shown in Scheme 14 and Scheme 15. 
Subsequently, using the protocol described by Simmons and Smith19 for asymmetric 
cyclopropanation, we introduced the cyclopropane ring in the molecule (Scheme 30). 
The cyclopropanation of 5b proceeded in 77% yield to yield a 2:1 mixture of 
diastereomers. 
 
PMBO OH PMBO
CHO
39 38
ZnEt2, CH2I2
CH2Cl2
−65 ºC, rt
77%(+)-9
CO2Me
HO PMBO OH
5b
5 steps
36 %
(COCl)2, Et3N
DMSO, CH2Cl2
−78 ºC→ rt
3 h, 79%  
Scheme 30 
 
We tried to improve the stereoselectivity of this reaction by using the 
methodology reported by Charette20 for asymmetric cyclopropanation of allylic 
alcohols. One of the most attractive features of this protocol is that high 
stereoselectivities are usually observed regardless of the substitution pattern of the 
olefin. 
 
For the synthesis of this dioxaborolane ligand 40, we followed the procedure 
described by Charette.20 This procedure starts with the reaction between butylboronic 
acid and diethanolamine to give 41 as a white solid in 89% yield. Subsequently, 41 
reacts with the amide of tartaric acid 42 to yield the desired dioxaborolane 40 with an 
overall yield of 83% (Scheme 31) 
                                                 
18  (a) Donaldson, W. A. Tetrahedron 2001, 57, 8589-8627. (b) Taylor, R. E.; Chen, Y.; Galvin, G. 
M.; Pabba, P. K. Org. Biomol. Chem. 2004, 2, 2127-2132. (c) Wessjohann, L. A.; Brandt, W. 
Chem. Rev. 2003, 103, 1625-1647. (d) Kim, S.-O. J. Nat. Pod. 1993, 56, 857-863. 
19  (a) Simmons, H. E.; Smith, R. D. J. Am. Chem. Soc. 1959, 81, 4256-4264. (b) Simmons, H. E.; 
Smith, R. D. J. Am. Chem. Soc., 1958, 80, 5323-5324. 
20  Lebel, H.; Marcoux, J.-F.; Molinaro, C.; Charette, A. B. Chem. Rev. 2003, 103, 977-1050. 
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BuB(OH)2
HO
N
H
OH
Et2O, CH2Cl2
4 Å ms
2 h, r.t.
89%
O B
N
O
Bu
H
41
OH
Me2NOC CONMe2
HO
42
NaCl, H2O
CH2Cl2
rt, 30 min
93%
O B
O
CONMe2
Me2NOC
Bu
40
41
 
Scheme 31 
 
Once 40 had been synthesized it was used in the cyclopropanation of intermediate 
5b to give 39 (Scheme 32). Despite the precedents reported in the literature when 
employing this strategy, the diastereoselectivity was low and comparable to that 
obtained before (Scheme 30) and the yield was even lower in this case (67% vs. 77%). 
 
PMBO OHPMBO OH
40, Et2Zn, CH2I2
DME−10 ºC, 20 min
67% (2:1)
5b 39  
Scheme 32 
 
3.8. Synthesis of aldehyde 43 
 
Following the same scheme described for the preparation of 5c (Scheme 24), the 
TBDPS protected aldehyde 43 was obtained (Scheme 33). Compound 5c was obtained 
in 39% yield in five steps from (+)-9. The Simmons-Smith cyclopropanation of the 
double bond of 44 was performed yielding a 2:1 mixture of diastereomers in favor of 
the desired one and in 58% yield. Finally, the Swern oxidation of the primary alcohol 
44 gave 43 in 17% overall yield (7 steps). 
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TBDPSO OH
5c
TBDPSO OH
TBDPSO
CHO
44
43
Et2Zn, CH2I2
CH2Cl2
58%, (2:1)
5 steps
39%CO2Me
HO
(+)-9
(COCl)2, Et3N
DMSO, CH2Cl2
−75 ºC→ rt
3 h, 79%
 
Scheme 33 
 
As in the former case no improvement in the stereoselectivity was achieved using 
Charette methodology, this method was not tested with the current substrate. 
 
4. Synthesis of the right side aldehyde 4 
 
For the preparation of this synthetic building block 4, a simple strategy was 
devised. Starting from the commercially available ketoester 13, protection of the ketone 
function was performed by reaction with ethyleneglycol in the presence of 
trimethylsilyl chloride (TMSCl), to afford acetal 12 quantitatively. Reduction of the 
ester 12 with LiAlH4 and the subsequent oxidation of the resulting alcohol to the 
aldehyde using the Swern reaction, furnished aldehyde 4 in 78% yield (2 steps). 
(Scheme 34). 
 
O
CO2Me
13
(CH2OH)2
TMSCl
CH2Cl2
reflux
48 h, 99%
CO2Me
12
OO
1. LiAlH4, THF
40 ºC,4 h
2. (COCl)2, Et3N
DMSO, CH2Cl2−78 ºC→ rt
3 h
78% (2 steps)
CHO
4
OO
 
Scheme 34 
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5. Model Aldol reactions 
 
We decided first to study some model reactions of the central ketones 3a and 3b 
with a variety of aldehydes. 
 
5.1. Model aldol reactions using ketone 3a 
 
We started using the lithium enolate of ketone 3a formed at −78 ºC with an in situ 
generated lithium diisopropyl amide (LDA) in a non protic solvent such as THF. 
Surprisingly, addition of benzaldehyde to the enolate of 3a failed to give any aldol 
product, recovering starting material. Performing the reaction at 0 ºC, no reaction was 
observed. The same negative result was obtained using isobutyraldehyde instead of 
benzaldehyde.  
 
We decided to explore two different methods to enolize ketone 3a. Both protocols 
take advantage of the π-facial diastereoselectivity in aldol reaction and consist in the 
use of boranes Bu2BOTf and Cy2BCl in the presence of an amine like DIPEA or Et3N 
(Scheme 35). 
 
O
PMBO OPMB aldehyde
L2BX, base
solvent
T, t
3a  
Scheme 35 
 
However, similar negative results were obtained with Bu2BOTf and 
diisopropylethylamine as the base in CH2Cl2 (−78 ºC or 0 ºC) and benzaldehyde or 
isobutyraldehyde. Reaction of 3a with Cy2BCl and Et3N in Et2O also failed to form an 
enolate of 3a reactive enough with these aldehydes. 
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5.2. Model aldol reactions using ketone 3b 
 
We tried the same reaction conditions for ketone 3b with benzaldehyde and 
isobutyraldehyde (Table 1). Using Bu2BOTf we recovered unchanged starting material 
in all the cases. With Cy2BCl and benzaldehyde no aldol product was obtained, but in 
the case of isobutyraldehyde (entry 6, Table 1), aldol 45 was obtained in 56% yield and 
in a 7:3 diastereomeric ratio (determined by GC/MS). The major aldol was assigned the 
anti configuration based on literature precedent for this type of boron enolates.21 
 
 
Table 1: Model aldol reaction using ketone 3b. 
L2BX, base
solvent
T, t
3b
RCHO
O
TBSO OTBS
R
OHO
TBSO OTBS
45: R = Me2CH  
Entry L2BX R Base Solvent 
T 
(ºC) 
t (h) 
Prod 
(%). 
1 Bu2BOTf Ph DIPEA CH2Cl2 −78 1 - 
2 Bu2BOTf Ph DIPEA CH2Cl2 0 16 - 
3 Bu2BOTf Me2CH DIPEA CH2Cl2 −78 1 - 
4 Cy2BCl Ph Et3N Et2O −78 1 - 
5 Cy2BCl Ph Et3N Et2O 0 16 - 
6 Cy2BCl Me2CH Et3N Et2O −78 1 45 (56) 
 
With these results we decided to follow the synthesis of myriaporone 1 using 
ketone 3b as the central key moiety. 
 
                                                 
21  (a) Paterson, I.; Goodman, J. M.; Isaka, M. Tetrahedron Lett. 1989, 30, 7121. (b) Paterson, I.; 
Norcross, R. D.; Ward, R. A.; Romea, P.; Lister, M. A. J. Am. Chem. Soc. 1994, 116, 11287-
11314. 
Results 
 96
The generality of this aldol reaction was studied with several commercially 
available aldehydes 46-56. These aldehydes were tested because their similarity with 
synthetic aldehydes 35-37 (Figure 2). 
 
CHO CHO
CHOCHO
CHO
CHO CHO
CHO
CHO
CHO
CHO
46 47 48 49
50 51 52 53
54 55 56
CHO
PMBO
CHO
35
TBDPSO
CHO
36 37  
 
Figure 2 
 
Optimizing the conditions in the aldol reaction between 3b and 46 (Scheme 39) 
by changing the temperature and the reaction time we obtained 45 in an 81% yield as a 
7:3 mixture of diastereomers (Scheme 36). 
 
Cy2BCl, Et3N
Et2O−78 ºC→ −20 ºC
16 h
81% ( 7:3 anti/syn)
O
OTBSTBSO
OH
3b 46 45
O
OTBSTBSO
CHO
 
 
Scheme 36 
 
Following the conditions of the reaction detailed in Scheme 40 for each aldehyde 
(46-56) of Figure 2 gave the results summarized in Figure 3. The diastereoselectivity of 
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each aldol adduct (45, 57-66) was determined by LC-MS and GC-MS. In each case, 
only the major diastereomer is shown. 
 
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
OH O
OTBSTBSO
81% (7:3) 45 75% 57 76% 58
56% (4:1) 59 63% (3:2) 60 74% (7:3) 61
47% (4:1) 62 80% (3:2) 63 65% (7:3) 64
78% (4:1) 65 43% (7:3) 66  
Figure 3 
 
With aldehydes 45-56 good results were obtained and the observed 
diastereoselectivities were of the same order as those described by Paterson22 with this 
kind of substrates. In the case of aldols 57 and 58 the reaction mixture was more 
complex because of the presence of an additional stereocenter. We did not determine 
the ratio of four diastereomers in these cases. 
 
We did some optimization experiments using aldehyde 51 in different solvents 
and temperatures (Table 2). 
 
Table 2: Aldol reaction between ketone 3b and aldehyde 51. 
                                                 
22  Paterson, I.; Gibson, K. R.; Oballa, R. M. Tetrahedron Lett. 1996, 37, 8585-8588. 
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CHO
O
OTBSTBSO Cy2BCl, Et3N
Solvent
T, 18 h O
OTBSTBSO
OH
653b51  
Entry Solvent T (ºC) Yield (%) dr (anti:syn) 
1 Et2O −78 → −20 78 4:1 
2 Et2O −78 20 9:1 
3 Et2O −78 → 0 79 1:1 
4 pentane −78 → −20 21 9:1 
5 hexane −78 → −20 15 4:1 
 
When the reaction was performed at −78 ºC (Table 2, entry 2) the 
diastereoselectivity improved (9:1 anti/syn), although the yield was low. On the other 
hand, warming the reaction up to 0 ºC led to a nonstereoselectivity aldol reaction (Table 
2, entry 4). 
 
Before continuing with the synthesis of myriaporone 1 we also tried the use of L-
proline as catalyst in the reaction between ketone 3b and aldehydes 36 and 37 using the 
procedure described by List et al.23 However we only recovered unchanged starting 
materials under the conditions examined (Scheme 37). 
 
R1O
CHO
L-proline
DMSO
36 (R1 = PMB)
37 (R1 = TBDPS)
O
OTBSTBSO
3b
 
Scheme 37 
 
 
 
                                                 
23  List, B.; Lerner, R. A.; Barbas III, C. F. J. Am. Chem. Soc. 2000, 122, 2395-2396. 
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6. First aldol reaction 
 
6.1. First aldol reaction with ketone 3b and aldehydes 2a-c 
 
Loh and Feng24 reported an anti-aldol reaction for the synthesis of tedanolide 
already described in the introduction using Paterson’s conditions.25 We performed the 
reaction between 2b and 3b at −20 ºC This reaction afforded tetrahydropyran derivative 
67 as a single diastereomer in 78% yield (Scheme 38). It must be noted that in the 
reaction of the boron enolate of 3b with aldehydes 2a and 2c only unchanged starting 
materials were recovered. 
 
O
OTBSTBSO
3b
O
HO
TBSO
OPMB
Cy2BCl, Et3N
Et2O−78 ºC→ −20 ºC
16 h, 72%
2b 67
HOPMBO CHO
O
OTBS
 
Scheme 38 
 
The structure of 67 was determined by NMR methods. In Figure 4 are depicted 
the 1H NOE of the representative cross peaks observed. 
 
O
OTBS
OH
Me
H
HO
TBSO
H
OPMB
Me
H
H H
 
Figure 4 
 
                                                 
24  Loh, T.-P.; Feng, L.-H. Tetrahedron Lett. 2001, 42, 3223-3226. 
25  Paterson, I.; Tillyer, R. D. J. Org. Chem. 1993, 58, 4182-4184. 
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The result of Scheme 38 shows that in the initial aldol 68 undergoes a 6-endo-tet 
cyclization via the enolate 69 to form cyclic 67, as it is shown in Scheme 39. 
 
Cy2BCl, Et3N
Et2O
-78 ºC→ -20 ºC
16 h
PMBO
O
O- Et3NH
+
TBSO
OH
PMBO
CH2OH2O
O
OTBSTBSO
2b 3b
PMBO
O
O
OTBSTBSO
OH
Et3N
68 69
OTBS
O
HO
TBSO
OPMB
67
HO
OTBS
 
Scheme 39 
 
With this result we decided to change the synthesis introducing the epoxide at the 
end of the process. 
 
6.2. First aldol reaction with ketone 3b and aldehydes 35-37 
 
Using the conditions described in Scheme 40, we performed the aldol reaction 
between the three unsaturated aldehydes 35-37 and ketone 3b. The reactions were 
performed under the same conditions and the final aldols 70-72 were obtained as 7:3 
mixture of diastereomers (Table 3). 
 
Table 3: Aldol reaction between ketone 3b and aldehydes 35-37. 
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CHOR1
Cy2BCl, Et3N
Et2O−78 ºC → −20 ºC
16 h
(7:3 ant i/syn)
R1
O
TBSO OTBS
OH
3b 35-37 70-72
O
TBSO OTBS
 
Entry Aldehyde R1 Aldol Yield (%) dr (anti:syn) 
1 35 (Z) -CH=CHMe 70 72 7:3 
2 36 -CH2OPMB 71 81 7:3 
3 37 -CH2TBDPS 72 89 7:3 
 
Using aldehyde 35, aldol 70 was obtained in 72% yield (Table 3, entry 1). Aldols 
71 and 72 were obtained in better yields (Table 3, entries 2 and 3) and the syntheses of 
36 and 37 were easier to reproduce in consistent yields than that of 35. Therefore we 
continued the synthesis of 1 using these two aldehydes instead of 35.  
 
After performing the left aldol reaction, to continue with the synthesis of 
myriaporone 1 was necessary to protect the new hydroxyl group generated. For the 
protection as TBS ether of hydroxyl groups in 71 and 72 we used t-butyldimethylsilyl 
triflate (TBSOTf) and 2,6-lutidine in CH2Cl2 at room temperature for 16 h.26 The 
protected ethers 73-74 was obtained in excellent yield (Scheme 40). 
 
RO
O
TBSO OTBS
OH
71 R= PMB
72 R= TBDPS
TBSOTf
2,6-lutidine
CH2Cl2
rt, 16 h
RO
O
TBSO OTBS
TBSO
73 R= PMB, 98%
74 R= TBDPS, 96%  
Scheme 40 
 
 
 
 
                                                 
26  Corey, E. J.; Rücker, H. C.; Hua, D. H. Tetrahedron Lett. 1981, 22, 3455-3458. 
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7. Second aldol reaction 
 
For the next C-C bond formation we needed a syn aldol reaction. This relative 
configuration can be achieved using Bu2BOTf with DIPEA as base in CH2Cl2.27 
 
We tried this conditions between the TBS protected the aldols 73 and 74 and the 
aldehyde 4 (Scheme 41). Unfortunately, the unaltered starting materials were recovered 
in both cases. After trying the same reaction allowing it to reach room temperature and 
increasing the reaction time, only traces of aldols were observed. 
 
RO
O
TBSO OTBS
TBSO
Bu2BOTf, DIPEA
CH2Cl2−78 ºC → 0 ºC
3 h73: R= PMB
74: R= TBDPS
4
CHO
OO
 
Scheme 41 
 
To find the experimented conditions for this reaction, we decided to use 
derivative 75 as model, which was prepared by silylation of aldol 65 (Scheme 42). 
 
O
TBSO OTBS
HO O
TBSO OTBS
TBSO
TBSOTf
2,6-lutidine
CH2Cl2
rt, 16 h
97%
65 75  
Scheme 42 
 
However, as before, ketone 75 failed to give the desired aldol by reaction with 
aldehyde 4 using Bu2BOTf and DIPEA. 
 
                                                 
27  Brown, H. C.; Dhar, R. K. Bakshi, R. K. Pandiarajan, P. K.; Singaram, B. J. Am. Chem. Soc. 
1989, 111, 3441-3442. 
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The use of TiCl4 and DIPEA has been described as a method for the formation of 
syn aldol products.28 However, with 73 and 74 we only obtained the starting materials 
using these conditions. No positive results were obtained at temperatures higher than 
−78 ºC or using Et3N as the base. 
 
We decided then to introduce some modifications in the molecule in order to 
avoid a possible steric hindrance. We tried a different approach. Thus, we tried to 
change the order aldol reactions introducing the right side aldehyde first. Additionally, 
we decided to try a lees hindered ketone such as 3-pentanone instead ketone 3b. 
 
8. From the right side to the left side of the molecule 
 
Retrosynthetic plan for the change in the order aldol reactions is summarized in 
Scheme 43. After an aldol reaction between ketone 3b and aldehyde 4 and protection of 
the hydroxyl group, the resulting adduct 77 would react with aldehydes 36-37 to give 
76 which, after a deprotection and epoxidation yield 1. 
 
HO OH
OOH OOH
O
1
TBSO OTBS
O
RO
O OO
TBS
TBSO OTBS
O
CHO
RO
O OO
TBS
36 R= PMB
37 R= TBDPS
3b 4
O
OTBSTBSO
CHO
OO
76
77
TBS
 
                                                 
28 Evans, D. A.; Rieger, D. L.; Bilodeau, M T.; Urpi, F. J. Am. Chem. Soc. 1991, 113, 1047-1049. 
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Scheme 43 
 
The first aldol reaction was tried with aldehyde 4 and ketone 3b, with Bu2BOTf 
and DIPEA to give the syn relative stereochemistry. However, under these conditions, 
the starting materials were recovered. When the reaction was performed via the Ti (IV) 
enolate, we obtained the desired aldol unit 78 (Scheme 44) in 68% yield as a >95:5 
syn:anti diastereomeric ratio. 
 
3b 4
O
OTBSTBSO
CHO
OO
TiCl4, DIPEA
CH2Cl2−78 ºC,1.5 h
68%
(>95:5 syn/ant i)
O
TBSO OTBS
O OHO
78  
Scheme 44 
 
The generated hydroxyl function of 78 was protected as the TBS ether under the 
standard conditions giving 79 in 97% yield (Scheme 45). 
 
TBSOTf,
2,6-lutidine
CH2Cl2
rt, 16 h
97%
O
TBSO OTBS
O OO
TBS
78
79  
Scheme 45 
 
For the next aldol reaction, we tried the reaction between 79 and aldehydes 36 and 
37. However using Cy2BCl and Et3N in Et2O, ketone 79 failed to give the expected 
product. Similarly negative was the reaction between ketone 79 and aldehyde 51. 
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9. Synthesis of bis-deoxymyriaporone. Aldol reaction using 
3-pentanone 
 
In Scheme 46 is shown the retrosynthesis for the synthesis of deoxymyriaporone 
81 in which the central ketone 3b has been replaced by 3-pentanone (80).  
 
O
OH O OH O
RO
CHO
O
OHC
O O
4
36: R= PMB
37: R= TBDPS
RO
OH O
PMBO
OH O OH O
83: R = PMB
84: R = TBDPS
80
81 82
 
Scheme 46 
 
The results for the first aldol reaction with 3-pentanone 80 were satisfactory. 
Thus, reaction of 80 with 36 and 37 proceeded in yields very similar to the ones 
obtained in the aldols reactions with ketone 3b. In this case, a ca. 1:1 mixture of 
diastereomers 83/83’ and 84/84’ were obtained (Scheme 47). 
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CHO
R
O
R
OOH
36: R = PMBO
37: R = TBDPS
83: R = PMBO
84: R = TBDPS
80 R
OOH
83': R = PMBO
84': R = TBDPS
Cy2BCl, Et3N
CH2Cl2−78 ºC→ −20 ºC
 
Aldehyde Products Yield (%) 
36 83/83’ 91 
37 84/84’ 98 
 
Scheme 47 
 
We continued the synthesis with the mixture of both diastereomers 83/83’ and 
84/84’, which could not be separated by chromatography. Here after, we will depict 
these mixture of diastereomers. 
 
Before the second aldol reaction, the hydroxyl group of the aldols 83 and 84 was 
protected as usual with TBSOTf and 2,6-lutidine in CH2Cl2. The protected aldols 85 
and 86 were obtained in excellent yields (Scheme 48). 
 
RO
OOH
83: R= PMB
84: R= TBDPS
TBSOTf
2,6-lutidine
CH2Cl2
rt, 16 h
RO
OTBSO
85: R= PMB, 98%
86: R= TBDPS, 99%  
Scheme 48 
 
For the second aldol reaction we tested the conditions with Bu2BOTf and 
diisopropylethylamine in CH2Cl2 (Scheme 49). However, with this less hindered ketone 
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the second aldol also failed. We also tried the reaction with TiCl4 but, again, we just 
recovered the starting materials. 
 
RO
OTBSO
85: R= PMB
86: R= TBDPS
Bu2BOTf, DIPEA
CH2Cl2−78 ºC → 0 ºC
3.5 h
 
Scheme 49 
 
10. From the right side to the left side using 3-pentanone 
 
Finally, we decided to do both changes at the same time, to use 3-pentanone 
instead of ketone 3b and change the order to perform the aldol reactions. The details of 
the retrosynthesis are summarized in Scheme 50. 
 
OOH OOH
O O
RO
O OO
TBS
O CHO
ROO OO
TBS
O
OHC
O O
4
36: R = PMB
37: R = TBDPS
80
87
81 82a: R = PMB
82b: R = TBDPS
TBS
 
Scheme 50 
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For the aldol reaction between 3-pentanone 80 and aldehyde 4 we tried first the 
usual conditions, Bu2BOTf and DIPEA in CH2CL2 at 0 ºC over 3 h. Unfortunately, 
aldol 87 was not obtained and we recovered the starting materials. On the other hand, 
after changing reaction time, temperature, concentration, and the base, without 
satisfactory results, we decided to try the previous tested conditions using TiCl4 
(Scheme 51). In this case, the aldol was obtained but the acetal suffered cleavaged 
during the work up, yielding diketone 88 in 77% yield. With 88 we could not perform a 
regioselective second aldol reaction with aldehydes 35-37. 
 
Bu2BOTf, DIPEA
CH2Cl2−78 ºC, 0ºC
3.5 h480
480
TiCl4, DIPEA
CH2Cl2−78 ºC,1.5 h
77%
O HO O
88
O
CHO
OO
 
Scheme 51 
 
As expected, reaction between 80 and 4 with Cy2BCl/Et3N afforded anti aldol 89 
(Scheme 52). In this case, the acetal function was not cleavaged. Even though 89 has 
not the desired relative configuration, we decided to try the next aldol reaction with 
intermediate 89. 
 
480
O HO O O
Cy2BCl, Et3N
Et2O−78 ºC, −20 ºC
18 h, 71%
89  
Scheme 52 
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Protection of the hydroxyl group of 89 with TBSOTf gave 90 in 85% yield 
(Scheme 53). All attempts of performing aldol reactions between ketone 90 and 
aldehydes 36 and 37 using Cy2BCl/Et3N failed. 
 
O HO O O
89
TBSOTf
2,6-lutidine
CH2Cl2
85%
O O O O
TBS
90  
Scheme 53 
 
11. Synthesis of cyclopropyl-myryaporone analogues 
 
For the synthesis of the cyclopropyl analogues, we chose the best conditions 
found in the assays previously performed with several simple aldehydes. Therefore, 
reaction of ketone 3b and aldehyde 38 with Cy2BCl/Et3N afforded aldol 91 in 61% 
yield (Scheme 54). However, the reaction between 3b and the TBDPS protected 
aldehyde 43 under the same conditions, gave the unchanged starting materials. 
 
PMBO
CHO
38
O
OTBSTBSO
Cy2BCl, Et3N
CH2Cl2−78 ºC, −20 ºC
16 h, 61%
3b
PMBO
O
TBSO OTBS
OH
91
 
Scheme 54 
 No reaction was observed between 91 and aldehyde 4 after several attempts 
under all the condition tested for this reaction. 
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12. Activity assays 
 
In Figure 5 are shown the intermediates synthesized during this work (2a, 92-95) 
for the synthesis of 1 that were tested for biological activity in PharmaMar. 
 
O
HO OH
OH
HO
O
HO OH
OH
HO
O
HO OH
OH
CHO
O
2a 92
93 94 95
O
HO
HO
OH
HO
OH
 
Figure 5 
 
The activity of some pentanone derivatives intermediates (88-89, 96) was also 
measured (Figure 6). All these compounds were tested in mammalian and colon cancer 
cells. Noone of these compounds have activity for these therapeutic applications.  
 
HO
OOH
O HO O OO HO O
96
88 89
 
Figure 6 
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We concluded in agreement with the structure-activity studies done by Taylor29 
and PharmaMar, that the presence of the oxirane ring and the Z-double bond is 
necessary for the biological activity 
                                                 
29  Hines, J.; Roy, M.; Cheng, C.; Agapakis, C. M.; Taylor, R. E.; Crews, C. M. Mol. Biosyst., 2006, 
2, 371-379. 
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• We have prepared fragments 2a-b, 3a-b, 4 and 35-37 for the convergent 
synthesis of myriaporone 4. 
R1 CHO
35: R1 = -CH=CHMe
36: R1 = -CH2OPMB
37: R1 = -CH2OTBDPS
R1 CHO
O
R2O
O
OHC
OR2
O O
2a: R1 = -CH=CHMe
2b: R1 = -CH2OPMB
2c: R1 = -CH2OTBDPS
3a: R2= PMB
3b: R2= TBS
4
 
 
• We have also prepared cyclopropyl aldehydes 38 and 43 by the cyclopanation of 
the α,β-unsaturated aldehydes using the procedure described by Simmons and 
Smith. Using the conditions described by Charette we have not obtained better 
diastereoselectivities. 
38: R1 = -CH2OPMB
43: R1 = -CH2OTBDPS
R1 CHO
 
 
• The aldol reaction of ketone 3b takes place with different aldehydes using 
Cy2BCl and Et3N to obtain aldols 70-72, 91 with an anti relative configuration 
and TiCl4 and DIPEA to obtain aldol 79 with a syn relative configuration. 
O
TBSO OTBS
O OO
TBS
79
R1
O
TBSO OTBS
OH
70-72
PMBO
O
TBSO OTBS
OH
91  
 
• The reaction between aldehyde 2b and ketone3b gave cycle 67. 
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O
HO
TBSO
OPMB
HO
OTBS
 
 
• Several attempts to form aldols from 70-72 and 91 with aldehyde 4 failed. 
Similarly unsuccessful were the attempts to obtained the aldol products from 
ketone 79 and aldehydes 35-38. 
 
• Aldol 83 and 84, analogues of aldols 71-72, were also prepared using 3-
pentanone and aldehydes 36 and 37. 
R
OOH
83: R = PMBO
84: R = TBDPS  
 
• None of the synthesized fragments were active in the biological essays 
performed at PharmMar. 
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Materials and methods 
 
All reactions were carried out under N2 or Ar. Solvents were dried using a 
Solvent Purification System (SPS) or using standard procedures,1 except for DMF that 
was purchased from Aldrich anhydrous and packaged under N2. Analytical thin layer 
chromatography was carried out using TLC-aluminium sheets with 0.2 mm of silica gel 
(Merk GF234). Flash chromatography purifications were carried out using flash grade 
silica gel (SDS Chromatogel 60 ACC, 40-60 µm). NMR spectra were recorded at 23 ºC 
on the following spectrometers: Bruker Avance 400 Ultrashield (400 MHz for 1H, and 
100 MHz for 13C) and Bruker Avance 500 Ultrashield (500 MHz for 1H, and 125 MHz 
for 13C) at the Institut Català d’Investigació Química (ICIQ); Bruker AC-300 (300 
MHz for 1H and 75 MHz for 13C) at the Departamento de Química Orgánica (UAM); 
Bruker AMX-300 (300 MHz for 1H and 75 MHz for 13C) and Bruker AMX-500 (500 
MHz for 1H, and 125 MHz for 13C) at the SidI (UAM), Varian Unity 300 (300 MHz for 
1H, and 75 MHz for 13C) and Varian Unity Inova 500 (500 MHz for 1H, and 125 MHz 
for 13C) at PharmaMar, S. A. U. Mass spectra were recorded on a Waters LCT Premier 
(ESI) and Waters GCT (EI, CI) spectrometers at the ICIQ or on a H.P. 5988 A 
spectrometer at the Universidad de Santiago de Compostela or in a NG Auto Spec 
spectrometer at the UAM (SidI) or on a HP 1100 LC/MS at PharmaMar, S. A. U. 
Specific rotation was determined by using a Jasco P-1030 polarimeter (sodium lamp, 
photomultiplier tube detector with a 589 nm filter and polarimetry cell of 100 mm 
length) at PharmaMar, S. A. U. 
                                                 
1  (a) Burfield, D. R.; Lee, K.-H.; Smithers, R. H. J. Org. Chem. 1977, 42, 3060-3065. (b) Burfield, 
D. R.; Smithers, R. H. J. Org. Chem. 1978, 43, 3966-3968. (c) Perrin, D. D.; Armarego, S. L. F.; 
Perrin, D. R. Purification of Laboratory Chemicals; Pergamon: New York, 1980. 
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1. Synthesis of the central side ketone 
 
Dimethyl 2,2'-(1,3-Dioxolane-2,2-diyl)diacetate (15)2 
 
MeO2C CO2Me
O O
 
 
To a stirred solution of dimethyl 1,3-acetone dicarboxylate (20.0 g, 114.9 
mmol) in dry toluene (550 mL) under nitrogen atmosphere were added ethylene glycol 
(16.0, mL, 287.4 mmol) and p-TsOH (2.0 g, 11.49 mmol) The reaction mixture was 
then heated under reflux for 16 h and quenched with saturated aqueous NaHCO3 
solution. The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 (2 x 100 mL). The combined organic layers were washed with water, brine and 
dried over Na2SO4. Removal of solvent under reduced pressure afforded 15 (22.6 g, 
89%) as a colorless oil. Rf = 0.40 (2:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
3.90 (s, 4H), 3.55 (s, 6H), 2.80 (s, 4H). 13C NMR (CDCl3, 100 MHz) δ 65.75 (2CH2), 
52.28 (2CH3), 42.50 (2CH2). HRMS-ESI Calcd for C9H14O6Na [M+Na]+ 241.0688, 
Found 241.0697. 
 
2,2'-(1,3-Dioxolane-2,2-diyl)diethanol (10) 
 
O O
OHHO
 
 
To a stirred suspension of LiAlH4 (6.2 g, 183.5 mmol) in dry THF (300 mL) at 
0 ºC was added dropwise a solution of 15 (20.00 g, 91.7 mmol) in dry THF (50 mL) 
under nitrogen atmosphere. The reaction mixture was allowed to warm to room 
temperature and then heated at 40 ºC for 4 h. It was then cooled to 0 ºC, diluted with 
                                                 
2  Yadav, J. S.; Bandyopadhyay, A.; Kunwar, A. C. Tetrahedron Letters 2001, 42(29), 4907-4911. 
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ether and quenched with dropwise addition of saturated aqueous Na2SO4. Solvent was 
removed in vacuo and the residue was chromatographied (100% EtOAc) to afford 102 
as colorless oil (14.28 g, 96%). Rf = 0.45 (100% EtOAc). 1H NMR (CDCl3, 400 MHz) 
δ 4.03 (s, 4H), 3.75 (t, J = 5.61 Hz, 4H), 2.65 (bs, 2H), 1.96 (t, J = 5.61 Hz, 4H). 13C 
NMR (CDCl3, 100 MHz) δ 112.02 (C), 64.71 (2CH2), 58.53 (2CH2), 38.37 (2CH2). 
HRMS-ESI Calcd for C7H14O4Na [M+Na]+ 185.0790, Found 185.0778. 
 
2,2-Bis(2-(4-methoxybenzyloxy)ethyl)-1,3-dioxolane (16) 
 
OPMBPMBO
O O
 
 
Diol 10 (149.20 mg, 0.92 mmol) was dissolved in 15 mL of dry CH2Cl2 and 
NaH (55 mg, 2.30 mmol) was added at 0 ºC. After 10 min stirring, PMBCl (0.25 mL, 
1.84 mmol) was added dropwise. The mixture was stirred at rt during 16 h. Afterwards 
25 mL of a saturated solution of NH4Cl was added and 30 mL of Et2O. The phases 
were separated and the aqueous layer was extracted with 2 x 20 mL of Et2O. The 
combined organic phases were dried over MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The crude was chromatography (10:1 hexane-
EtOAc) to give 16 (292 mg, 79%) as a colorless oil. Rf = 0.37 (10:1 hexane-EtOAc). 
1H NMR (CDCl3, 400 MHz) δ 7.22 (d, J = 8.57 Hz, 2H), 6.88 (d, J = 8.57 Hz, 4H), 
4.42 (s, 4H), 3.97 (s, 4H), 3.81 (s, 6H), 3.55 (t, J = 6.47 Hz, 4H), 2.98 (t, J = 6.47 Hz, 
4H). 13C NMR (CDCl3, 100 MHz) δ 159.77 (C), 134.19 (2C), 129.94 (4CH2), 114.41 
(4CH2), 110.19 (2C), 73.37 (2CH2), 66.53 (2CH2), 65.43 (2CH2), 55.92 (2CH3), 38.06 
(2CH2). HRMS-ESI Calcd for C23H30NaO6 [M+Na]+ 425.4669, Found 425.4678. 
 
1,5-Bis(4-methoxybenzyloxy)pentan-3-one (3a) 
 
O
OPMBPMBO
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Acetal 16 (299.5 mg, 0.74 mmol) was dissolved in 20 mL of THF, 10 mL of a 
HCl (5%) aqueous solution were added and the reaction was stirred for 1 h under 
reflux. Afterwards, 20 mL of water were added and the phases were separated. The 
aqueous layer was extracted with 2 x 10 mL of CH2Cl2. The combined organic phases 
were dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified by 
flash chromatography in 4:1 hexane-EtOAc to give 3a (266.7 mg, 96%) as a yellow oil. 
Rf = 0.36 (4:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.24 (d, J = 8.76 Hz, 
4H), 6.87 (d, J = 8.76 Hz, 4H), 4.44 (s, 4H), 3.80 (s, 6H), 3.71 (t, J = 5.15, 4H), 2.70 (t, 
J = 5.15, 4H). 13C NMR (CDCl3, 100 MHz) δ 210.8 (C), 159.8 (2C), 129.8 (2C), 128.5 
(4CH), 114.2 (4CH), 74.7 (2CH2), 65.0 (2CH2), 45.1 (2CH2). HRMS-ESI Calcd for 
C21H26NaO5 [M+Na]+ 381.1678, Found 381.1683. 
 
 
 
 
 
1,5-Bis-(tert-butyldimethylsilanyloxy)methylpentan-3-one (3b) 
 
O
OTBSTBSO
 
 
Amberlyst-15 (0.80 g) was added to a stirred solution of diol 10 (11.90 g, 73.40 
mmol) in 150 mL of a mixture of CH2Cl2/MeOH (2:1). After 16 h at room temperature 
200 mL of a saturated aqueous solution of NaHCO3 were added. The organic phase 
was separated and the aqueous layer was extracted with 2 x 50 mL of CH2Cl2. The 
combined organic phases were dried over MgSO4, filtered and concentrated in vacuo. 
The crude was dissolved in 100 mL of dry CH2Cl2 and at 0 ºC imidazol (50.00 g, 
734.00 mmol) was added and the solution was stirred during 15 min, afterwards TBSCl 
(55.30 g, 367 mmol) was added and stirred at room temperature during 1 hour. A 
saturated aqueous solution of NH4Cl was added, the organic phase was separated and 
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the aqueous phase was extracted with CH2Cl2. The combined organic phases were 
dried over MgSO4. Solvent was evaporated under reduced pressure and the crude 
product purified by flash chromatography (10:1 hexane-EtOAc) to give 3b (17.43 g, 
58% yield) as a colorless oil. Rf = 0.46 (10:1 hexane-EtOAc). 1H NMR (CDCl3, 400 
MHz) δ 3.88 (t, J = 6.47 Hz, 4H), 2.65 (t, J = 6.47 Hz, 4H), 0.87 (s, 18H), 0.05 (s, 
12H). 13C NMR (CDCl3, 100 MHz) δ 208.78 (C), 58.80 (2CH2), 46.69 (2CH2), 26.03 
(6CH3), 18.38 (2C), -5.16 (4CH3). HRMS-ESI Calcd for C17H38O3Si2Na [M+Na]+ 
369.2257, Found 369.2245. 
 
 
 
 
 
Dimethyl 3-(2-Methoxy-2-oxoethyl)pent-2-enedioate (19) 
 
MeO2C CO2Me
CO2Me  
 
To a stirred solution of ketone 11 (1.00 g, 62.32 mmol) in 15 mL of toluene, 
Ph3PCHCO2Me (2.90 g, 9.12 mmol) was added. The reaction was refluxed during 18 h 
to yield compound 19 (0.99 g, 72%) as a yellow solid which was filtered and purified 
by column chromatography Rf = 0.3 (4:1 Hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) 
δ 5.96 (s, 1H), 3.87 (s, 2H), 3.70 (s, 3H) 3.69 (s, 6H), 3.30 (s, 2H). 13C NMR (CDCl3, 
100 MHz) δ 170.4 (C), 170.0 (C), 165.9 (C), 146.0 (C), 122.3 (CH), 52.2 (CH3), 52.0 
(CH3), 51.3 (CH3), 43.6 (CH2), 36.5 (CH2). HRMS-ESI Calcd for C10H14NaO6 
[M+Na]+ 253.0688, Found 253.0685. 
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1,5-Bis[(tert-butyldimethylsilyl)oxy]-3-[2-(tert-butyldimethylsilyloxy)ethyl]-pente-
2-ene (21) 
 
OTBSTBSO
OTBS  
 
At 0 ºC and under N2, a suspension of triester 19 (2.47 g, 10.73 mmol) in 50 mL 
of dry THF, LiAlH4 (1.22 g, 32.19 mmol) was added slowly. The reaction was heated 
at 40 ºC during 4 h. After the addition of 10 g Na2SO4.10H2O, the crude was filtered 
and the residue concentrated in vacuo to yield trialcohol 20 in good yield (1.29 g, 
82%), which was used directly in the next step of the synthesis. Trialcohol 20 (1.16 g, 
7.83 mmol) was redissolved in 50 mL of CH2Cl2 and imidazol (1.87 g, 27.44 mmol) 
and TBSCl (3.59 g, 23.81 mmol) were added at 30 ºC. The mixture was stirred 
overnight at the same temperature. 100 mL of water were added and the phases were 
separated. The aqueous phase was extracted with 3 x 50 mL of CH2Cl2, dried with 
anhydrous Na2SO4 and concentrated in vacuo, the residue was purified by column 
chromatography Rf = 0.4 (8:1 Hexane:EtOAc) to yield trisilylether 21 (7.12 g, 91%). 
1H NMR (CDCl3, 400 MHz) δ 5.43 (m, 1H), 4.20(d, J = 6.2 Hz, 2H), 4.15 (t, J = 6.9 
Hz, 3H), 3.61 (t, J = 6.9 Hz, 3H), 2.36 (m, 2H), 2.24 (m, 2H) 0.90 (s, 9H), 0.88 (s, 
18H), 0.06 (s, 6H), 0.04 (s, 12H). 13C NMR (CDCl3, 100 MHz) δ 138.8 (C), 122.4 
(CH), 61.2 (2CH2), 59.4 (CH2), 42,5 (CH2), 36.3 (CH2), 26.0 (6CH3), 24.7 (4CH3), 18.3 
(2C), 17.8 (C), -5.2 (4CH3), -5.0 (2CH3). HRMS-ESI Calcd for C25H56O3Si3Na 
[M+Na]+ 511.3435, Found 511.3437 
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2. Synthesis of the left aldehyde with TBDPS as protecting 
group 
 
Methyl (S)-3-(tert-Butyldiphenylsilyloxy)-2-methylpropanoate (8c) 
 
CO2Me
TBDPSO
 
 
To a stirred solution of ethyl (S)-(+)-3-hydroxy-2-methylpropionate (2.99 mL, 
27.09 mmol) in 15 mL of dry CH2Cl2, imidazol (2.77 g, 40.63 mmol) and TBDPSCl 
(2.76 g, 40.63 mmol) was added dropwise at 0 ºC. After the addition the reaction was 
stirred during 16 h at room temperature. Rf = 0.47 (4:1 hexane-EtOAc). The reaction 
crude was washed with 50 mL of a NH4Cl saturated aqueous solution, phases were 
separated and the aqueous layer was extracted with CH2Cl2. The combined organic 
phases were dried over Na2SO4, filtered and concentrated under reduced pressure to 
yield 8c (9.60 g, 98%) as a colorless oil which could be used in the next step without 
further purifications. 1H NMR (CDCl3, 400 MHz) δ 7.64 (d, J = 6.5 Hz, 4H), 7.43-7.35 
(m, 6H), 3.82 (dd, J = 9.5, 7.0 Hz, 1H), 3.72 (dd, J = 9.5, 5.5 Hz, 1H), 3.68 (s, 3H), 
1.16 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H). 13C NMR (CDCl3, 100 MHz) δ 175.30 (C), 
135.52 (4CH), 133.45 (2C), 129.58 (2CH), 127.59 (4CH), 65.87 (CH2), 51.47 (C), 
42.35 (CH3), 26.66 (3CH3), 19.18 (CH), 13.41 (CH3). HRMS-ESI Calcd for 
C21H28O3SiNa [M+Na]+ 379.1705, Found 379.1688. [α]D25 = −16.5 (c 1.1, CHCl3).  
 
(R)-3-(tert-Butyldiphenylsilyloxy)-2-methylpropan-1-ol (33) 
 
TBDPSO OH  
 
At 0 ºC and under N2 atmosphere, a solution 1.0 M in hexane of DIBAL-H 
(187.31 mL, 187.31 mmol) was added to a solution of ester 8c (31.77 g, 89.19 mmol) 
in 140 mL of dry CH2Cl2. The reaction was stirred at 0 ºC during 3 h. 100 mL of 
Na+/K+ tartrate saturated solution and 100 mL of EtOAc were added and the mixture 
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stirred until the phases were separated. The aqueous layer was extracted with 3 x 50 
mL of EtOAc. The combined organic phases were dried over Na2SO4, filtered and 
concentrated under reduced pressure to yield 33 (20.51 g, 71%) as a colorless oil. The 
product was used in the next step without further purifications. Rf = 0.34 (4:1 
hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.68 (d, J = 6.6 Hz, 4H), 7.44-7.36 (m, 
6H), 3.88 (dd, J = 10.1, 4.5 Hz, 1H), 3.62 (m, 2H), 3.37 (dd, J = 10.1, 7.7 Hz, 1H), 1.83 
(m, 1H), 0.98 (s, 9H), 0.96 (d, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 134.02 
(2C), 132.61 (4CH), 130.11 (2C), 128.43 (4CH), 66.52 (CH2), 66.41 (CH2), 38.87 
(CH), 25.63 (3CH3), 19.22 (C), 13.02 (CH3). HRMS-ESI Calcd for C20H29O2Si (M+H)+ 
329.1931, Found 329.1933. [α]D25= −18.9 (c 1.3, CHCl3). 
 
(S)-3-(tert-Butyldiphenylsilyloxy)-2-methylpropanal (7c) 
 
CHO
TBDPSO  
 
At −78 ºC and under N2 atmosphere, (COCl)2 (5.41 mL, 62.05 mmol) was 
dissolved in 50 mL of dry CH2Cl2 and DMSO (8.80 mL, 124.10 mmol) was added 
dropwise, after 30 min, a solution of alcohol 33 (12.74 g, 38.78 mmol) was added and 
the mixture was stirred during 1 h. Then Et3N (35.13 mL, 252.07 mmol) was added and 
the reaction was allowed to reach room temperature and was completed after 2 h. The 
reaction was quenched by addition of 100 mL of saturated aqueous NaHCO3, the 
phases were separated and the aqueous phase was extracted twice with 2x50 mL of 
CH2Cl2. The combined organic phases were dried over MgSO4, filtered and the solvent 
was evaporated under reduced pressure to yield aldehyde 7c (9.75 g, 77%) which is 
used in the next reaction without further purifications. Rf = 0.43 (8:1 hexane:EtOAc). 
1H NMR (CDCl3, 400 MHz) δ 9.72 (s, 1H), 7.65 (d, J = 6.41 Hz, 4H), 7.42-7.34 (m, 
6H), 3.92 (m, 2H), 2.55 (m, 1H), 1.12 (d, J = 7.1 Hz, 3H), 1.03 (s, 9H). 13C NMR 
(CDCl3, 100 MHz) δ 204.11 (C), 134.17 (2C), 132.65 (4CH), 130.13 (2C), 128.40 
(4CH), 62.74 (CH2), 49.49 (CH), 25.62 (3CH3), 19.28 (C), 10.05 (CH3). HRMS-ESI 
Calcd for C20H26O2SiK (M+K)+ 365.6025, Found 365.6016. [α]D25= −17.1 (c 1.2 
CHCl3). 
Experimental Section 
 132
 
(R,E)-Ethyl 5-(tert-butyldiphenylsilyloxy)-2,4-dimethylpent-2-enoate (6c) 
 
TBDPSO
CO2Et  
 
 To a stirred solution of aldehyde 7c (12.66 g, 38.78 mmol) in 50 mL of CH2Cl2, 
(ethoxycarbonyl)ethylidene triphenylphosphorane3 (25.29g, 69.79 mmol) was added 
and the reaction was stirred over 16 h at room temperature. 100 mL of water was added 
and the phases were separated, the aqueous layer was extracted twice with 50 mL 
CH2Cl2 and the combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure. The product was purificated by silica gel flash 
chromatography (9:1 hexane:EtOAc) to yield compound 6c (11.98 g, 76%) as pale 
yellow oil. Rf = 0.47 (8:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.67-7.62 (m, 
4H), 7.44-7.34 (m, 6H), 5.78 (dd, J = 9.6, 1.3 Hz, 1H), 3.68 (s, 3H), 3.54 (d, J = 5.9 Hz, 
2H), 3.44-3.33 (m, 1H), 1.89 (d, J = 1.3 Hz, 3H), 1.04 (s, 9H), 1.02 (d, J = 5.9 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ 168.3 (C), 144.4 (2C), 135.7 (2CH), 135.6 (2CH), 
134.0 (C), 129.6 (2CH), 129.6 (2CH), 129.4 (CH), 127.8 (CH), 127.6 (CH), 67.7 
(CH2), 60.3 (CH2), 36.2 (C), 26.8 (3CH3), 19.3 (C), 16.3 (CH3); 14.3 (CH3), 12.6 
(CH3). HRMS-ESI Calcd for C27H39O3Si (M+C2H5)+ 439.2669, Found. 439.2668. 
[α]D25 = -41.9 (c 1.2, CHCl3). 
 
(R,E)-5-(tert-butyldiphenylsilyloxy)-2,4-dimethylpent-2-en-1-ol (5c) 
 
TBDPSO OH  
 
 To a stirred solution of ester 6c (6.20g, 15.10 mmol) in 20 mL of CH2Cl2, a 1.0 
M solution in hexanes of DIBAL-H (31.71 mL, 31.71 mmol) was added at 0 ºC, after 3 
h. the reaction was completed. 50 mL of saturated aqueous solution of Na+/K+ tartrate 
and 50 mL of EtOAc was added and stirred until separation of phases. The aqueous 
                                                 
3  Bestmann, H. J.; Haeberlein, H.; Eisele, W. Chem Ber. 1966, 99, 1198-1207. 
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phase was extracted with 2x50 mL of EtOAc. The combined organic phases were dried 
over MgSO4, filtered and the solvent was eliminated under reduced pressure. The 
product was chromatography (4:1 hexane:EtOAc) and 5c was obtained as a colorless 
oil (5.57 g, 96%). Rf = 0.22 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.68-
7.63 (m. 4H), 7.46-7.35 (m. 6H), 5.16 (dq, J = 11.9, 6.9 Hz, 1H), 3.95 (s, 2H), 3.51 (dd, 
J = 9.6, 5.6 Hz, 1H), 3.47 (dd, J = 9.6, 8.2 Hz, 1H), 2.63 (m, 1H), 1.92 (bs, 1H), 1.62 
(d, J = 1.3 Hz, 3H), 1.04 (s, 9H), 1.00 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz) 
δ 144.4 (2C), 135.7 (2CH), 135.6 (2CH), 134.0 (C), 129.6 (2CH), 129.6 (2CH), 129.4 
(CH), 127.8 (CH), 127.6 (CH), 68.9 (CH2), 68.5 (CH2), 35.0 (C), 26.8 (3CH3), 19.3 
(C), 17.2 (CH3); 13.9 (CH3). HRMS-ESI Calcd for C23H32NaO2Si [M−H]+ 391.2069, 
Found 391.2052. [α]D25 = −14.8 (c 1.0 CHCl3). 
 
(R,E)-5-(tert-butyldiphenylsilyloxy)-2,4-dimethylpent-2-enal (37) 
 
CHO
TBDPSO  
 
At −78 ºC and under N2 atmosphere, (COCl)2 (80 µL, 0.87 mmol) was 
dissolved in dry 10 mL CH2Cl2, then DMSO (0.12, 1.74 mmol) was added and stirred 
during 30 min, after a solution of alcohol 5c (0.20 g, 054 mmol) was added dropwise, 
and the mixture was stirred at −78 ºC during 1 h. Then Et3N (0.49 mL, 3.52 mmol) was 
added dropwise, the reaction was allowed to reach room temperature and, after 3 h, the 
reaction was quenched with 10 mL of saturated aqueous solution of NaHCO3, the 
phases were separated and the aqueous one was extracted with 3 x 10 mL CH2Cl2. The 
product was purified by flash chromatography (4:1 hexane:EtOAc) to yield aldehyde 
37 (0.13 g, 68%) as a colorless oil. Rf = 0.57 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 
400 MHz) δ 9.35 (s, 1H), 7.63 (d, J = 6.82 Hz, 4H), ), 7.44-7.34 (m, 6H), 6.21 (dd, J = 
9.6, 1.3 Hz, 1H), 3.66 (dd, J = 9.6, 5.6 Hz, 1H), 3.60 (dd, J = 9.6, 8.2 Hz, 1H), 2.93 (m, 
1H) 1.72 (d, J = 1.3 Hz, 3H), 1.06 (d, J = 6.2 Hz, 3H), 1.04 (s, 9H). 13C NMR (CDCl3, 
100 MHz) δ 192.95 (CH), 154.42 (CH), 135.93 (C), 134.02 (2C), 132.61 (4CH) 130.12 
(2CH), 128.44 (4CH), 70.52 (CH2), 37.87 (CH), 25.60 (3CH3), 19.23 (C), 17.88 (CH3), 
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9.21 (CH3). HRMS-ESI Calcd for C23H30O2SiNa [M+Na]+ 389.1913, Found 389.1808. 
[α]D25 = −45.2 (c 1.1, CHCl3).  
 
(2S,3R,4S)- 5-(tert-butyldiphenylsilyoxy)-2,4-dimethyl-2-oxiranyl-1-pentanol (34) 
 
TBDPSO
O
OH
 
 
At −78 ºC a solution of TBHP (0.27 mL, 1.47 mmol) and Ti(O-iPr)4 (0.24 mL, 
0.81 mmol) in 25 mL of CH2Cl2 were stirred and a solution of allylic alcohol 5c (0.30 
g, 0.81 mmol) in 10 mL of CH2Cl2 was added. After 20 min (-)-DET (0.14 mL, 0.81 
mmol) was slowly added and the reaction was warmed until 0 ºC in 1.5 h. 10 mL of a 
solution of tartaric acid (10%) was added and was stirred during 30 min at 0 ºC and 
during 30 min at r.t. The phases were separated. The organic phase was concentrated 
and was solved again in 20 mL Et2O, and 20 mL of a solution of NaOH 1 N was added 
at 0 ºC, and was stirred during 30 min left. The organic phase was separated, dried and 
concentrated. The product was chromatographied (6:1 hexane:EtOAc) and 
epoxialcohol 34 was obtained as a colorless oil (0.21 g, 68% 10:1). Rf = 0.54 (4:1 
hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.65 (m, 4H), 7.44-7.37 (m, 6H), 3.66 
(dd, J = 12.2, 4.5 Hz, 1H), 3.62 (dd, J = 10.2, 5.4 Hz, 1H), 3.56 (dd, J = 8.5, 4.9 Hz, 
1H), 3.54 (dd, J = 7.4, 1.7 Hz, 1H), 2.88 (d, J = 9.4 Hz, 1H), 1.79 (m, 1H), 1.27 (s, 3H), 
1.07 (d, J = 6.9 Hz, 3H), 1.06 (s, 9H). 13C NMR (CDCl3, 100 MHz) δ 134.03 (2C), 
130.11 (6CH), 129.52 (4CH), 71.92 (CH), 67.24 (CH2), 66.67 (CH2), 59.01 (C), 33.37 
(CH), 26.82 (3CH3), 20.98 (CH3), 19.24 (C), 14.60 (CH3). HRMS-ESI Calcd for 
C23H32O3SiNa [M+Na]+ 407.2018, Found 407.2017. [α]D25 = +21.4 (c 1.0, CHCl3). 
 
(2S,3R)-3-[(S)-1-(tert-Butyldiphenylsilyloxy)propan-2-yl]-2-methyloxirane-2- 
carbaldehyde (2c) 
 
CHO
TBDPSO
O  
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Following the same procedure to synthesize aldehyde 37, compound 2c was 
obtained using the following amounts of reagents: epoxyalcohol 34 (0.15 g, 0.38 
mmol), (COCl)2 (53 µL, 0.61 mmol), DMSO (86 µL, 22 mmol) and Et3N (0.34 mL, 
2.47 mmol), in 5 mL of CH2Cl2. The mixture was stirred for 2 h at room temperature, 
after the work-up the crude of the reaction was purified by flash chromatography (6:1 
hexane-EtOAc) to obtain aldehyde 2c as pale yellow oil (103 mg, 69%, dr = 10:1). Rf = 
0.62 (4:1 EtOAc). 1H NMR (CDCl3, 400 MHz) δ 8.86 (s, 1H), 7.61-7.57 (m, 4H), 7.45-
7.35 (m, 6H), 3.64 (dd, J = 10.3, 5.0 Hz, 1H), 3.52 (dd, J = Hz, 1H), 2.99 (d, J = 9.1 
Hz, 1H), 1.95 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H), 1.04 (s, 3H), 1.03 (s, 9H). 13C NMR 
(CDCl3, 100 MHz) δ 192.8 (CH), 134.1 (2C), 130.2 (6CH), 129.5 (4CH), 72.1 (CH), 
66.1 (CH2), 59.0 (C), 33.2 (CH), 26.7 (3CH3), 21.0 (CH3), 19.2 (C), 14.6 (CH3). 
HRMS-ESI Calcd for C24 H34 O4 Na Si (M+NaOCH4)+ 437.2124, Found 437.2123. 
[α]D25 = +61.4 (c 1.7, CHCl3). 
 
(2R,3R,4R)-5-(tert-Butyldiphenylsilyloxy)-2,4-dimethyl-2-cyclopropyl-1-pentanol 
(44) 
 
TBDPSO OH
 
 
 
At -60 ºC and under N2, in 2 mL of dry CH2Cl2, a 1.0 M solution of ZnEt2 in 
hexanes (1.92 mL, 1.92 mmol) and CH2I2, (0.15 mL, 1.92 mmol) were stirred until 
formation of a white precipitate. Then the solution was warmed until 0 ºC for 5 min 
and cooled until -65 ºC. The allylic alcohol 5c (0.71 g, 1.92 mmol) was added in 2 mL 
of dry CH2Cl2 and the reaction was warmed until r.t. and stirred during 15 more min 
The reaction was treated with 4 mL of saturated solution NH4Cl (pH 8) and the organic 
phase was separated; the aqueous phase extracted with Et2O and the combine organic 
phases were dried over MgSO4, filtered and concentrated. The crude of the reaction 
was chromatographied (6:1 hexane-EtOAc), to yield the hydroxycyclopropane 44 as a 
colorless oil (0.43 g, 58%, dr = 2:1). 1H NMR (CDCl3, 400 MHz) δ 7.67 (m, 4H), 7.40 
(m, 6H), 4.63 (s, OH), 3.68(dd, J= 9.7, 4.4 Hz, 1H), 3.60 (dd, J= 9.8, 4.4 Hz, 1H), 3.48 
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(d, J = 4.6 Hz, 1H), 3.25 (d, J= 5.4 Hz, 1H), 1.85 (m, 1H), 1.06 (d, J= 3.0 Hz, 3H), 1.05 
(s, 9H), 1.02 (s, 3H), 0.53 (m, 1H), 0.48 (m, 1H), 0.18 (m, 1H). 13C NMR (CDCl3, 100 
MHz) δ 134.0 (2C), 130.2 (6CH), 129.5 (4CH), 70.8 (CH2), 67.3 (CH2), 44.5 (CH), 
26.7 (3CH3), 22.0 (CH3), 19.2 (C), 18.5 (C), 17.3 (CH2), 16.9 (CH), 14.5 (CH3). 
HRMS-ESI Calcd for C24H34O2NaSi (M+NaOCH4)+ 405.2226, Found 405.2226. [α]D25 
= +23.1 (c 1.0, CHCl3). 
 
(1S,2R)-2-[(R)-1-(tert-Butyldiphenylsilyloxy)propan-2-yl]-1-methylcyclopropane 
carbaldehyde (43)  
 
CHO
TBDPSO
 
 
Following the same procedure to synthesize aldehyde 37, compound 43 was 
obtained using the following amounts of reagents: hydroxycyclopropane 44 (0.20 g, 
0.52 mmol), (COCl)2 (73 µL, 0.87 mmol), DMSO (0.12 mL, 1.67 mmol) and Et3N 
(0.47 mL, 3.40 mmol), in 5 mL of CH2Cl2. The mixture was stirred for 2 h at room 
temperature, after the work-up the crude of the reaction was purified by flash 
chromatography (4:1 hexane-EtOAc) to give 43 as a colorless oil (0.15 g, 75%, dr = 
2:1). Rf = 0.42 (4:1 EtOAc). 1H NMR (CDCl3, 400 MHz) δ 8.61 (2, 1H), 7.66 (m, 2H), 
7.62 (m, 2H), 7.38 (m, 6H), 3.54 (dd, J= 9.8, 4.3 Hz, 1H), 3.46 (dd, J= 9.8, 6.6 Hz, 1H), 
1.43 (m, 1H), 1.20 (s, 3H), 1.05 (s, 9H), 1.00 (d, J = Hz, 6.6 Hz, 3H) 0.63-0.61 (m, 
3H). 13C NMR (CDCl3, 100 MHz) δ 202.3 (C), 135.6 (2C), 129.6 (6CH), 127.6 (4CH), 
67.9 (CH2), 35.6 (CH), 32.0 (C), 26.8 (CH2), 19.3 (CH), 18.5 (CH3), 17.1 (3CH3), 14.5 
(C), 11.4 (CH3). HRMS-ESI Calcd for C24H32O2 SiNa [M+Na]+ 403.2069, Found 
403.2049. [α]D25 = +27.3 (c 1.1, CHCl3). 
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3. Synthesis of the left side aldehyde with PMB as protecting 
group 
 
(S)-Methyl 3-(4-Methoxybenzyloxy)-2-methylpropanoate (8b) 
 
CO2Me
PMBO
 
 
At 0 ºC and under nitrogen atmosphere, PMB-TCA4 (21.49 g, 76 mmol) was 
added to a solution of methyl (S)-(+)-3-hydroxy-2-methylpropionate (9.4 ml, 83.7 
mmol) in dry THF (70 mL). Then triflic acid (0.2ml, 2.28mmol) was added dropwise 
and the final mixture was stirred for 1.5 h. The reaction was quenched by addition of 50 
mL of saturated aqueous solution of NaHCO3. The phases were separated and the 
aqueous phase was extracted with Et2O (2x50 mL). The combined organic phases were 
washed with brine, dried over anhydrous Na2SO4, filtered and the solvent was 
eliminated under reduced pressure until the volume was reduced to ¼ of the initial 
volume. By addition of hexane a white solid was formed, which was filtered through a 
pad of celite©. The filtrates were concentrated in vacuo. The product was purified by 
column chromatography (9:1 hexane-EtOAc). 8b (17.92 g, 99%) was obtained as 
yellow oil. Rf = 0.49 (8:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.27-7.20 (m, 
2H), 6.89-6.83 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.69 (s, 3H), 3.63 (dd, J =9.1, 7.3 
Hz, 1H), 3.45 (dd, J =9.2, 5.9 Hz, 1H), 2.76 (m, 1H), 1.16 (d, J =7.1, 3H). 13C NMR 
(CDCl3, 100 MHz) δ 176.5 (C), 159.7 (C), 129.9 (C), 129.5 (2CH), 115.0 (2CH), 76.6 
(CH2), 73.7 (CH2), 56.1 (CH3), 52.6 (CH3), 41.1 (CH), 13.5 (CH3). HRMS-ESI Calcd 
for C13H18O4Na [M+Na]+ 261.1103, Found 261.1107. [α]D25 = +25.2 (c 1.1, CHCl3). 
 
(R)-3-(4-Methoxybenzyloxy)-2-methylpropan-1-ol (22) 
 
PMBO OH  
 
                                                 
4  Patil, V. J. Tetrahedron Lett. 1996, 37, 1481-1484. 
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At 0 ºC, a solution of 8b (10.0 g, 41.86 mmol) in 50 mL of dry THF, was added 
dropwise to a suspension of LiAlH4 (1.7g, 41.86 mmol) in thf 20 mL of dry THF. After 
1 hour 50 mL of Na+/K+ tartrate aqueous saturated solution and 20 mL of Et2O was 
added and the mixture was stirred until the separation of the phases. The aqueous phase 
was extracted with 3x20 mL of Et2O. The combined ethereal phases were dried over 
MgSO4, filtered and the solvent evaporated under reduced pressure to yield alcohol 22 
(7.13 g, 81%) as a yellow oil, which was used in the next step without further 
purifications. Rf = 0.26 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.28-7.20 
(m, 2H), 6.91-6.86 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.58 (m, 2H), 3.52 (dd, J =9.1, 
4.6 Hz, 1H), 3.39 (dd, J =8.8, 8.4 Hz, 1H), 2.06 (m, 1H), 0.87 (d, J =7.0, 3H). 13C 
NMR (CDCl3, 100 MHz) δ 160.1 (C), 130.0 (C), 19.8 (2CH), 115.1 (2CH), 76.4 (CH2), 
74.5 (2CH2), 67.3 (CH2), 56.2 (CH3), 34.8 (CH), 12.7 (CH3). HRMS-ESI Calcd for 
C12H18O3Na [M+Na]+ 233.1154, Found 233.1156. [α]D25 = +13.3 (c 1.1, CHCl3). 
 
(S)-3-(4-Methoxybenzyloxy)-2-methylpropanal (7b) 
 
CHO
PMBO  
 
At −78 ºC and under N2 atmosphere, (COCl)2 (0.67 mL, 7.72 mmol) is added 
over 10 mL dry CH2Cl2, DMSO (1.09, 15.43 mmol) is then added and the mixture was 
stirred for 30 min A solution of alcohol 22 (1.01 g, 4.82 mmol) was added in 10 mL of 
dry CH2Cl2 and, after 1 h at this temperature, Et3N was added dropwise and the 
solution was allowed to reach room temperature. After completion, 20 mL of water was 
added, the organic phase was separated and the aqueous one extracted with 2x 10 mL 
of CH2Cl2; the combined organic phases were dried over MgSO4, filtered and the 
solvent concentrated under reduced pressure to yield the aldehyde 7b as a yellow oil 
(0.63 g, 68%). The crude of the reaction was employed in the next step without further 
purifications); Rf = 0.65 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 9.70 (d, J 
= 1.6 Hz, 1H), 7.28-7.20 (m, 2H), 6.90-6.86 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.64 
(dd, J =9.5, 6.7 Hz, 1H), 3.59 (dd, J =9.5, 5.6 Hz, 1H), 2.64 (m, 1H), 1.10 (d, J = 6.9 
Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 202.4 (C), 160.1 (C), 129.9 (C), 129.7 (2CH), 
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115.1 (2CH), 73.7 (CH2), 73.1 (CH2), 56.2 (CH3), 47.3 (CH), 10.1 (CH3). HRMS-ESI 
Calcd for C12H16O3Na [M+Na]+ 231.0997, Found 231.0997. [α]D25 = +28.3 (c 1.4, 
CHCl3). 
 
(R,E)-Ethyl 5-(4-Methoxybenzyloxy)-2,4-dimethylpent-2-enoate (6b) 
 
CO2Et
PMBO
 
 
Aldehyde 7b (7.30 g, 0.35 mol) was dissolved in 25 mL of CH2Cl2, the 
Ph3PC(Me)CO2Et (10.41 g, 0.63 mmol) was added and the reaction was stirred during 
16 h at room temperature. The reaction was followed by TLC and after completion 30 
mL of saturated aqueous NH4Cl solution was added. The organic phase was separated 
and the aqueous one was extracted with 3 x 20 mL of CH2Cl2. The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure. The 
product was purified by flash chromatography to yield 6b as yellow oil (7.7 g, 76%). Rf 
= 0.41 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.30-7.22 (m, 2H), 6.90-
6.85 (m, 2H), 6.57 (dq, J =9.7, 1.4 Hz, 1H), 4.44 (s, 2H), 4.18 (q, J =7.1 Hz, 2H), 4.26 
(dd, J =9.4, 6.5 Hz, 1H), 4.20 (dd, J =9.5, 5.3 Hz, 1H), 3.80 (s, 3H), 2.83 (m, 1H), 1.86 
(d, J = 1.3 Hz, 3H), 1.30 (t, J =7.1 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H). 13C NMR (CDCl3, 
100 MHz) δ 169.2 (C), 160.1 (C), 146.8 (CH), 129.7 (C), 129.7 (2CH), 123.3 (C), 
114.8 (2CH), 81.3 (CH2), 73.7 (CH2), 62.1 (CH2), 56.1 (CH3), 34.6 (CH), 18.3 (CH3), 
14.3 (CH3), 13.5 (CH3). HRMS-ESI Calcd for C17H24O4Na [M+Na]+ 315.1772, Found 
315.1773. [α]D25 = +25.0 (c 1.4, CHCl3). 
 
(4R,2E)-5-(4-Methoxybenzyloxy)-2,4-dimethyl-2-penten-1-ol (5b) 
 
PMBO OH  
 
To a solution of ester 6b (9.30 g, 31.81 mmol) in 45 mL of anhydrous CH2Cl2, 
DIBAL-H 1.0 M in hexanes (6.7 mL, 6.7 mmol) was slowly added at 0 ºC. After 3 h at 
rt the reaction was completed and the mixture was cooled until 0 ºC. Then 20 mL of 
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saturated Na+/K+ tartrate solution and 20 mL of EtOAc were added. The mixture of the 
reaction was stirred until complete separation of the phases. The organic phase was 
separated and the aqueous one extracted with 3 x 20 mL of EtOAc. The combined 
organic phases were washed with 50 mL NaCl saturated solution, dried over MgSO4, 
filtered and concentrated. The product was purify by flash chormatography (9:1 
hexane:EtOAC) to yield alcohol 5b as colorless oil (7.01 g, 88%). Rf = 0.25 (4:1 
hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.30-7.22 (m, 2H), 6.90-6.85 (m, 2H), 
5.23 (dq, J =9.0, 1.2 Hz, 1H), 4.44 (s, 2H), 3.99 (bs, 2H), 3.80 (s, 3H), 3.30 (dd, J =9.1, 
6.5 Hz, 1H), 3.24 (dd, J =9.2, 7.1 Hz, 1H), 2.73 (m, 1H), 1.68 (d, J = 1.3 Hz, 3H), 0.98 
(d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 159.8 (C), 132.1 (C), 129.7 (C), 
129.5 (2CH), 125.8 (CH), 114.1 (2CH), 81.3 (CH2), 73.5 (CH2), 70.1 (CH2), 55.8 
(CH3), 35.2 (CH), 18.7 (CH3), 13.6 (CH3).  
HRMS-ESI Calcd for C15H22O3Na [M+Na]+ 273.1467, Found 273.1465. [α]D25 = +21.5 
(c 1.2, CHCl3). 
 
(4R,2E)-5-(4-Methoxybenzyloxy)-2,4-dimethyl-2-pentenal (36) 
 
CHO
PMBO  
 
Following the procedure described by Swern, alcohol (5b) (1.00 g, 3.99 mmol) 
was oxidized to aldehyde using (COCl)2 (0.44 mL, 5.99 mmol), DMSO (0.57 mL, 7.99 
mmol), Et3N (2.84 mL, 19.97 mmol), after 1 h the reaction was completed and the 
work-up was done. The product was purified by flash chromatography (10:1 
hexane:EtOAc), to yield aldehyde 36 as a colorless oil (0.74 g, 75%). Rf = 0.63 (7:3 
hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 9.39 (s, 1H), 7.24-7.21 (m, 2H), 6.90-
6.85 (m, 2H), 5.33 (dq, J =9.5, 1.3 Hz, 1H), 4.45 (s, 2H), 3.81 (s, 3H), 3.43 (dd, J =9.2, 
5.9 Hz, 1H), 3.39 (dd, J =9.2, 6.9 Hz, 1H), 3.01 (m, 1H), 1.77 (d, J = 1.3 Hz, 3H), 1.08 
(d, J = 6.8 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 195.4 (C), 159.2 (C), 156.8 (CH), 
139.3 (C), 130.2 (2CH), 129.2 (C), 113.8 (2CH), 73.7 (CH2), 72.8 (CH2), 55.3 (CH3), 
34.2 (CH), 16.4 (CH3), 9.4(CH3). HRMS-ESI Calcd for C15H20O3Na [M+Na]+ 
271.1310, Found 271.1302. [α]D25 = +27.2 (c 1.8, CHCl3). 
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(2S,3R,4S)-2,4-Dimethyl-5-(4-methoxybenzyloxy)-2-oxiranyl-1-pentanol (32) 
 
PMBO
O
OH
 
 
Following the same procedure described for the synthesis of 34 and using 
TBHP (0.27 mL, 1.47 mmol), Ti(O-iPr)4 (0.24 mL, 0.81 mmol) in 25 mL of CH2Cl2 
was stirred, a solution of allylic alcohol (0.20 g, 0.81 mmol) in 10 mL of CH2Cl2. and (-
)-DET (0.14 mL, 0.81 mmol). Epoxyalcohol 32 was obtained as yellow oil (0.16 g, 
72% yield dr = 10:1). Rf = 0.54 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
7.68-7.64 (m, 2H), 7.40-7.36 (m, 2H), 5.17 (bs, OH), 4.63 (s, 2H), 3.87 (s, 3H), 3.75 (d, 
J = 10.2 Hz, 1H), 3.50 (d, J = 9.5 Hz, 1H), 3.46 (dd, J = 7.1, 1.3 Hz, 1H), 3.21 (dd, J = 
7.1, 4.8 Hz, 1H), 2.90 (d, J = 9.2 Hz, lH), 1.81 (m, 1H), 1.27 (s, 3H), 1.07 (d, J = 6.9 
Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 159.5 (C), 129.9 (C), 129.7 (2CH), 114.3 
(2CH), 76.5 (CH2), 73.5 (CH2), 72.5 (CH), 67.3 (CH2) 59.2 (C), 55.7 (CH3), 30.3 (CH), 
21.1 (CH3), 15.1 (CH3). HRMS-ESI Calcd for C1H22NaO4 [M+Na]+ 289.1416, Found 
289.1417. 
 
(2S,3R)-3-[(S)-1-(4-Methoxybenzyloxy)propan-2-yl]-2-methyloxirane-2-
carbaldehyde (2b) 
 
CHO
PMBO
O  
 
Following the procedure described by Swern, alcohol 32 (0.15 g, 0.56 mmol) 
was oxidized to aldehyde using (COCl)2 (78 µL, 0.90 mmol), DMSO (0.13 mL, 1.79 
mmol), Et3N (0.51 mL, 3.64 mmol), after 1 h the reaction was completed and the work-
up was done. The product was purified by flash chromatography (8:1 hexane:EtOAc), 
to yield aldehyde 2b as a colorless oil (0.13 g, 79%, dr = 10:1). 1H NMR (CDCl3, 400 
MHz) δ 8.89 (s, 1H), 7.29-7.23 (m, 2H), 6.90-6.86 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 
3.66 (dd, J = 10.2, 4.8 Hz, lH), 3.54 (dd, J = 10.1, 6.3 Hz, lH), 2.92 (d, J = 9.1 Hz, lH), 
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1.92 (m, lH), 1.14 (d, J = 7.1 Hz, 3H), 1.04 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ 
199.9 (C), 159.1 (C), 130.0 (C), 129.0 (2CH), 113.7 (2CH), 76.6 (CH2), 72.7 (C), 71.6 
(CH2), 63.5 (CH), 55.1 (CH3), 33.3 (CH), 14.7 (CH3), 10.7 (CH3). HRMS-ESI Calcd 
for C15H20O4Na [M+Na]+ 287.1259, Found 287.1255. [α]D25 = +12.5 (c 1.1, CHCl3). 
 
{(1S,2R)-2-[(R)-1-(4-Methoxybenzyloxy)propan-2-yl]-1-methylcyclopropyl} 
methanol (39) 
 
PMBO OH
 
 
Following the same procedure described for the synthesis of 44, alcohol 39 was 
obtained using allylic alcohol 5b (1.00 g, 4.00 mmol), 1.0 M solution of ZnEt2 in 
hexanes (7.99 mL, 7.99 mmol) and CH2I2, (1.29 mL, 15.98 mmol). The crude of the 
reaction was chromatographied (8:1 hexane-EtOAc), to yield the hydroxycyclopropane 
(39) as a colorless oil (0.81 g, 77%, dr = 2:1). Rf = 0.35 (7:3 hexane:EtOAc). 1H NMR 
(CDCl3, 400 MHz) δ 7.68-7.64 (m, 2H), 7.40-7.36 (m, 2H), 5.17 (bs, OH), 4.63 (s, 2H), 
3.87 (s, 3H), 3.56 (d, J = 0.6 Hz, 1H), 3.49 (m, 1H), 3.48 (m, 1H), 3.40 (d, J = 0.6 Hz, 
1H), 2.63 (m, 1H), 1.03 (s, 9H), 0.99 (d, J = 6.7 Hz, 3H), 0.92-0.75 (m, 3H). 13C NMR 
(CDCl3, 100 MHz) δ 159.7 (C), 129.8 (C), 114.2 (2C), 78.1 (CH2), 73.3 (CH2), 71.3 
(CH2), 55.8 (CH3), 18.2 (C), 17.5 (CH), 17.3 (CH2), 15.1 (CH3). HRMS-ESI Calc for 
C16H24O3Na [M+Na]+ 287.1623, Found 287.1622. [α]D25 = +25.2 (c 1.0, CHCl3). 
 
(1S,2R)-2-[(R)-1-(4-Methoxybenzyloxy)propan-2-yl]-1-methylcyclopropane 
carbaldehyde (38) 
 
CHO
PMBO
 
 
Following the Swern protocol of oxidation, aldehyde 38 was otained using 
alcohol 39 (0.50 g, 1.89 mmol), (COCl)2 (0.21 mL, 2.84 mmol), DMSO (0.27 mL, 3.78 
mmol)and Et3N (1.34 mL, 9.45 mmol) to yield aldehyde 38 (0.39 mg, 79%). Rf = 0.71 
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(7:3 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 8.63 (s, 1H), 7.28-7.23 (m, 2H), 
6.88-6.86 (m, 2H), 4.47 (s, 2H), 3.80 (s, 3H), 3.50 (dd, J = 9.0, 5.2 Hz, 1H), 3.40 (dd, J 
= 9.1, 6.5 Hz, 1H), 3.33 (dd, J = 9.1, 5.06 Hz, 1H), 3.24 (dd, J = 9.0, 7.1 Hz, 1H), 2.01 
(m, 1H), 1.24 (s, 3H), 1.0 (d, J = 6.7 Hz, 3H), 0.98 (m, 1H), 0.76 (dd, J = 6.7, 4.8 Hz, 
1H), 0.64 (dd, J = 6.7, 4.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 205.0 (C), 159.7 
(C), 129.8 (C), 129.6 (2CH), 114.2 (2CH), 77.8 (CH2), 73.3 (CH2), 55.8 (CH3), 40.30 
(CH), 31.9 (C), 29.1 (CH2), 28.2 (CH), 14.8 (CH3). HRMS-ESI Calcd for C16H22O3Na 
[M+Na]+ 285.1467, Found 285.1470. [α]D25 = +12.5 (c 1.1, CHCl3). 
 
4. Synthesis of the left side aldehyde with the Z double bond 
 
(2S)-2-Methyl-3-trityloxy-propan-1-ol (28) 
 
O
Ph Ph
Ph OH
 
 
A solution of hydroxyester (–)-9 (5.68 g, 48.54 mmol) in dry CH2Cl2 was 
stirred at room temperature. TrCl (20.25 g, 72.9 mmol) and Et3N (10.8 mL, 77.69 
mmol) were added, and the mixture was stirred over 16 h. Then a saturated aqueous 
solution of NaHCO3 was added, the organic phase was separated and after the usual 
extractive procedure, the combined organic phases were dried over MgSO4, filtered and 
the solvent evaporated under reduced pressure to yield the protected hydroxyester as a 
yellow solid. The product was used without further purification in the next step. Over a 
suspension of LiAlH4 (1.46 g, 38.50 mmol) in 40 ml of dry THF, a solution of the 
protected hydroxyester in 100 ml of dry THF was added at 0 ºC dropwise. The mixture 
was heated at 40 ºC during 2 h. Then the solution was cooled until 0 ºC and a saturated 
aqueous solution of Na+/K+ tartrate was added and stirred until complete separation of 
the phases. The organic was separated and he aqueous extracted with EtOAc. The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The product was obtained as colorless oil (15.86 g, 93% in two steps) and used without 
further purifications. 1H NMR (CDCl3, 400 MHz) δ 7.46 (d, J =7.7 Hz, 6H), 7.32 (t, J 
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= 7.3 Hz, 6H), 7.26 (t, J = 7.2 Hz, 6H), 3.65-3.56 (m, 2H), 3.27 (dd, J = 9.1, 4.6 Hz, 
1H), 3.07 (dd, J = 8.7, 8.0 Hz, 1H), 2.38-2.32 (bs, OH), 2.12-2.02 (m, 1H), 0.90 (d, J = 
6.9 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 143.9 (C), 128.6 (CH), 127.8 (CH), 127.0 
(CH), 86.9 (CH), 67.7 (CH2), 67.4 (CH2), 36.0 (CH), 13.8 (CH3). HRMS-ESI Calcd for 
C23H24O2Na [M+Na]+ 355.1674, Found 355.1674. [α]D25 = −27.0 (c 0.9, CHCl3). 
 
(2R)-2-Methyl-3-trityloxy-propanal (29) 
 
CHO
O
Ph Ph
Ph
 
 
Under N2 and at −78 ºC, (COCl)2 (9.85 g, 77.63 mmol) was solved in 200 mL 
of dry CH2Cl2, DMSO (7.4 mL, 103.50 mmol) was then added and after 30 min, a 
solution of alcohol 28 was added dropwise. The mixture was stirred for 1 h and Et3N 
(36.0 mL, 258.75 mmol) was added slowly and the reaction was allowed to reach room 
temperature. The reaction finished after 2.5 h at room temperature. The reaction was 
quenched with 200 mL of water, the phases were separated and the organic layers were 
dried over MgSO4 and filtered The solvent was evaporated under reduced pressure to 
yield the product as yellow oil (42.0 g, 81%) which was used in the next step without 
further purifications. 1H NMR (CDCl3, 400 MHz) δ 9.72 (d, J = 1.6 Hz, 1H), 7.44 (d, J 
= 7.4 Hz, 6H), 7.32 (t, J = 7.7 Hz, 6H), 7.26 (t, J =7.2 Hz, 3H), 3.42 (dd, J = 9.4, 5.2 
Hz, 1H), 3.37 (dd, J = 9.2, 6.6 Hz, 1H), 2.63 (m, 1H), 1.15 (d, J =7.0 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) δ 204.0 (CH), 143.7 (C), 128.6 (CH), 127.8 (CH), 127.1 
(CH), 86.7 (C), 63.6 (CH2), 44.0 (CH), 10.8 (CH3). HRMS-ESI Calcd for C23H22O2Na 
[M+Na]+ 353.1517, Found 353.1520. [α]D25 = −29.7 (c 0.9, CHCl3). 
 
(2S,3Z)-2-Methyl-1-trityloxy-3-pentene (30) 
 
O
Ph Ph
Ph
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Over a suspension of ethyltriphenylphosphoniumbromide (3.20 g, 81.36 mmol) 
in 100 mL of dry THF at −78°C, BuLi (30.5 mL, 76.30 mmol; 2.50 M in hexane) was 
slowly added. Afterwards the cooling bath was removed and the orange solution was 
allowed to reach room temperature. 30 min later, the solution (dark red) was cooled 
again to –78 ºC and aldehyde 29 (16.80 g , 50.85 mmol) solved in 100 mL of dry THF 
was slowly added. It was warmed ro room temperature and stirred for 3 h. Afterwards, 
200 mL of water were added. The organic phase was separated and the aqueous one 
was extracted with EtOAc (2x100 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated in vacuo. It was further purified by flash 
chromatography with hexane:EtOAc (10:1) to yield the olefin 30 (15.50 g, 89%) as 
viscous oil. 1H NMR (CDCl3, 400 MHz) δ 7.49 (d, J = 7.5 Hz, 6H), 7.32 (t, J = 7.7 Hz, 
6H), 7.25 (t, J =7.3 Hz, 3H), 5.51 (dq, J =10.9, 6.7 Hz, 1H), 5.25 (ddq, J =10.7, 9.4, 1.5 
Hz, 1H), 3.02 (dd, J =8.4, 6.5 Hz, 1H), 2.94 (dd, J =8.3, 7.0 Hz, 1H), 2.82 (m, 1H), 
1.69 (dd, J =6.8, 1.5 Hz, 3H), 1.05 (d, J =6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 
144.5 (C), 133.9 (CH), 128.8 (CH), 127.6 (CH), 126.8 (CH), 123.9 (CH), 86.2 (C), 
68.1 (CH2), 32.4 (CH), 17.9 (CH3), 13.1 (CH3). HRMS-ESI Calcd for C25H26ONa 
[M+Na]+ 365.1881, Found 365.1883. [α]D25 = +38.7 (c 1.1, CHCl3). 
 
(2S,3Z)-2-Methyl-3-pentene-1-ol (7a) 
 
OH  
 
To a stirred solution of olefin 30 (14.80 g, 43.22 mmol) in 100 mL of CH2Cl2 
and 50 mL of MeOH, p-toluenesulfonic acid (0.80 g, 4.32 mmol) was added. The 
reaction was stirred at room temperature during 16 h., then 100 mL of aqueous 
saturated NaHCO3 solution were added, the organic phase was separated and the 
aqueous extracted with 2x50 mL of CH2Cl2. The combined organic phases were dried 
over MgSO4, filtered, and the solvent was distilled at atmosphere pressure (ca. 40 ºC), 
and after, the product was purified by distillation under 1mbar of pressure and trapping 
the product at -190 ºC. The volatile alcohol 7a was obtained solved in about 20 mL of 
CH2Cl2 and was used directly in the next step. 1H NMR (CDCl3, 400 MHz) δ 5.61 (dq, 
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J =11.0, 6.7 Hz, 1H), 5.17 (ddq, J =10.9, 9.5, 1.5 Hz, 1H), 3.50 (dd, J =10.4, 5.9 Hz, 
1H), 3.35 (dd, J =10.4, 8.1 Hz, 1H), 2.72 (m, 1H), 1.67 (dd, J =6.6, 1.8 Hz, 3H), 1.64 
(bs, OH), 0.96 (d, J =6.8 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 133.0 (CH), 126.1 
(CH), 67.6 (CH2), 34.3 (CH), 16.7 (CH3), 13.1 (CH2). HRMS-ESI Calcd for C6H12ONa 
[M+Na]+ 123.0786, Found 123.0788. [α]D25 = −26.6 (c 1.1, CHCl3). 
 
(2E,4S,5Z)-2,4-Dimethyl-hepta-2,5-dien-1-ol (5a) 
 
OH  
 
Oxalyl chloride (8.22 g, 64.80 mmol) was solved in 100 mL of dry CH2Cl2 and, 
at –78 ºC, DMSO (6.1 mL, 86.44 mmol) was added. After 30 min at that temperature, 
the solution of 7a in ca. 20 mL of CH2Cl2 was added. 1h later, still at −78 ºC, Et3N 
(21.9 g, 216.0 mmol); was syringed and afterwards it was allowed to reach room 
temperature. 2h later, Ph3P=C(Me)CO2Et (39.1 g, 108.1 mmol) was added to the crude 
of reaction. It was stirred for 16 h at room temperature and then the reacting mixture 
was concentrated and redissolved in cold Et2O. The excess of the yellow precipitated 
phosporane was filtered and the residue purified by flash chromatography (8:1 
hexane:EtOAc) to yield the α,β-unsaturated ester of 7a as a yellow oil. At −78 ºC and 
under argon atmosphere, the α,β-unsaturated ester of 7a (3.44 g, 18.91 mmol) was 
solved in 50 mL of dry THF and a 1.0 M solution of DIBAL-H in hexanes (47.27 mL, 
47.27 mmol) was slowly added. The reaction finished after 2 h at room temperature. 
Then the mixture was cooled in an ice bath, and 40 mL of a saturated aqueous solution 
of Na/K tartrate was added. The organic phase was separated and the aqueous was 
extracted with 3x50 mL of EtOAc. The organic phases were dried with MgSO4, filtered 
and the solvent evaporated under reduced pressure. The product was purified by 
column chromatography (Hexane/EtOAc, 4:1) to yield the alcohol 5a as colourless oil 
(2.12 g, 80%). 1H NMR (CDCl3, 400 MHz) δ 5.37 (dq, J =11.1, 6.6 Hz, 1H), 5.27 (dd, 
J =8.9, 1.1 Hz, 1H), 5.24 (ddq, J =10.6 Hz, 9.1, 1.5 Hz, 1H), 3.96 (s, 2H), 3.40 (m, 1H), 
1.71 (d, J =1.0 Hz, 3H), 1.66 (dd, J =6.7, 1.6 Hz, 3H), 1.57 (bs, OH), 1.02 (d, J =6.8 
Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 135.1 (CH), 133.0 (C), 130.8 (CH), 121.9 
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(CH), 68.8 (CH2), 30.4 (CH), 21.4 (CH3), 13.7 (CH3), 12.9 (CH3). HRMS-ESI Calcd 
for C9H16ONa [M+Na]+ 163.1099, Found 163.1101. [α]D25 = +74.2 (c 1.1, CHCl3). 
 
(2E,4S,5Z)-2,4-Dimethylhepta-2,5-dienal (35) 
 
CHO  
 
Alcohol 5a (350 mg, 2.50 mmol) was solved in dry THF and MnO2 (4.34 g, 
50.0 mmol) was added at room temperature. After 1 h the reaction was finished and 
filtered over Celite which was washed several times with EtOAc. The crude was 
concentrated under reduced pressure to yield the aldehyde as colorless oil (306 mg, 
89%) with enough purity to be used in the next step. 1H NMR (CDCl3, 400 MHz) δ 
9.36 (s, 1H), 6.31 (dd, J =9.5, 1.1 Hz, 1H), 5.49 (dq, J =10.7, 6.8 Hz, 1H), 5.31 (ddq, 
J1=10.6, 9.0, 1.6 Hz, 1H), 3.66 (m, 1H), 1.79 (d, J =1.1 Hz, 3H), 1.65 (dd, J =6.8, 1.7 
Hz, 3H), 1.14 (d, J =6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 195.4 (CH), 157.8 
(CH), 137.0 (C), 132.2 (CH), 124.6 (CH), 31.7 (CH), 20.4 (CH), 13.0 (CH3), 9.2 (CH3). 
HRMS-ESI Calcd for C9H14ONa [M+Na]+ 161.0942, Found 161.0939. [α]D25 = +120.8 
(c 1.1, CHCl3). 
 
(2R,3R,4S,5Z)-2,4-Dimethyl-2-oxiranyl-5-hepten-1-ol (31) 
 
O
OH
 
 
Following the same procedure described for the synthesis of 34 and using 
TBHP (0.27 mL, 1.47 mmol), Ti(O-iPr)4 (0.24 mL, 0.81 mmol) in 25 mL of CH2Cl2 
was stirred, a solution of allylic alcohol (114 mg, 0.81 mmol) in 10 mL of CH2Cl2. and 
(-)-DET (0.14 mL, 0.81 mmol). Epoxyalcohol 31 was obtained as yellow oil (57 mg, 
45% yield dr = 10:1). Rf = 0.44 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
5.53 (dq, J = 10.6, 6.9 Hz, 1H), 5.21 (ddq, J = 10.5, 9.3, 1.6 Hz, 1H), 5.06 (bs, OH), 
3.71 (d, J = 9.9 Hz, 1H), 3.48 (d, J = 9.7 Hz, 1H), 2.73 (m, 1H), 2.54 (d, J = 9.0 Hz, 
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1H), 1.64 (dd, J = 6.8, 1.7 Hz, 3H), 1.27 (s, 3H), 1.09 (d, J = 7.0 Hz, 3H). 13C NMR 
(CDCl3, 100 MHz) δ 135.1 (CH), 122.1 (CH), 68.6 (CH), 67.9 (CH2), 58.9 (C), 30.6 
(CH), 21.3 (CH3), 14.3 (CH3), 12.8 (CH3). HRMS-ESI Calcd for C9H16O2Na [M+Na]+ 
179.1048, Found 179.1044. [α]D25 = +64.2 (c 1.3, CHCl3). 
 
(2S,3R)-2-Methyl-3-[(S,Z)-pent-3-en-2-yl]oxirane-2-carbaldehyde (2a) 
 
CHO
O  
 
Alcohol 31 (390.6 mg, 2.50 mmol) was solved in dry THF and MnO2 (4.34 g, 
50.0 mmol) was added at room temperature. After 2 h the reaction was finished and 
filtered over Celite which was washed several times with EtOAc. The crude was 
concentrated under reduced pressure to yield the aldehyde as colorless oil (300.7 mg, 
78%) with enough purity to be used in the next step. 1H NMR (CDCl3, 400 MHz) δ 
9.53 (s, 1H), 6.36 (dq, J = 10.5, 6.7 Hz, 1H), 6.01 (ddq, J = 10.3, 9.2, 1.5 Hz, 1H), 3.01 
(m, 1H), 2.84 (d, J = 9.2 Hz, 1H), 1.81 (dd, J = 6.7, 1.6 Hz, 3H), 1.30 (s, 3H), 1.10 (d, J 
= 7.0 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 201.4 (C), 138.3 (CH), 128.0 (CH), 73.1 
(C), 66.3 (CH), 32.2 (CH), 17.9 (CH3), 14.7 (CH3), 13.1 (CH3). HRMS-ESI Calcd for 
C23H30O2SiNa [M+Na]+ 389.1913, Found 389.1808. [α]D25 = +72.2 (c 1.4, CHCl3). 
 
(4R,2E)-Ethyl 5-hydroxy-2,4-dimethyl-2-pentenoate (23)5 
 
CO2Et
HO
 
 
To a stirred solution of the eter 6b (0.25 g, 0.86mmol) in 5 mL of CH2Cl2 and 2 
mL of H2O, DDQ (0.45 g, 1.98 mmol) is added dropwise, the reaction was stirred at r.t. 
during 4.5 h. Then the reaction was filtered over SiO2 washing with 20 mL Et2O. The 
product (0.13 g, 85%) was used in the next step without futher purifications. Rf = 0.36 
(4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 5.70 (dq, J =9.7, 1.4 Hz, 1H), 4.33 
                                                 
5  Miyazawa, M., Ishibashi, N., Ohnuma, S., Miyashita, M. Tetrahedron Lett. 1997, 38, 3419-3422. 
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(dd, J =9.4, 6.5 Hz, 1H), 4.24 (dd, J =9.5, 5.3 Hz, 1H), 4.19 (q, J = 7.0 Hz, 2H), 2.41 
(m, 1H), 1.89 (d, J = 1.3 Hz, 3H), 1.30 (t, J =7.1 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) δ 167.2 (C), 147.1 (CH), 124.2 (C), 68.5 (CH2), 61.8 (CH2), 
36.6 (CH), 17.7 (CH3), 14.2 (CH3), 13.6 (CH3). HRMS-ESI Calcd for C9H16O3Na 
[M+Na]+ 195.0997, Found 195.0995. [α]D25 = +13.9 (c 1.2, CHCl3). 
 
(4R,2E)-Ethyl 2,4-dimethyl-5-oxo-2-pentenoate (24) 
 
OHC CO2Et  
 
At −78 ºC, (COCl)2 (0.10 mL, 1.2 mmol) is added over 5 mL dry CH2Cl2, 
DMSO (0.17 mL, 2.40 mmol) is then added and the mixture was stirred for 30 min A 
solution of alcohol 23 (125 mg, 0.75 mmol) was added in 5 mL of dry CH2Cl2 and, 
after 1 h at this temperature, Et3N (0.18 mL, 1.27 mmol) was added dropwise and the 
solution was allowed to reach room temperature. After 3 h, 10 mL of water was added, 
the organic phase was separated and the aqueous one extracted with 2x 10 mL of 
CH2Cl2; the combined organic phases were dried over MgSO4, filtered and the solvent 
concentrated under reduced pressure to yield the aldehyde 24 as a yellow oil (74 mg, 
58%); Rf = 0.66 (6:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 9.68 (d, J = 1.6 
Hz, 1H), 6.72 (dq, J = 9.1, 1.4 Hz, 1H), 4.19 (q, J = 7.0 Hz, 2H), 3.11 (m, 1H), 2.32 (d, 
J = 1.3 Hz, 3H), 1.30 (t, J =7.1 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H). 13C NMR (CDCl3, 
100 MHz) δ 202.7 (CH), 169.3 (C), 146.4 (CH), 127.1 (C), 61.8 (CH2), 39.6 (CH), 15.7 
(CH3), 14.9 (CH3), 13.7 (CH3). HRMS-ESI Calcd for C9H14O3Na [M+Na]+ 193.0841, 
Found 193.0840. [α]D25 = +13.9 (c 1.2, CHCl3). 
 
(2S)-3-(4-Methoxybenzyloxy)-2-methylpropyl acetate (25) 
 
OAcPMBO  
 
At room temperature, over a solution of alcohol 22 (125 mg, 0.59 mmol) in 5 
mL CH2Cl2, Et3N (0.13 mL, 0.89 mmol), Ac2O (0.11 mL, 1.18 mmol), and DMAP (7.3 
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mg, 0.06 mmol) were successively added. The mixture was stirred for 6h, washed with 
3 x 10 mL of water and the organic phase was dried over MgSO4, filtered and the 
solvent concentrated under reduced pressure to yield the acetate 25 as an oil (146 mg, 
98%). 1H NMR (CDCl3, 400 MHz) δ 7.28-7.23 (m, 2H), 6.88-6.86 (m, 2H), 4.61 (s, 
2H), 4.44 (dd, J =9.5, 6.7 Hz, 1H), 4.19 (dd, J =9.3, 5.0 Hz, 1H), 3.81 (s, 3H), 3.42 (dd, 
J = 7.1, 1.3 Hz, 1H), 3.27 (dd, J = 7.2, 4.9 Hz, 1H), 2.63 (m, 1H), 0.95 (d, J = 1.3 Hz, 
3H). 13C NMR (CDCl3, 100 MHz) δ 172.7 (C), 159.1 (C), 130.0 (C), 129.0 (2CH), 
113.7 (2CH), 76.6 (CH2), 72.8 (CH2), 55.1 (CH3), 69.1 (CH2), 31.7 (CH), 20.1 (CH3), 
15.0 (CH3). HRMS-ESI Calcd for C9H20O4Na [M+Na]+ 275.1259, Found 275.1257. 
 
(R)-2-Methyl-3-oxopropyl acetate (26) 
 
OHC
OAc  
 
To a stirred solution of the 25 (215 mg, 0.85 mmol) in 5 mL of CH2Cl2, DDQ 
(231.5 mg, 1.02 mmol) and 2 mL of H2O were added at 0 ºC. The reaction was 
completed after 1.5 h at rt, filtered over SiO2 to remove the excess of DDQ and the 
byproducts of the reaction, finally the residue was concentrated to dryness, obtaining 
63 mg of the corresponding alcohol in 56% yield. At −78 ºC, (COCl)2 (64 µL, 0.77 
mmol) is added over 5 mL dry CH2Cl2, DMSO (0.11 mL, 1.54 mmol) is then added and 
the mixture was stirred for 30 min A solution of the alcohol (63 mg, 0.48 mmol) was 
added in 5 mL of dry CH2Cl2 and, after 1 h at this temperature, Et3N (0.12 mL, 0.81 
mmol) was added dropwise and the solution was allowed to reach room temperature. 
After 3 h, 10 mL of water was added, the organic phase was separated and the aqueous 
one extracted with 2x 10 mL of CH2Cl2; the combined organic phases were dried over 
MgSO4, filtered and the solvent concentrated under reduced pressure to yield the 
aldehyde 26 as a yellow oil (45 mg, 72%); Rf = 0.68 (4:1 hexane:EtOAc). 1H NMR 
(CDCl3, 400 MHz) δ 9.58 (d, J = 2.3 Hz, 1 H), 4.18 (d, J =6.1 Hz, 2H), 2.65 (m, 1H), 
2.02 (s, 3H), 1.15 (d, J = 7.3 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 202.7 (CH), 
171.7 (C), 63.4 (CH2), 44.7 (CH), 19.9 (CH3), 10.9 (CH3). HRMS-ESI Calcd for 
C6H10O3Na [M+Na]+ 153.0528, Found 153.0523. 
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(2S,3Z)-2-Methyl-3-pentenyl acetate (27) 
 
OAc  
 
Over a suspension of ethyltriphenylphosphoniumbromide (0.32 g, 8.14 mmol) 
in 10 mL of dry THF at −78°C, BuLi (3.1 mL, 7.63 mmol; 2.50 M in hexane) was 
slowly added. Afterwards the cooling bath was removed and the orange solution was 
allowed to reach room temperature. 30 min later, the solution (dark red) was cooled 
again to –78 ºC and aldehyde 26 (0.66 g , 5.09 mmol) solved in 10 mL of dry THF was 
slowly added. It was warmed ro room temperature and stirred for 3 h. Afterwards, 20 
mL of water were added. The organic phase was separated and the aqueous one was 
extracted with EtOAc (2 x 10 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated in vacuo. It was further purified by flash 
chromatography with hexane:EtOAc (10:1) to yield the olefin 27 (156 mg, 21%) as 
viscous oil. 1H NMR (CDCl3, 400 MHz) δ 5.51 (m, 1H), 5.17 (m, 1H), 3.91 (q, 2H), 
3.92 (dd, J = 7.1, 1.3 Hz, 1H), 3.77 (dd, J = 7.2, 4.9 Hz, 1H), 2.86 (m, 1H), 2.05 (s, 
3H), 1.64 (q, 3H), 0.99 (d, 3H). 13C NMR (CDCl3, 100 MHz) δ 171.3 (C), 132.3 (CH), 
125.4 (CH), 68.8 (CH2), 31.1 (CH), 21.1 (CH3), 17.4 (CH3), 13.2 (CH3). HRMS-ESI 
Calcd for C8H14O2Na [M+Na]+ 165.0891, Found 165.0893. 
 
5. Synthesis of the right side aldehyde 
 
Methyl 2-(2-Ethyl-1,3-dioxolan-2-yl)acetate (12)6 
 
CO2Me
OO
 
 
To a stirred solution of methyl 1-acetone carboxylate 13 (9.64 mL, 76.84 mmol) 
in dry CH2Cl2 (250 mL) under nitrogen atmosphere were added ethylene glycol (10.71 
mL, 182.10 mmol) and TMSCl (48.68 mL, 425.70). The reaction mixture was then 
                                                 
6  Langer, P.; Freifeld, I. Synlett 2001, 4, 523-525. 
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heated under reflux for 48 h and quenched with saturated aqueous NaHCO3 solution. 
The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 x 
100 mL). The combined organic layers were washed with water, brine and dried over 
Na2SO4. Removal of solvent under reduced pressure afforded 12 (13.18 g, 99%) as a 
colorless oil. Rf = 0.37 (2:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 3.98 (s, 
4H), 3.69 (s, 6H), 2.67 (s, 2H), 1.82 (q, J = 7.53 Hz, 2H), 0.94 (t, J = 7.53 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) δ 170.0 (C), 109.6 (C), 65.2 (2CH2), 51.7 (CH3) 42.1 (CH2), 
30.6 (CH2), 7.8 (CH3).  
HRMS-ESI Calcd for C9H14O6Na [M+Na]+ 197.0790, Found 197.0799. 
  
2-(2-Ethyl-1,3-dioxolan-2-yl)acetaldehyde (4)3 
 
CHO
OO
 
 
To a suspension of LiAlH4 (2.15 g, 56.74 mmol) in 50 mL of dry THF and at 0 
ºC, a solution of ester 12 (13.18 g, 75.76 mmol) in 20 mL of dry THF is added. After 
the addition, the reaction was heated at 40 ºC during 4 h. The reaction was hydrolyzed 
with 100 mL of saturated solution of sodium potassium tartrate, and was stirred until 
the salts were solved. After that, 100 mL of EtOAc is added and the phases were 
separated. The aqueous phase was extracted with EtOAc (2 x 50 mL). The combined 
organic phases were dried over MgSO4, filtered and evaporated under reduced pressure 
affording the alcohol with enough purity to oxidize it without further treatments. At 
−78 ºC, (COCl)2 (7.86 mL, 86.61 mmol) was dissolved in 50 mL of dry CH2Cl2, and at 
the same temperature DMSO (8.19 mL, 115.47 mmol) was added. The solution was 
stirred during 30 min, and then a solution of the crude alcohol (8.44 g, 57.44 mmol) 
was added. The mixture was stirred during 1 hour, followed by the addition of Et3N 
(41.06 mL, 288.69 mmol) and after 30 more min at −78 ºC, the reaction was allowed to 
reach room temperature and was finished after 4 h by the addition of 100 mL of 
saturated aqueous solution of NaHCO3 was added. The phases were separated, the 
aqueous layer was extracted with 2 x 50 mL of CH2Cl2, the combined organic phases 
were dried over MgSO4, filtered and concentrated in vacuo. The product was purified 
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by flash chromatography (3:1 hexane:EtOAc) to yield 4 (8.44 g, 78%) as a yellow oil. 
Rf = 0.52 (4:1 hexane:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 9.74 (t, J = 2.95 Hz), 
3.94 (s, 4H), 2.68 (d, J = 2.95 Hz, 2H), 1.71 (q, J = 7.40 Hz, 2H), 0.94 (t, J = 7.40 Hz, 
3H). 13C NMR (CDCl3, 100 MHz) δ 200.6 (C), 109.8 (C), 65.1 (2CH2), 50.2 (CH2), 
31.3 (CH2), 7.8 (CH2). HRMS-ESI Calcd for C7H12O3 [M+Na]+ 144.0786, Found 
144.0775. 
 
6. Aldol reaction using Cy2BCl 
 
General Procedure 
 
Under Ar atmosphere and at -78 ºC, 1.0 M solution of Cy2BCl in hexanes (1.5 
mmol), was diluted with dry Et2O (0.5 mL). Afterwards, freshly distilled Et3N (1.7 
mmol) and ketone (3 or 3-pentanone) (1.0 mmol) solved in dry Et2O (0.5 mL) were 
sequentially added. The mixture was stirred 45 min at 0 ºC, a white solid appeared, and 
then the reaction was cooled until −78 ºC when a solution of aldehyde (1.0 mmol) in 
dry Et2O (0.5 mL) was added. After 1 h, the reaction was warmed until −20 ºC and 
stirred during 16 h. MeOH (5mL), pH= 7 buffer (2 mL) and H2O2 (2 mL) were added 
and the mixture stirred for 1 h. The organic phase was separated and the aqueous one 
extracted with EtOAc. The combined organic phases were dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified by flash chromathography 
(hexane-EtOAc) to yield the aldols as inseparable mixture of diastereomers. 
 
(4R,5S)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxymethyl)-5-
hydroxyl-6-methyl-3-heptanone (45) 
 
OOH
TBSO OTBS
 
 
Product 45 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100.0 
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mg, 0.29 mmol) and aldehyde 46 (26 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 45 (98.4 mg, 81% 
yield, dr = 7:3) as a colorless oil. Rf = 0.35 (20:1 hexane-EtOAc).  
1H NMR (CDCl3, 400 MHz) δ 4.06 (t, J = 6.6 Hz, 2H), 3.76 (ddd, J = 9.7, 8.0, 4.2 Hz, 
1H), 3.55 (dd, J = 7.8, 4.3 Hz, 1H), 3.45 (dd, J = 9.7, 5.2 Hz, 1H), 2.71 (t, J = 6.6 Hz, 
2H), 2.82 (m, 1H), 1.89 (m, 1H), 0.99 (d, J = 6.6 Hz, 6H), 0.88 (s, 9H), 0.84 (s, 9H), 
0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 73.1 (CH), 59.2 
(CH2), 58.6 (CH2), 57.2 (CH), 47.4 (CH2), 32.2 (CH), 26.1 (3CH3), 25.8 (3CH3), 19.3 
(2CH3), 18.2 (C), 18.0 (C), −5.4 (2CH3), −5.8 (2CH3). HRMS-ESI Calcd for 
C21H46NaO4Si2 [M+Na]+ 441.2832, Found 441.2832. 
 
(4R,5S)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxymethyl)-5-
hydroxyl-6-methyl-3-octanone (57) 
 
OOH
TBSO OTBS
 
 
Product 57 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 47 (30 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 57 (94.1 mg, 75% 
yield) as a colorless oil. Rf = 0.46 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
4.06 (t, J = 6.6 Hz, 2H), 3.75 (dd, J = 9.7, 8.0, 4.1 Hz, 1H), 3.55 (dd, J = 7.8, 4.3 Hz, 
1H), 3.45 (dd, J = 9.7, 5.2 Hz, 1H), 2.71 (t, J = 6.6 Hz, 2H), 2.83 (m, 1H), 1.87 (m, 
1H), 1.55 (m, 2H), 0.97 (d, J = 6.6 Hz, 3H), 0.91 (t, J = 6.5 Hz, 3H), 0.88 (s, 9H), 0.84 
(s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 73.1 
(CH), 59.2 (CH2), 58.6 (CH2), 57.2 (CH), 47.4 (CH2), 37.2 (CH), 25.9 (3CH3), 25.8 
(3CH3), 24.8 (CH2), 16.8 (CH3), 18.2 (C), 18.1 (C), 13.6 (CH3), −5.4 (2CH3), −5.7 
(2CH3). HRMS-ESI Calcd for C22H48NaO4Si2 [M+Na]+ 455.2989, Found 455.2991. 
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(4R,5S)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxymethyl)-5-
hydroxyl-6-methyl-3- nonanone (58) 
 
OOH
TBSO OTBS
 
 
Product 58 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 48 (36 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 58 (97.2 mg, 75% 
yield,) as a yellow oil. Rf = 0.52 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
4.05 (t, J = 6.6 Hz, 2H), 3.77 (dd, J = 9.7, 8.0, 4.2 Hz, 1H), 3.54 (dd, J = 7.8, 4.3 Hz, 
1H), 3.46 (dd, J = 9.7, 5.2 Hz, 1H), 2.70 (t, J = 6.6 Hz, 2H), 2.81 (m, 1H), 1.88 (m, 
1H), 1.32 (m, 2H), 1.25 (m, 2H), 0.97 (d, J = 6.6 Hz, 3H), 0.91 (t, J = 6.7 Hz, 3H), 0.88 
(s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H).  
13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 73.1 (CH), 59.2 (CH2), 58.6 (CH2), 57.2 
(CH), 47.4 (CH2), 33.8 (CH), 29.9 (CH2), 25.9 (3CH3), 25.8 (3CH3), 21.8 (CH2), 18.2 
(C), 18.1 (C), 15.1 (CH3), 13.6 (CH3), −5.4 (2CH3), −5.7 (2CH3). HRMS-ESI Calcd for 
C23H50NaO4Si2 [M+Na]+ 469.3145, Found 469.3142. 
 
(4R,5S)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxymethyl)-5-
hydroxyl-6-hepten-3-one (59) 
 
OOH
TBSO OTBS
 
 
Product 59 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 53 (19 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 59 (65.4, 56% yield, dr 
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= 4:1) as a colorless oil. Rf = 0.45 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 
5.81 (m, 1H), 5.32 (m, 1H), 5.18 (m, 1H), 4.18 (dd, J = 7.9, 4.4 Hz, 1H), 3.88 (t, J = 
6.7 Hz, 2H), 3.69 (dd, J = 9.9, 8.0 Hz, 1H), 3.36 (dd, J = 9.9, 8.0 Hz, 1H), 3.15 (m, 
1H), 2.73 (t, J = 6.7 Hz, 2H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C 
NMR (CDCl3, 100 MHz) δ 213.7 (C), 138.7 (C), 117.6 (C), 69.1 (CH), 59.2 (CH), 58.6 
(CH2), 57.2 (CH2), 47.4 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), −5.4 
(2CH3), −5.7 (2CH3). HRMS-ESI Calcd for C20H42O4NaSi2 [M+Na]+ 425.2519, Found 
425.2510. 
 
(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxymethyl)-5-
hydroxyl-6-octen-3-one (60) 
 
OOH
TBSO OTBS
 
 
Product 60 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 54 (24 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 60 (76.1 mg, 63% 
yield, dr = 3:2) as a colorless oil. Rf = 0.43 (20:1 hexane-EtOAc).  
1H NMR (CDCl3, 400 MHz) δ 5.70-5.68 (m, 2H), 4.18 (dd, J = 7.9, 4.3 Hz, 1H), 3.88 
(t, J = 6.7 Hz, 2H), 3.68 (dd, J = 9.9, 8.0 Hz, 1H), 3.32 (dd, J = 9.5, 7.9 Hz, 1H), 3.17 
(m, 1H), 2.73 (t, J = 6.7 Hz, 2H), 2.05 (m, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 
0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 132.4 (C), 127.1 (C), 70.1 
(CH), 59.1 (CH), 58.6 (CH2), 57.2 (CH2), 47.4 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 
(C), 18.1 (C), 17.1 (CH3), −5.4 (2CH3), −5.7 (2CH3). HRMS-ESI Calcd for 
C21H44O4NaSi2 [M+Na]+ 439.2676, Found 439.2669. 
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(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-6-nonen-3-one (61) 
 
OOH
TBSO OTBS
 
 
Product 61 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 55 (28 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 61 (92.4 mg, 74% 
yield, dr = 7:3) as a colorless oil. Rf = 0.37 (20:1 hexane-EtOAc).  
1H NMR (CDCl3, 400 MHz) δ 5.70-5.68 (m, 2H), 4.15 (dd, J = 7.8, 4.2 Hz, 1H), 3.88 
(t, J = 6.7 Hz, 2H), 3.68 (dd, J = 9.9, 8.0 Hz, 1H), 3.32 (dd, J = 9.4, 8.0 Hz, 1H), 3.19 
(m, 1H), 2.73 (t, J = 6.7 Hz, 2H), 2.05 (m, 2H), 1.08 (t, J = 6.5 Hz, 3H), 0.88 (s, 9H), 
0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 135.7 
(C), 130.4 (C), 69.1 (CH), 59.2 (CH), 58.6 (CH2), 57.2 (CH2), 47.4 (CH2), 26.9 (CH2), 
25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), 14.1 (CH3), −5.4 (2CH3), −5.7 (2CH3). 
HRMS-ESI Calcd for C22H46NaO4Si2 [M+Na]+ 453.2832, Found 453.2823. 
 
(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-7-phenyl-6-hepten-3-one (62) 
 
OOH
TBSO OTBS
 
 
Product 62 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 56 (36 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 62 (65.3 mg, 47% 
yield, dr = 4:1) as a yellow oil. Rf = 0.44 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 
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MHz) δ 7.65-7.25 (m, 5H), 6.47 (s, 1H), 6.22 (dd, J = 15.8, 7.1 Hz, 1H), 4.18 (dd, J = 
7.9, 4.5 Hz, 1H), 3.88 (t, J = 6.7 Hz, 2H), 3.68 (dd, J = 9.9, 8.0 Hz, 1H), 3.35 (dd, J = 
9.6, 8.0 Hz, 1H), 3.20 (m, 1H), 2.73 (t, J = 6.7 Hz, 2H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 
(s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 136.1 (C), 129.2 (CH), 
128.7 (2CH), 128.5 (2CH), 127.7 (CH), 126.0 (CH), 68.1 (CH), 59.3 (CH), 58.6 (CH2), 
57.2 (CH2), 47.4 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), −5.4 (2CH3), 
−5.7 (2CH3). HRMS-ESI Calcd for C26H46NaO4Si2 [M+Na]+ 501.2832, Found 
501.2820. 
 
(4R,5S)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-6-methyl-6-hepten-3-one (63) 
 
OOH
TBSO OTBS
 
 
Product 63 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 49 (24 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 63 (96.7 mg, 80% 
yield, dr = 3:2) as a yellow oil. Rf = 0.51 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 
MHz) δ 5.32 (m, 1H), 5.18 (m, 1H), 4.17 (dd, J = 7.9, 4.6 Hz, 1H), 3.89 (t, J = 6.7 Hz, 
2H), 3.68 (dd, J = 9.9, 8.0 Hz, 1H), 3.34 (d, J = 9.4, 8.0 Hz, 1H), 3.18 (m, 1H), 2.74 (t, 
J = 6.7 Hz, 2H), 1.81 (m, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C 
NMR (CDCl3, 100 MHz) δ 213.7 (C), 143.7 (C), 112.6 (CH2), 69.8 (CH), 57.2 (CH2), 
56.4 (CH), 56.1 (CH2), 47.4 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), 17.2 
(CH3), −5.4 (2CH3), −5.7 (2CH3). HRMS-ESI Calcd for C21H41NaO4Si2 [M+Na]+ 
439.2676, Found 439.2674. 
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(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-6-methyl-6-octen-3-one (64) 
 
OOH
TBSO OTBS
 
 
Product 64 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 50 (28 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 64 (81.2 mg, 65% 
yield, dr = 7:3) as a colorless oil. Rf = 0.42 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 
400 MHz) δ 5.42 (m, 1H), 4.18 (dd, J = 7.9, 4.5 Hz, 1H), 3.88 (t, J = 6.7 Hz, 2H), 3.68 
(dd, J = 9.9, 8.0 Hz, 1H), 3.36 (d, J = 9.6, 8.0 Hz, 1H), 3.16 (m, 1H), 2.73 (t, J = 6.7 
Hz, 2H), 2.52 (m, 3H), 1.82 (m, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 
6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 138.7 (C), 119.6 (CH2), 70.7 (CH), 57.1 
(CH2), 56.4 (CH), 56.2 (CH2), 47.5 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 
(C), 13.5 (CH3), 12.1 (CH3),−5.4 (2CH3), −5.7 (2CH3). HRMS-ESI Calcd for 
C22H46NaO4Si2 [M+Na]+ 453.2832, Found 453.2832. 
 
(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-6-methyl-6-nonen-3-one (65) 
 
OOH
TBSO OTBS
 
 
Product 65 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 51 (33 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 65 (100.6 mg, 78% 
yield, dr = 4:1) as a yellow oil. Rf = 0.38 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 
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MHz) δ 5.42 (m, 1H), 4.16 (dd, J = 7.9, 4.1 Hz, 1H), 3.88 (t, J = 6.7 Hz, 2H), 3.68 (dd, 
J = 9.9, 8.0 Hz, 1H), 3.35 (d, J = 9.4, 8.0 Hz, 1H), 3.17 (m, 1H), 2.73 (t, J = 6.7 Hz, 
2H), 2.48 (m, 2H), 1.81 (m, 3H), 1.08 (t, J = 6.5 Hz, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 
0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 135.5 (C), 121.6 
(CH2), 72.0 (CH), 57.1 (CH2), 56.4 (CH), 56.2 (CH2), 47.7 (CH2), 25.9 (3CH3), 25.8 
(3CH3), 22.1 (CH2), 18.2 (C), 18.1 (C), 15.0 (CH3), 12.4 (CH3),−5.4 (2CH3), −5.7 
(2CH3). HRMS-ESI Calcd for C23H48NaO4Si2 [M+Na]+ 467.2989, Found 467.2989. 
 
(4R,5S,6E)-1-(tert-Butyldimethylsilyloxy)-4-(tert-butyldimethylsilyloxy methyl)-5-
hydroxyl-6-methyl-7-phenyl-6-hepten-3-one (66) 
 
OOH
TBSO OTBS
 
 
Product 66 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 52 (40 µL, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield 66 (61.5 mg, 43% 
yield, dr = 7:3) as a yellow oil. Rf = 0.41 (20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 
MHz) δ 7.65-7.25 (m, 5H), 6.45 (s, 1H), 4.17 (dd, J = 7.9, 4.3 Hz, 1H), 3.88 (t, J = 6.7 
Hz, 2H), 3.68 (dd, J = 9.9, 8.0 Hz, 1H), 3.37 (d, J = 9.5, 8.0 Hz, 1H), 3.14 (m, 1H), 
2.73 (t, J = 6.7 Hz, 2H), 1.80 (m, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 
6H). 13C NMR (CDCl3, 100 MHz) δ 213.7 (C), 136.3 (C), 135.3 (C), 128.6 (2CH), 
128.5 (2CH), 127.7 (CH), 127.6 (CH), 123.9 (CH), 70.5 (CH), 57.3 (CH2), 56.9 (CH), 
56.1 (CH2), 47.1 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), 13.8 (CH3), −5.4 
(2CH3), −5.7 (2CH3). HRMS-ESI Calcd for C27H48NaO4Si2 [M+Na]+ 515.2989, Found 
515.2992. 
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(2R,3R,4R,5S)-6-{(E)-2-[(tert-Butyldimethilsilyl)oxy]ethyliden}-5-{[(tert-
butyldimethyilsilyl)oxy]methyl}-3-methyl-2-{(1R)-1-methyl-2-[(4-
methoxybencyl)oxy]ethyl}-3,4,5,6-tetrahydro-2H-pyran-3,4-diol (67) 
 
O
HO
TBSO
OPMB
HO
OTBS
 
 
 Product 67 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 2b (77 mg, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (20:1 hexane-EtOAc) to yield the pirane 67 (0.12 g, 
65% yield) as a colorless oil. Rf = 0.46 (20:1 hexane-EtOAc1H NMR (CDCl3, 400 
MHz) δ 7.30-7.27 (m, 2H), 6.90-6.87 (m, 2H), 4.48 (s, 2H), 4.35 (td, J = 7.1, 2.0 Hz, 
1H), 4.28 (dd, J = 7.4, 1.5 Hz, 1H), 4.27 (d, J = 2.1 Hz, 1H), 4.21 (dd, J = 6.0, 1.5 Hz, 
1H), 4.18 (d, J = 3.8 Hz, 1H), 3.94 (dd, J = 9.3, 8.9 Hz, 1H), 3.81 (s, 3H), 3.68 (dd, J = 
9.5, 4.9 Hz, 1H), 3.51 (dd, J = 7.0, 6.7 Hz, 1H) 3.28 (dd, J = 7.2, 4.8 Hz, 1H), 3.14 (m, 
1H), 2.05 (m, 1H), 1.17 (s, 3H), 0.91 (s, 9H), 0.90 (s, 9H), 0.80 (d, J = 6.0 Hz, 3H), 
0.09 (s, 6H), 0.06 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 159.2 (C), 152.3 (C), 130.5 
(C), 129.2 (2CH), 113.8 (2CH), 98.3 (CH), 83.9 (C), 73.8 (CH), 73.6 (CH), 72.9 (CH2), 
72.8 (CH2), 59.4 (CH2), 58.0 (CH2), 55.3 (CH3), 50.0 (CH), 35.2 (CH), 26.1 (3CH3), 
25.9 (3CH3), 20.9 (CH3), 18.4 (C), 18.3 (C), 9.7(CH3), -5.0 (CH3), -5.1 (CH3), -5.4 
(CH3), -5.4 (CH3). HRMS-ESI Calcd for C32H58O7Si2Na [M+Na]+ 633.3619, Found 
633.3626. ). The structure was confirmed by 2D-NMR techniques (HSQC, HMBC, 
ROESY, COSY). 
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(4R,5S,6E,8S,9Z)-1-[(tert-Butyldimethylsilyl)oxy]-4-{[(tert-butyldimethyl 
silyl)oxy]methyl}-5-hydroxy-6,8-dimethylundeca-6,9-dien-3-one (70) 
 
OOH
TBSO OTBS
 
 
Product 70 was synthesized following the general procedure described above 
using Cy2BCl (0.22 mL, 0.22 mmol), Et3N (35 µL, 0.25 mmol), ketone 3b (50 mg, 0.15 
mmol) and aldehyde 35 (40 mg, 0.29 mmol) in 1.5 mL Et2O. The product was purified 
by flash chromatography (20:1 hexane-EtOAc) to yield the aldol 70 (51 mg, 72% yield) 
as a colorless oil. Rf = 0.46 (20:1 hexane-EtOAc). Spectroscopic data are referred to the 
major isomer. 1H NMR (CDCl3, 400 MHz) δ 5.34 (dq, J =11.1, 6.6 Hz, 1H), 5.23 (d, J 
= 8.9 Hz, 1H), 5.14 (ddd, J = 10.6 Hz, 9.1, 1.5 Hz, 1H), 4.15 (dd, J = 9.6, 3.9 Hz, 1H), 
3.86 (t, J = 6.8 Hz, 2H), 3.68 (dd, J = 9.7, 8.3 Hz, 1H), 3.39 (dd, J = 9.5, 8.0 Hz, 1H), 
3.37 (m, 1H), 3.16 (m, 1H), 2.74 (t, J = 6.7 Hz, 3H), 1.69 (d, J = 1.0 Hz, 3H), 1.66 (dd, 
J = 6.7, 1.6 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 
0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.2 (C), 135.2 (CH), 132.8 (C), 130.9 
(CH), 122.9 (CH), 73.6 (CH), 62.4 (CH2), 58.4 (CH2), 57.2 (CH), 47.9 (CH2), 30.5 
(CH), 25.9 (3CH3), 25.8 (3CH3), 21.6 (CH3), 17.4 (C), 17.3 (C), 13.3 (CH3), 12.5 
(CH3), -5.6 (2CH3), -5.6 (2CH3). HRMS-ESI Calcd for C26H52O4Si2Na [M+Na]+ 
507.3302, Found 507.3300. The structure was confirmed by 2D-NMR techniques 
(HSQC, COSY). 
 
(4R,5S,6E,8R)-1-[(tert-Butyldimethylsilyl)oxy]-4-{[(tert-
butyldimethylsilyl)oxy]methyl}-5-hydroxy-6,8-dimethyl-9-(4-methoxybenzyl)non-
6-en-3-one (71) 
 
OOH
PMBO
TBSO OTBS
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 Product 71 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 36 (72.0 mg, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (20:1 hexane-EtOAc) to yield the aldol 71 (172 mg, 
81% yield) as a colorless oil. Rf = 0.46 (20:1 hexane-EtOAc). Spectroscopic data are 
referred to the major isomer. 1H NMR (CDCl3, 400 MHz) δ 7.27-7.22 (m, 2H), 6.89-
6.84 (m, 2H), 5.21 (dq, J = 8.9, 1.1 Hz, 1H), 4.42 (s, 2H), 4.22 (d, J = 8.5 Hz, 1H), 3.90 
(t, J = 7.0 Hz, 2H), 3.80 (s, 3H), 3.70 (dd, J = 9.8, 8.2 Hz, 1H), 3.59 (dd, J = 9.9, 4.9 
Hz, 1H), 3.29 (dd, J = 8.9, 6.5 Hz, 1H), 3.23 (dd, J = 9.1, 7.4 Hz, 1H), 3.00 (m, 1H), 
2.76 (t, J = 6.8, 2H), 2.71 (m, 1H), 1.66 (s, 3H), 0.96 (d, J = 6.7, 3H), 0.88 (s, 9H), 0.84 
(s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 213.2 (C), 153.1 (C), 
134.9 (C), 129.9 (C), 129.0 (2CH), 125.2 (CH), 113.7 (2CH), 74.7 (CH2), 72.6 (CH2), 
72.3 (CH), 58.4 (CH2), 57.3 (CH), 55.9 (CH3), 55.3 (CH2), 47.9 (CH2), 32.8 (CH), 25.9 
(3CH3), 25.8 (3CH3), 19.2 (CH3), 18.1 (2C), 11.8 (CH3), -5.6 (2CH3), -5.6 (2CH3). 
HRMS-ESI Calcd for C32H58O6Si2Na [M+Na]+ 617.3670, Found 617.3672. The 
structure was confirmed by 2D-NMR techniques (HSQC, COSY). 
 
(1S,2R)-5-[(tert-Butyldimethylsilyl)oxy]-2-{[(tert-butyldimethylsilyl)oxy]methyl}-1-
hydroxy-1-[(1S,2R)-1-methyl-2-{(1R)-1-methyl-2-[(4-
methoxybenzyl)oxy]ethyl}cyclopropyl]pentan-3-one (91) 
 
OOH
PMBO
TBSO OTBS
 
 
91 was synthesized following the general procedure described above using 
Cy2BCl (0.17 mL, 0.17 mmol), Et3N (28 µL, 0.19 mmol), ketone 3b (40 mg, 0.12 
mmol) and aldehyde 38 (76.0 mg, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (20:1 hexane-EtOAc) to yield the 91 (43 mg, 61% 
yield) as a colorless oil. Rf = 0.46 (20:1 hexane-EtOAc). Spectroscopic data are referred 
to the major isomer1H NMR (CDCl3, 400 MHz) δ 7.27-7.22 (m, 2H), 6.89-6.84 (m, 
2H), 4.01 (t, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.70 (dd, J = 9.8, 8.2 Hz, 1H), 3.61 (d, J = 
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8.6 Hz, 1H), 3.59 (dd, J = 9.9, 4.9 Hz, 1H), 3.56 (d, J = 0.6 Hz, 1H), 3.49 (m, 1H), 3.48 
(m, 1H), 3.40 (d, J = 0.6 Hz, 1H), 2.73 (t, J = 6.6, 3H), 2.63 (m, 1H), 0.99 (d, J = 6.7 
Hz, 3H), 0.92-0.75 (m, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C 
NMR (CDCl3, 100 MHz) δ 213.1 (C), 159.7 (C), 129.8 (C), 114.2 (2C), 78.1 (CH2), 
73.3 (CH2), 70.2 (CH), 58.3 (CH2), 56.3 (CH), 55.8 (CH3), 55.4 (CH2), 47.8 (CH2), 
25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 17.5 (CH), 17.3 (CH2), 17.1 (2C), 15.1 (CH3), -5.6 
(2CH3), -5.6 (2CH3). HRMS-ESI Calcd for C33H60O6Si2Na [M+Na]+ 631.3826, Found 
631.3822. The structure was confirmed by 2D-NMR techniques (HSQC, COSY). 
 
(2S, 3E, 5S, 6R)-9-(tert-Butyldimethylsilyloxy)-6-[2-(tert-
butyldimethylsilyloxy)ethyl]-1-(tert-butyldiphenylsilyloxy)-5-hydroxy-2,4-
dimethyl-non-3-en-7-one (72) 
 
OOH
TBDPSO
TBSO OTBS
 
 
Product 72 was synthesized following the general procedure described above 
using Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 3b (100 mg, 
0.29 mmol) and aldehyde 37 (106 mg, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (20:1 hexane-EtOAc) to yield the aldol 72 (184 mg, 
89% yield) as a colorless oil. Rf = 0.36 (15:1 hexane-EtOAc). Spectroscopic data are 
referred to the major isomer. 1H NMR (CDCl3, 400 MHz) δ 7.63-7.60 (m, 4H), 7.46-
7.33 (m, 6H), 5.15 (d, J = 9.8 Hz, 1H), 4.17 (dd, J = 7.9, 4.1 Hz, 1H), 3.88 (t, J = 6.7 
Hz, 2H), 3.66 (dd, J = 9.9, 8.0 Hz, 1H), 3.51 (dd, J = 9.9, 4.9 Hz, 1H), 3.48 (dd, J = 
9.7, 5.5 Hz, 1H), 3.37 (dd, J = 9.6, 8.0 Hz, 1H), 2.96 (td, J = 7.9, 5.1 Hz, 1H), 2.73 (t, J 
= 6.6, 2H), 2.67 (d, J = 4.1, 1H), 2.59 (m, 1H), 1.55 (s, 3H), 1.04 (s, 9H), 1.01 (d, J = 
6.6, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 
MHz) δ 212.8 (C), 135.7 (2C), 135.6 (4CH), 135.1 (C), 130.7 (2CH), 129.6 (4CH), 
127.6 (CH), 76.1 (CH), 68.2 (CH2), 62.6 (CH2), 58.4 (CH2), 57.2 (CH), 48.0 (CH2), 
35.2 (CH3), 26.9 (3CH3), 25.9 (3CH3), 25.8 (3CH3), 19.3 (C), 18.2 (C), 18.1 (C), 17.3 
(CH3), 11.9 (CH3), -5.4 (2CH3), -5.7 (2CH3). HRMS-ESI Calcd for C40H68O5Si3Na 
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[M+Na]+ 735.4272, Found 735.4272. The structure was confirmed by 2D-NMR 
techniques (HSQC, COSY). 
 
(4R,5S,6E,8R)-5-Hydroxy-4,6,8-trimethyl-9-(4-methoxybenzyl)non-6-en-3-one (83) 
 
OOH
PMBO
 
 
83 was synthesized following the general procedure described above using 
Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 80 (86.1 mg, 0.29 
mmol) and aldehyde 36 (72 mg, 0.29 mmol) in 1.5 mL Et2O. The product was purified 
by flash chromatography (10:1 hexane-EtOAc) to yield the 83 (88.3 mg, 91% yield) as 
a colorless oil. Rf = 0.46 (4:1 hexane-EtOAc). Spectroscopic data are referred to the 
major isomer. 1H NMR (CDCl3, 300 MHz) δ 7.27-7.22 (m, 2H), 6.89-6.84 (m, 2H), 
5.21 (d, J = 8.7 Hz, 1H), 4.41 (s, 2H), 4.12 (d, J = 7.2 Hz, 1H), 3.82 (s, 3H), 3.25 (d, J 
= 6.9 Hz, 2H), 2.89-2.62 (m, 2H), 2.54 (m, 2H), 1.62 (s, 3H), 1.03 (t, J = 6.7 Hz, 3H), 
0.97 (d, J = 6.0 Hz, 3H), 0.94 (d, J = 6.1 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 216.6 
(C), 159.1 (C), 134.8 (C), 132.4 (CH), 130.5 (C), 129.1 (2CH), 113.7 (2CH), 80.2 
(CH2), 74.9 (CH), 72.6 (CH2), 55.3 (CH3), 48.6 (CH), 36.4 (CH), 32.8 (CH2), 20.5 
(CH3), 14.2 (CH3), 11.2 (CH3), 7.4 (CH3). HRMS-ESI Calcd for C20H30NaO4 [M+Na]+ 
357.2042, Found 357.2043. The structure was confirmed by 2D-NMR techniques 
(HSQC, COSY). 
 
(3E,4R,5S,8R)-9-(tert-Butyldiphenylsilyloxy)-5-hydroxy-4,6,8-trimethylnon-6-en-3-
one (84) 
 
OOH
TBDPSO
 
 
84 was synthesized following the general procedure described above using 
Cy2BCl (0.43 mL, 0.43 mmol), Et3N (0.07 mL, 0.49 mmol), ketone 80 (86.1 mg, 0.29 
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mmol) and aldehyde 37 (106 mg, 0.29 mmol) in 1.5 mL Et2O. The product was 
purified by flash chromatography (10:1 hexane-EtOAc) to yield the 84 (124.7 mg, 95% 
yield) as a colorless oil. Rf = 0.46 (4:1 hexane-EtOAc). Spectroscopic data are referred 
to the major isomer. 1H NMR (CDCl3, 400 MHz) δ 7.69-7.61 (m, 4H), 7.45-7.33 (m, 
6H), 5.15 (d, J = 9.7 Hz, 1H), 3.59 (dd, J = 9.9, 8.0 Hz, 1H), 3.54 (dd, J = 9.9, 4.9 Hz, 
1H), 3.43 (d, J = 6.7, 1H), 3.20 (m, 1H), 2.56 (m, 1H), 2.43 (q, J = 6.6 Hz, 2H), 1.71 
(d, J =1.0 Hz, 3H), 1.19 (d, J =6.6 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 1.04 (s, 9H), 1.01 
(3, J =6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ 212.8 (C), 135.7 (2C), 135.6 (4CH), 
135.1 (C), 130.7 (2CH), 129.6 (4CH), 127.6 (CH), 74.9 (CH), 48.6 (CH), 36.9 (CH), 
32.8 (CH2), 25.9 (3CH3), 20.5 (CH3), 19.3 (C), 14.2 (CH3), 11.2 (CH3), 7.4 (CH3). 
HRMS-ESI Calcd for C28H40NaO3Si [M+Na]+ 475.2644, Found 475.2644. The 
structure was confirmed by 2D-NMR techniques (HSQC, COSY).  
  
7. Aldol reaction using TiCl4 
 
General Procedure 
 
To a stirred solution of ketone (1.00 mmol) in 0.5 mL of CH2Cl2, 1.20 mmol of a 
1.0 M solution of TiCl4 in CH2Cl2 was added. After 10 min at 0 ºC, DIPEA (1.40 
mmol) was added at −78 ºC. The mixture was stirred during 15 min at −78 ºC, and a 
solution of aldehyde (1.10 mmol) in 0.5 mL of CH2Cl2 was added. The reaction was 
stirred during 4 h at the same temperature and 10 mL of saturated solution of NH4Cl 
were added. The organic phase was separated and the aqueous one extracted with 2 x 
10 mL of CH2Cl2. The combined organic phases were dried over anhydrous Na2SO4, 
filtered and concentrated. The crude was purified by flash chromatography (hexane-
EtOAc) to yield the aldols as inseparable mixture of diastereomers. 
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(4S,5R)-1-(tert-Butyldimethylsilyloxy)-4-[2-(tert-butyldimethyl silyloxy) ethyl]-7-
(1,3-dioxolan-2-yl)-5-hydroxylundecan-3-one (78) 
 
O
TBSO OTBS
O OHO  
 
Following the general procedure described above, using ketone 3b (345 mg, 
1.00 mmol), TiCl4 (1.20 mL, 1.20 mmol), DIPEA (0.24 mL, 1.40 mmol) and aldehyde 
4 (159 mg, 1.10 mmol); aldol 78 (335 mg, 68% yield) was obtained as a colorless oil. 
Rf = 0.46 (4:1 hexane-EtOAc). Spectroscopic data are referred to the major isomer. 1H 
NMR (CDCl3, 400 MHz) δ 4.01 (m, 2H), 3.97 (m, 2H), 3.86 (t, J = 6.7 Hz, 2H), 3.66 
(dd, J = 9.9, 7.9 Hz, 1H), 3.57 (m, 1H), 3.37 (dd, J = 9.6, 7.9 Hz, 1H), 2.71 (t, J = 6.6, 
2H), 2.59 (m, 1H), 1.89 (m, 2H), 1.67 (q, J = 7.5 Hz, 2H), 0.91 (t, J = 7.5 Hz, 3H), 0.88 
(s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 212.8 
(C), 112.7 (C), 64.8 (2CH2), 60.1 (CH), 62.6 (CH2), 58.9 (CH2), 58.4 (CH2), 54.6 (CH), 
48.0 (CH2), 37.6 (CH2), 29.8 (CH2), 25.9 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), 8.1 
(CH3), -5.4 (2CH3), -5.7 (2CH3). HRMS-ESI Calcd for C24H50NaO6Si2 [M+Na]+ 
513.3044, Found 513.3044. The structure was confirmed by 2D-NMR techniques 
(HSQC, COSY). 
 
(4S,5R)-5-Hydroxy-4-methylnonane-3,7-dione (88) 
 
O HO O  
Following the general procedure described above, ketone 80 (86.13 mg, 1.00 
mmol), TiCl4 (1.20 mL, 1.20 mmol), DIPEA (0.24 mL, 1.40 mmol) and aldehyde 4 
(159 mg, 1.10 mmol); 88 (143.4 mg, 77% yield) was obtained as a colorless oil. Rf = 
0.46 (4:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 4.31 (dt, J = 9.0, 4.7 Hz, 1H), 
2.72 (dq, J = 9.0, 7.2 Hz, 1H), 2.51 (d, J = 4.7 Hz, 2H), 2.46 (q, J = 7.3 Hz, 4H), 1.14 
(d, J = 7.2 Hz, 3H), 1.05 (t, J = 7.3 Hz, 3H), 1.04 (t, J = 7.3 Hz, 3H). 13C NMR (CDCl3, 
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100 MHz) δ 215.1 (C), 211.7 (C), 68.2 (CH), 49.7 (CH), 45.5 (CH2), 36.8 (CH2), 35.7 
(CH2), 11.6 (CH3), 7.5 (CH3), 7.5 (CH3). HRMS-ESI Calcd for C10H18O3Na [M+Na]+ 
209.1154, Found 209.1154. 
 
8. Hydroxyl protection of aldol products 
 
General Procedure 
 
To a stirred solution of 0.18 mmol of the aldol in 5 mL of CH2Cl2, 0.26 mmol of 
TBSOTf and 0.35 mmol of 2,6-lutidine were sequentially added at 0 ºC. The reaction 
was stirred at this temperature for 30 min and then, saturated solution of NH4Cl.was 
added. The organic phase was separated, and after extraction of the aqueous layer with 
CH2Cl2, the combined organic layers were dried over Na2SO4, filtered and 
concentrated. The product was purified by flash chromatography (30:1 hexane:EtOAc) 
to yield the protected aldol. 
 
(4R,5S,6E,8R)-9-[(tert-Butyldimethylsilyl)oxy]-1,5-bis[(tert-
butyldimethylsilyl)oxy]-4-{[(tert-butyldimethylsilyl)oxy]methyl}-6,8-dimethylnon-
6-en-3-one (74) 
 
OTBSO
TBDPSO
TBSO OTBS
 
 
Following the general procedure described above, using aldol 72 (128.4 mg, 
0.18 mmol), of TBSOTf (60 µL, 0.26 mmol), 2,6-lutidine (41 µL , 0.35 mmol); TBS-
protected aldol 74 (143.0 mg, 96% yield) was obtained as a colorless oil. Rf = 0.39 
(30:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.64-7.60 (m, 4H), 7.47-7.33 (m, 
6H), 5.13 (d, J = 9.8 Hz, 1H), 4.27 (dd, J = 7.9, 4.1 Hz, 1H), 3.86 (t, J = 6.7 Hz, 2H), 
3.55 (dd, J = 9.9, 8.0 Hz, 1H), 3.51 (dd, J = 9.9, 4.9 Hz, 1H), 3.48 (dd, J = 9.7, 5.5 Hz, 
1H), 3.43 (dd, J = 9.6, 8.0 Hz, 1H), 3.11 (td, J = 7.9, 5.1 Hz, 1H), 2.74 (t, J = 6.6, 2H), 
2.59 (m, 1H), 1.53 (s, 3H), 1.04 (s, 9H), 1.00 (d, J = 6.6, 3H), 0.95 (s, 9H), 0.88 (s, 
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9H), 0.84 (s, 9H), 0.07 (s, 6H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) 
δ 210.7 (C), 135.7 (2C), 135.6 (4CH), 135.1 (C), 130.7 (2CH), 129.6 (4CH), 127.6 
(CH), 77.4 (CH), 63.2 (CH2), 61.6 (CH2), 58.2 (CH2), 57.0 (CH), 48.0 (CH2), 35.2 
(CH3), 25.9 (3CH3), 25.9 (3CH3), 25.8 (3CH3), 19.3 (C), 18.2 (C), 18.1 (C), 18.1 (C), 
17.3 (CH3), 11.9 (CH3), –5.2 (2CH3), –5.4 (2CH3), –5.7 (2CH3). HRMS-ESI Calcd for 
C46H82O5Si4Na [M+Na]+ 849.5137, Found 849.5140. 
 
(3E,5S,6R)-5,9-Di(tert-butyldimethylsilyloxy)-6-[2-(tert-butyldimethyl silyloxy) 
ethyl]-4-methyl-3-nonen-7-one (75) 
 
OTBSO
TBSO OTBS
 
 
Following the general procedure described above, using aldol 65 (80.1 mg, 0.18 
mmol), of TBSOTf (60 µL, 0.26 mmol), 2,6-lutidine (41 µL, 0.35 mmol); TBS-
protected aldol 75 (97.6 mg, 97% yield) was obtained as a colorless oil. Rf = 0.24 (30:1 
hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 5.40 (m, 1H), 4.25 (dd, J = 7.9, 4.1 Hz, 
1H), 3.86 (t, J = 6.7 Hz, 2H), 3.62 (dd, J = 9.9, 8.0 Hz, 1H), 3.41 (d, J = 9.4, 8.0 Hz, 
1H), 3.31 (m, 1H), 2.72 (t, J = 6.7 Hz, 2H), 2.49 (m, 2H), 1.80 (m, 3H), 1.09 (t, J = 6.5 
Hz, 3H), 0.95 (s, 9H), 0.88 (s, 9H), 0.84 (s, 9H), 0.07 (s, 6H), 0.05 (s, 6H), 0.03 (s, 6H). 
13C NMR (CDCl3, 100 MHz) δ 210.1 (C), 135.7 (C), 121.3 (CH2), 76.0 (CH), 56.9 
(CH2), 56.3 (CH), 56.2 (CH2), 47.7 (CH2), 30.0 (3CH3), 25.9 (3CH3), 25.8 (3CH3), 25.8 
(3CH3), 22.1 (CH2), 18.2 (C), 18.1 (C), 18.1 (C), 15.3 (CH3), 12.4 (CH3), −5.3 (2CH3), 
−5.4 (2CH3), −5.7 (2CH3). HRMS-ESI Calcd for C29H62O4Si3Na [M+Na]+ 581.3854, 
Found 581.3856. 
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(2S,3E,5S,6R)-5,9-Di(tert-butyldimethylsilyloxy)-6-[2-(tert-butyldimethylsilyloxy) 
ethyl]-1-(4-methoxybenzyloxy)-2,4-dimethyl-non-3-en-7-one (73) 
 
OTBSO
PMBO
TBSO OTBS
 
 
Following the general procedure described above, using aldol 71 (107.1 mg, 
0.18 mmol), of TBSOTf (60 µL, 0.26 mmol), 2,6-lutidine (41 µL , 0.35 mmol); TBS-
protected aldol 73 (125.1 mg, 98% yield) was obtained as a colorless oil. Rf = 0.34 
(30:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.28-7.22 (m, 2H), 6.89-6.83 (m, 
2H), 5.19 (dq, J = 8.9, 1.1 Hz, 1H), 4.42 (s, 2H), 4.31 (d, J = 8.7 Hz, 1H), 3.86 (t, J = 
7.0 Hz, 2H), 3.80 (s, 3H), 3.61 (dd, J = 9.8, 8.2 Hz, 1H), 3.59 (dd, J = 9.9, 4.9 Hz, 1H), 
3.38 (dd, J = 8.9, 6.5 Hz, 1H), 3.23 (dd, J = 9.1, 7.4 Hz, 1H), 3.16 (m, 1H), 2.75 (t, J = 
6.9 Hz, 2H), 2.71 (m, 1H), 1.63 (s, 3H), 0.95 (d, J = 6.7, 3H), 0.93 (s, 9H), 0.88 (s, 9H), 
0.84 (s, 9H), 0.06 (s, 6H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 
211.3 (C), 152.6 (C), 134.4 (C), 129.9 (C), 129.0 (2CH), 125.2 (CH), 113.7 (2CH), 
76.1 (CH2), 72.7 (CH2), 72.0 (CH), 58.4 (CH2), 57.6 (CH), 55.9 (CH3), 55.3 (CH2), 
48.1 (CH2), 32.8 (CH), 25.9 (3CH3), 25.9 (3CH3), 25.8 (3CH3), 19.5 (CH3), 18.1 (2C), 
18.0 (C), 11.8 (CH3), -5.5 (2CH3), -5.6 (2CH3), -5.6 (2CH3). HRMS-ESI Calcd for 
C38H72O6Si3Na [M+Na]+ 731.4534, Found 731.4538. 
 
(4S,5R)-1,5-Di(tert-butyldimethylsilyloxy)-4-[2-(tert-butyldimethyl silyloxy) ethyl]-
7-(1,3-dioxolan-2-yl)undecan-3-one (77) 
 
O
TBSO OTBS
O OO
TBS  
 
Following the general procedure described above, using aldol 78 (88.3 mg, 0.18 
mmol), of TBSOTf (60 µL, 0.26 mmol), 2,6-lutidine (41 µL, 0.35 mmol); TBS-
protected aldol 77 (143.4 mg, 77% yield) was obtained as a colorless oil. Rf = 0.31 
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(30:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 4.00 (m, 2H), 3.96 (m, 2H), 3.84 
(t, J = 6.7 Hz, 2H), 3.59 (dd, J = 9.9, 7.9 Hz, 1H), 3.69 (m, 1H), 3.46 (dd, J = 9.6, 7.9 
Hz, 1H), 2.70 (t, J = 6.6 Hz, 2H), 2.72 (m, 1H), 1.96 (m, 2H), 1.68 (q, J = 7.5 Hz, 2H), 
0.96 (s, 9H), 0.92 (t, J = 7.5 Hz, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.07 (s, 6H), 0.05 (s, 
6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 210.9 (C), 113.4 (C), 64.1 (2CH2), 
60.3 (CH), 62.5 (CH2), 58.9 (CH2), 58.7 (CH2), 55.0 (CH), 48.1 (CH2), 37.6 (CH2), 
29.9 (CH2), 25.9 (3CH3), 25.8 (3CH3), 25.8 (3CH3), 18.2 (C), 18.1 (C), 18.1 (C), 8.1 
(CH3), -5.4 (2CH3), -5.5 (2CH3), -5.7 (2CH3). HRMS-ESI Calcd for C30H64O6Si3Na 
[M+Na]+ 627.3908, Found 627.3904. 
 
(4R,5S,8R,E)-5-(tert-butyldimethylsilyloxy)-9-(4-methoxybenzyloxy)-4,6,8-
trimethylnon-6-en-3-one (85) 
 
PMBO
OTBSO  
 
Following the general procedure described above, using aldol 83 (88.3 mg, 
0.264 mmol), of TBSOTf (88 µL, 0.383 mmol), 2,6-lutidine (60 µL , 0.516 mmol); 
TBS-protected aldol 85 (116.1 mg, 98% yield) was obtained as a colorless oil. Rf = 0.31 
(20:1 hexane-EtOAc). 1H NMR (CDCl3, 300 MHz) δ 7.28-7.22 (m, 2H), 6.89-6.83 (m, 
2H), 5.20 (d, J = 8.7 Hz, 1H), 4.41 (s, 2H), 4.27 (d, J = 7.2 Hz, 1H), 3.79 (s, 3H), 3.23 
(d, J = 6.9 Hz, 2H), 2.88-2.61 (m, 2H), 2.54 (m, 2H), 1.62 (s, 3H), 1.03 (t, J = 6.7 Hz, 
3H), 0.97 (d, J = 6.0 Hz, 3H), 0.94 (d, J = 6.1 Hz, 3H), 0.92 (s, 9H), 0.07 (s, 6H). 13C 
NMR (CDCl3, 100 MHz) δ 215.4 (C), 159.6 (C), 133.5 (C), 129.4 (C), 129.2 (2CH), 
125.2 (CH), 114.4 (2CH), 81.1 (CH2), 77.5 (CH), 73.0 (CH2), 55.6 (CH3), 49.6 (CH), 
35.2 (CH), 34.9 (CH2), 29.9 (3CH3), 18.5 (C), 18.1 (CH3), 12.8 (CH3), 10.7 (CH3), 8.2 
(CH3) -5.5 (2CH3). HRMS-ESI Calcd for C26H44O4SiNa [M+Na]+ 448.3009, Found 
448.3008. 
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(4R,5S,8R,E)-5-(tert-butyldimethylsilyloxy)-9-(tert-butyldiphenylsilyloxy)-4,6,8-
trimethylnon-6-en-3-one (86) 
 
TBDPSO
OTBSO  
 
Following the general procedure described above, using aldol 84 (122.4 mg, 0.270 
mmol), of TBSOTf (90 µL, 0.392 mmol), 2,6-lutidine (62 µL, 0.527 mmol); TBS-
protected aldol 86 (151.5 mg, 99% yield) was obtained as a colorless oil. Rf = 0.35 
(20:1 hexane-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.69-7.61 (m, 4H), 7.45-7.33 (m, 
6H), 5.14 (d, J = 10.1 Hz, 1H), 4.32 (d, J = 7.8 Hz, 1H), 3.87 (t, J = 6.6 Hz, 2H), 3.63 
(dd, J = 9.9, 8.2 Hz, 1H), 3.48 (dq, J = 15.7, 4.9 Hz, 1H), 3.35 (dd, J = 9.6, 7.9 Hz, 
1H), 2.97 (td, J = 7.8, 5.0 Hz, 1H), 2.73 (t, J = 6.6, 2H), 2.67 (d, J = 4.8, 1H), 2.59 (m, 
1H), δ 1.04 (s, 9H), 1.01 (d, J = 6.6, 3H), 1.55 (s, 3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.05 
(s, 6H), 0.03 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 215.6 (C), 135.8 (2C), 135.6 
(4CH), 133.3 (C), 130.7 (2CH), 129.6 (4CH), 125.1 (CH), 77.3 (CH), 70.5 (CH2), 49.5 
(CH), 38.2 (CH), 34.9 (CH2), 27.3 (3CH3), 25.8 (3CH3), 19.0 (C), 18.2 (C), 18.1 (CH2), 
12.8 (CH3), 10.7 (CH3), 8.2 (CH3) -5.5 (2CH3). HRMS-ESI Calcd for C34H54O3Si2Na 
[M+Na]+ 566.3611, Found 566.3613. 
 
9. Deprotection for activity assays 
 
(4R,5S,6E,8S,9Z)-1,5-dihydroxy-4-(hydroxymethyl)-6,8-dimethylundeca-6,9-dien-
3-one (92) 
 
O
HO OH
OH  
 
To a solution of the silyl ether 70 (15 mg, 0.031 mmol) in 1.0 mL of THF, 1.0 M 
solution of TBAF in THF (125 µL, 0.125 mmol) was added at 0 ºC. The reaction was 
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allowed to reach rt and stirred for 2 h. The reaction was followed by TLC until 
completion. 2 mL of aqueous saturated solution of NH4Cl was added, the phases were 
separated and the aqueous layer was extracted with 2 x 5 mL of CH2Cl2. The combined 
organic phases were concentrated. The crude was redissolved in 10 mL of 1:1 CH2Cl2-
MeOH and filtered through a pad of celite. The crude was employed to measure the 
biological activity without further purifications. 1H NMR (CDCl3, 400 MHz) δ 5.35 (dq, 
J =11.1, 6.6 Hz, 1H), 5.22 (d, J = 8.9 Hz, 1H), 5.15 (ddd, J = 10.6 Hz, 9.1, 1.6 Hz, 1H), 
4.28 (dd, J = 9.7, 3.9 Hz, 1H), 3.99 (t, J = 6.8 Hz, 2H), 3.82 (dd, J = 9.7, 8.3 Hz, 1H), 
3.41 (d, J = 9.5, 1H), 3.35 (m, 1H), 3.13 (m, 1H), 2.71 (t, J = 6.7 Hz, 3H), 1.70 (d, J 
=1.1 Hz, 3H), 1.67 (dd, J = 6.7, 1.6 Hz, 3H), 1.03 (d, J =6.7 Hz, 3H). 
 
(4R,5S,8R,E)-1,5,9-trihydroxy-4-(hydroxymethyl)-6,8-dimethylnon-6-en-3-one (93) 
 
HO
O
HO OH
OH  
 
To a solution of the silyl ether 72 (18 mg, 0.025 mmol) in 1.5 mL of THF, 1.0 M 
solution of TBAF in THF (150 µL, 0.150 mmol) was added at 0 ºC. The reaction was 
allowed to reach rt and stirred for 2 h. The reaction was followed by TLC until 
completion. 2 mL of aqueous saturated solution of NH4Cl was added, the phases were 
separated and the aqueous layer was extracted with 2 x 5 mL of CH2Cl2. The combined 
organic phases were concentrated. The crude was redissolved in 10 mL of 1:1 CH2Cl2-
MeOH and filtered through a pad of celite. The crude was employed to measure the 
biological activity without further purifications. 1H NMR (CDCl3, 400 MHz) δ 5.20 (d, 
J = 8.7 Hz, 1H), 4.28 (d, J = 9.7, 3.9 Hz, 1H), 3.99 (t, J = 6.8 Hz, 2H), 3.82 (dd, J = 9.7, 
8.3 Hz, 1H), 3.55 (dd, J = 9.9, 8.0 Hz, 1H), 3.51 (dd, J = 9.9, 4.9 Hz, 1H), 3.41 (d, J = 
9.5, 8.1 Hz, 1H), 3.35 (m, 1H), 2.71 (t, J = 6.7 Hz, 3H), 2.59 (m, 1H), 1.66 (d, J =1.0 
Hz, 3H), 1.19 (d, J =6.7 Hz, 3H). 
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(2S,3S,4S,5R,Z)-6-(2-hydroxyethylidene)-5-(hydroxymethyl)-2-((S)-1-
hydroxypropan-2-yl)-3-methyltetrahydro-2H-pyran-3,4-diol (94) 
 
O
HO
HO
OH
HO
OH
 
 
To a solution of 67 (20 mg, 0.0327 mmol) in 1.5 mL of THF, 1.0 M solution of 
TBAF in THF (131 µL, 0.131 mmol) was added at 0 ºC. The reaction was allowed to 
reach rt and stirred for 2 h. The reaction was followed by TLC until completion. 2 mL 
of aqueous saturated solution of NH4Cl was added, the phases were separated and the 
aqueous layer was extracted with 2 x 5 mL of CH2Cl2. The combined organic phases 
were concentrated. The crude was redissolved in 10 mL of 1:1 CH2Cl2-MeOH and 
filtered through a pad of celite. After solvent evaporation, the crude was redissolved in 
2 mL of 1:1 mixture of CH2Cl2-H2O and DDQ (8.1 mg, 0.0360) was added at rt The 
reaction was stirred at rt for 1h, filtered through a pad of celite and employed to 
measure the biological activity without further purifications. 1H NMR (CDCl3, 400 
MHz) δ 4.39 (s, 2H), 4.31 (td, J = 7.3, 1.9 Hz, 1H), 4.15 (dd, J = 7.4, 1.7 Hz, 1H), 4.12 
(d, J = 2.2 Hz, 1H), 4.06 (dd, J = 6.0, 1.4 Hz, 1H), 4.01 (d, J = 3.7 Hz, 1H), 3.95 (dd, J 
= 9.3, 8.8 Hz, 1H), 3.69 (dd, J = 9.6, 4.9 Hz, 1H), 3.48 (dd, J = 7.2, 6.7 Hz, 1H) 3.26 
(dd, J = 7.2, 4.8 Hz, 1H), 3.13 (m, 1H), 2.07 (m, 1H), 1.15 (s, 3H), 0.80 (d, J = 6.0 Hz, 
3H). 
 
(1S,2R)-1,5-dihydroxy-2-(hydroxymethyl)-1-((1S,2R)-2-((R)-1-hydroxypropan-2-
yl)-1-methylcyclopropyl)pentan-3-one (95) 
 
HO
O
HO OH
OH  
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To a solution of 91 (15 mg, 0.0246 mmol) in 1.5 mL of THF, 1.0 M solution of 
TBAF in THF (100 µL, 0.100 mmol) was added at 0 ºC. The reaction was allowed to 
reach rt and stirred for 2 h. The reaction was followed by TLC until completion. 2 mL 
of aqueous saturated solution of NH4Cl was added, the phases were separated and the 
aqueous layer was extracted with 2 x 5 mL of CH2Cl2. The combined organic phases 
were concentrated. The crude was redissolved in 10 mL of 1:1 CH2Cl2-MeOH and 
filtered through a pad of celite. After solvent evaporation, the crude was redissolved in 
2 mL of 1:1 mixture of CH2Cl2-H2O and DDQ (6.1 mg, 0.0271 mmol) was added at rt 
The reaction was stirred at rt for 1h, filtered through a pad of celite and employed to 
measure the biological activity without further purifications. 1H NMR (CDCl3, 400 
MHz) δ 4.12 (t, J = 7.0 Hz, 2H), 3.78 (dd, J = 9.9, 8.2 Hz, 1H), 3.69 (d, J = 8.6 Hz, 1H), 
3.54 (dd, J = 9.9, 4.7 Hz, 1H), 3.51 (d, J = 0.7 Hz, 1H), 3.43 (m, 1H), 3.40 (m, 1H), 
3.37 (d, J = 0.6 Hz, 1H), 2.68 (t, J = 6.7, 3H), 2.55 (m, 1H), 0.99 (d, J = 6.7 Hz, 3H), 
0.92-0.75 (m, 3H). 
 
(4R,5S,8R,E)-5,9-dihydroxy-4,6,8-trimethylnon-6-en-3-one (96) 
 
HO
OOH  
 
To a solution of the silyl ether 84 (18 mg, 0.0398 mmol) in 1.0 mL of THF, 1.0 M 
solution of TBAF in THF (80 µL, 0.0800 mmol) was added at 0 ºC. The reaction was 
allowed to reach rt and stirred for 2 h. The reaction was followed by TLC until 
completion. 2 mL of aqueous saturated solution of NH4Cl was added, the phases were 
separated and the aqueous layer was extracted with 2 x 5 mL of CH2Cl2. The combined 
organic phases were concentrated. The crude was redissolved in 10 mL of 1:1 CH2Cl2-
MeOH and filtered through a pad of celite. The crude was employed to measure the 
biological activity without further purifications. 1H NMR (CDCl3, 400 MHz) δ 5.20 (d, 
J = 8.7 Hz, 1H), 3.55 (dd, J = 9.9, 8.0 Hz, 1H), 3.51 (dd, J = 9.9, 4.9 Hz, 1H), 3.41 (d, J 
= 9.5, 1H), 3.21 (m, 1H), 2.59 (m, 1H), 2.43 (q, J = 6.6 Hz, 2H), 1.71 (d, J =1.0 Hz, 
3H), 1.19 (d, J =6.6 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 1.03 (3, J =6.7 Hz, 3H). 
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10. Cytotoxicity assay protocol 
 
Cell lines and cell culture 
 
Human-derived established cell lines used in this study were purchased from 
ATCC (American Type Culture Collection) unless otherwise specified. 
 
A-549, human lung carcinoma 
HT-29, human colorectal adenocarcinoma 
MDA-MB 231, human breast adenocarcinoma 
 
All cell lines are maintained in RPMI medium culture supplemented with 10% 
Fetal calf serum (FCS), 2 mM L-glutamine and 100 Units/mL penicillin and 
streptomycin at 37 ºC and 5% CO2. Triplicate cultures were incubated for 72 h in the 
presence or absence of test compounds (at 10 concentrations ranging from 10 to 0.0026 
µg/mL). 
 
Cytotoxicity assay (srb) 
 
A colorimetric assay using sulforhodamine B (SRB) has been adapted for a 
quantitative measurement of cell growth and viability, following a previously described 
method.7 Cells are plated in 96-well microtiter plates at a density of 5x103/well and 
incubated for 24 h. After that, cells are treated with vehicle alone (control) or 
compounds at the concentrations indicated. One plate from each different cell line is 
fixed and stained, and used for Tz reference (see next paragraph). Treated cells are 
further incubated for 48 h. To quantify the cytotoxic potential of compounds the 
sulforhodamine B (SRB) protein stain method is used. 
 
                                                 
7 Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Waren, J. T.; 
Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug 
screening, J. Natl. Cancer Inst., 1990, 82, 1107-1112. 
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Cells are washed twice with phosphate buffered saline (PBS), fixed for 15 min 
in 1% glutaraldehyde solution, rinsed twice in PBS, and stained in 0.4% SRB solution 
for 30 min at room temperature. Cells are then rinsed several times in 1% acetic acid 
solution and air-dried. SRB was then extracted in 10 mM trizma base solution and the 
absorbance measured at 490 nm. Cell survival was determined as percentage of control 
cell growth. 
 
